

[illegible]

[illegible]

September 30, 2024 and 2023 and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2024. The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of September 30, 2024, and the results of operations, comprehensive loss, and changes in stockholders’ equity (deficit) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024, have been made. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 that are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2024.

Going ConcernPursuant to the requirements of Accounting Standard Codification (ASC) 205-40, Presentation of Financial Statements-Going Concern, management is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern for one year after the date that these financial 8 Table of Contentsstatements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have they been approved by the Board of Directors as of the date of these consolidated financial statements. Based on the Company’s current operating plan, it is anticipated that cash and cash equivalents of \$3.0 million as of September 30, 2024, will allow it to meet its liquidity requirements into the fourth quarter of 2024. The Company’s history of losses, negative cash flows from operations, liquidity resources currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.

On August 26, 2024, the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company was not in compliance with the Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) because the Company reported stockholders’ equity of less than \$2.5 million as of June 30, 2024. The notice from the Staff further stated that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”), the Company’s securities would be subject to delisting. As of September 30, 2024, the Company has a stockholders equity deficit of approximately \$0.97 million which is not in compliance with the Equity Rule. On October 15, 2024, the Company met with the Panel regarding the Company’s potential delisting from Nasdaq as a result of its violation of the Equity Rule. On October 22, 2024, the Company received the Panel’s decision which granted the Company until December 24, 2024 to regain compliance with the Equity Rule and all applicable criteria for continued listing on Nasdaq. If the Company is unable to regain compliance with the listing standards of the Nasdaq Capital Market by December 24, 2024, the Company’s securities may be delisted from Nasdaq. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. Recently Issued Accounting PronouncementsThe FASB has issued ASU 2023-07, “Segment Reporting (Topic 280)”. This standard will require all public entities “even those like the Company that have a single reportable segment” to disclose additional information about the title and position of the Chief Operating Decision Maker (the “CODM”), the measure or measures of segment profit and loss used by the CODM in assessing segment performance and deciding how to allocate resources, an explanation of how the CODM uses the reported measure(s) in assessing segment performance, significant segment expenses that are regularly provided to the CODM, and a reconciliation of segment profit and loss to the closest consolidated totals prepared under United States GAAP. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 will not change the way in which reportable segments are determined. However, the Company is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.

The FASB has issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This standard will require all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation of that information.

9 Table of ContentsFair Value of Financial InstrumentsFinancial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities. Comprehensive Income (Loss)All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three and nine months ended September 30, 2024 and 2023.

Foreign Currency and Currency TranslationTransactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable future.

The assets and liabilities of the Company’s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that are of a long-term investment nature, are recorded in other comprehensive loss.

LeasesThe Company accounts for lease contracts in accordance with ASC 842. As of September 30, 2024, the Company’s outstanding leases are classified as operating leases. The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company’s obligation to make lease payments under the lease. As the Company’s leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company’s credit risk. The Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:

- The lease payments due in any optional period;
- Penalties for failure to exercise (or not exercise) the option;
- Market factors, such as the availability of similar assets and current rental rates for such assets;
- The nature of the underlying leased asset and its importance to the Company’s operations; and
- 10 Table of Contents—The remaining useful lives of any related leasehold improvements.

Lease expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset. The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.

Revenue RecognitionWhen the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, Revenue from Contracts with Customers (ASC 606). (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, the Company satisfies a performance obligation. The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers:

- Whether achievement of a development milestone is highly susceptible to factors outside the entity’s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies;
- Whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;
- Whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and
- The complexity and inherent uncertainty underlying the achievement of the milestone.

The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation. The Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable. Grant revenue received from organizations that are not the Company’s customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses.

11 Table of Contents3.4 RevenueThe Company recognized \$10,000 and \$43,000 of revenue for the three and nine months ended September 30, 2024 respectively. This revenue is related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center. Revenues recognized for the three and nine months ended September 30, 2023 were \$16,000 and \$389,000 respectively.

4.4 Net Loss per Common ShareThe Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share”. Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. The following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months ended September 30, 2024 and 2023, as the result would be anti-dilutive:

	September 30, 2024	September 30, 2023	
Stock options	118,989	145,446	
Restricted Stock Units	39,747	34,798	
% convertible exchangeable preferred stock	6.6	5.6	
Series A preferred stock	440	440	
Series B preferred stock	118,989	79,248	
Common stock warrants	10,871	215,625	
Total shares excluded from calculation	11,030,759	475,563	
Series A preferred stock	440	440	
Prepaid Expenses and Other Current Assets	31	31	
Prepaid expenses and other current assets consisted of the following (in \$000s):			
September 30, 2024	31	December 31, 2023	31
Research and development tax credit receivable	\$ 1,248	\$ 2,933	
Prepayments and VAT receivable	\$ 374	\$ 792	
Other current assets	\$ 309	\$ 341	
Total	\$ 1,931	\$ 4,066	
Non-Current Assets	6	6	
As of September 30, 2024, the Company had non-current assets of \$0.4 million, which is primarily comprised of deposits held by a contract research organization in relation to the Company’s clinical trials.			
7.4 Accrued and Other Liabilities			
Accrued and other current liabilities consisted of the following (in \$000s):			
September 30, 2024	31	December 31, 2023	31
Accrued research and development	\$ 1,616	\$ 3,668	
Accrued legal and professional fees	\$ 277	\$ 570	
Other current liabilities	\$ 332	\$ 380	
Total	\$ 2,225	\$ 4,618	
12 Table of Contents			
8. Leases			
The Company currently has an operating lease liability relating to its facilities in Berkeley Heights, New Jersey. For the nine months ended September 30, 2024 and 2023, the Company recognized operating lease expenses of \$57,178 and \$55,982 respectively, including \$9,097 and \$7,902 respectively relating to a short term lease for offices in Dundee, Scotland. Cash payments made during the nine months ended September 30, 2024 and 2023 totaled \$38,058 and \$55,245, respectively, and were presented within cash outflows from operating activities. The remaining lease term as of September 30, 2024 is approximately 0.8 years for the Berkeley Heights facility. The discount rate used by the Company in determining the lease liability was 12%. Remaining lease payments for both facilities are as follows (in \$000s):			
September 30, 2024	\$ 16,202	September 30, 2023	\$ 38,789
Total future minimum lease obligation	\$ 54	Less discount	\$ (3)
Total	\$ 51	Total	\$ 51
9. Stock Based Compensation			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.			
ASU 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards			

shares of the Company's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. No fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the Company will round down to the next whole share. There were no exercises of these warrants during the nine months ended September 30, 2024 or September 30, 2023. Series A Preferred Stock total of 237,745 shares of the Company's Series A Preferred Stock were issued pursuant to a December 2020 Securities Purchase Agreement. Each share of Series B Preferred Stock was initially convertible into one third (1/3) share of common stock (the "Conversion Shares"), subject to adjustment in accordance with the Certificate of Designation. Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Certificate of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, (e) pay certain dividends or (f) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. The Purchaser may convert shares of Series B Preferred Stock through a conversion into shares of common stock if and solely to the extent that such conversion would not result in the Purchaser beneficially owning in excess of 9.99% of then-outstanding common stock or aggregate voting power of the Company (such limitation, the "Ownership Limitation") and any portion in excess of such limitation will remain outstanding as Series B Preferred Stock. During the year ended December 31, 2023, 118,745 shares of Series B Preferred Stock were converted, at the option of the holder, into 39,582 shares of common stock. During the nine months ended September 30, 2024, the remaining 119,000 shares of Series B Preferred Stock were converted, at the option of the holder, into 39,667 shares of common stock. Series A Preferred Stock total of 8,872 shares of the Company's Series A Preferred Stock were issued in a July 2017 Underwritten Public Offering. Each share of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing \$1,000 by the initial conversion price of \$600.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations. Table of Contents As of September 30, 2024 and December 31, 2023, 264 shares of the Series A Preferred Stock remain issued and outstanding. The 264 shares of Series A Preferred Stock issued and outstanding at September 30, 2024, are convertible into 440 shares of common stock. In the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company's ability to repurchase shares of Series A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock. Subject to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder of the Series A Preferred Stock to convert all or part of such holder's Series A Preferred Stock in the event that (i) the volume weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds 300% of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds \$500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of Series A Preferred Stock to convert all or part of such holder's Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock. The Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution. 6% Convertible Exchangeable Preferred Stock As of September 30, 2024, there were 335,273 shares of the Company's 6% Convertible Exchangeable Preferred Stock (the "6% Preferred Stock") issued and outstanding at an issue price of \$10.00 per share. Dividends on the 6% Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the 6% Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company's board of directors and must come from funds that are legally available for dividend payments. The 6% Preferred Stock has a liquidation preference of \$10.00 per share, plus accrued and unpaid dividends. As of September 30, 2024, there were no accrued and unpaid dividends. The Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company's common stock has exceeded \$888.300, which is 150% of the conversion price of the 6% Preferred Stock, for at least 20 trading days during any 30 day trading period, ending within five trading days prior to notice of automatic conversion. The 6% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances. Table of Contents The Company may, at its option, redeem the 6% Preferred Stock in whole or in part, out of funds legally available at the redemption price of \$10.00 per share. The 6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November 1, 2005 (the "Exchange Date") for the Company's 6% Convertible Subordinated Debentures (the "Debentures") at the rate of \$10.00 principal amount of Debentures for each share of 6% Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have substantially similar terms to those of the 6% Preferred Stock. No such exchanges have taken place to date. 11. A A A A A A A A A A Subsequent Events Dividends on 6% Preferred Stock On September 4, 2024, the board of directors of the Company passed a resolution to suspend payment of the quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock scheduled for November 1, 2024. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis. On October 15, 2024, 200,000 shares of the Company's 6% Convertible Exchangeable Preferred Stock was converted into 3 shares of common stock. As of October 23, 2024, all of the remaining 4,135,000 pre-funded warrants pursuant to the April 2024 Securities Purchase Agreement were fully exercised. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, including, without limitation, Management's Discussion and Analysis of Financial Condition and Results of Operations, contains "forward-looking statements" within the meaning of Section 27A of the Securities Exchange Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We intend that the forward-looking statements be covered by the safe harbor for forward-looking statements in the Exchange Act. The forward-looking information is based on various factors and was derived using numerous assumptions. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements are usually accompanied by words such as "believe," "anticipate," "plan," "seek," "expect," "intend" and similar expressions. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward looking statements due to a number of factors, including those set forth in Part I, A Item 1A, entitled "Risk Factors," of our Annual Report on Form 10-K for the year ended December 31, 2023, as updated and supplemented by Part II, A Item 1A, entitled "Risk Factors," of our Quarterly Reports on Form 10-Q, and elsewhere in this report. These factors as well as other cautionary statements made in this Quarterly Report on Form 10-Q, should be read and understood as being applicable to all related forward-looking statements wherever they appear herein. The forward-looking statements contained in this Quarterly Report on Form 10-Q represent our judgment as of the date hereof. We encourage you to read those descriptions carefully. We caution you not to place undue reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law. Such forward-looking statements are not guarantees of future performance and actual results will likely differ, perhaps materially, from those suggested by such forward-looking statements. In this report, "Cyclacel," the "Company," "we," "us," and "our" refer to Cyclacel Pharmaceuticals, Inc. Table of Contents Overview We are a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis control biology. We reported revenue of \$10,000 and \$43,000 for the three and nine months ended September 30, 2024, respectively, and revenues of \$16,000 and \$389,000 for the comparable three and nine months ended September 30, 2023, respectively. We do not expect to report a significant amount of revenue for the foreseeable future. Our primary focus has been on the development of our transcriptional regulation program, which is evaluating fadraciclib, a CDK2/9 inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating plogoseritib, a PLK1 inhibitor, in advanced cancers. We currently retain all marketing rights worldwide to the compounds associated with our drug programs. Fadraciclib Phase 1/2 Study In Advanced Solid Tumors and Lymphoma (065-101; NCT#04983810) In this ongoing study, a total of 47 heavily pretreated patients have been dosed in the Phase 1 part of the 065-101 study through eight dose levels. Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the study were presented at a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Patients received a median of four prior lines of therapy. Fadraciclib was generally well tolerated with good compliance between dose levels 1 and 5. The most common treatment related adverse events reported were nausea (66.0%), vomiting (46.8%), diarrhea (31.9%) fatigue (25.5%), and hyperglycemia (21.3%). A total of 25 drug-related serious adverse events (SAE) were reported in 8 patients. The most common SAEs reported were hyperglycemia (n=4), platelet count decrease (n=3), and accidental overdose (n=3). There were no drug-related SAEs at dose level 5 (100 mg bid, 5 days a week, for 4/4 weeks) which was selected for the Phase 2 proof of concept part of the 065-101 study. PKs were dose-proportional and exceeded the preclinical efficacy targets for both CDK2 and CDK9. PDs evaluated in peripheral blood showed suppression of CDKN2A/B by four hours post treatment in most patients who received 100 mg bid or higher. A total of 34 patients had measurable target lesions at baseline. Two partial responses were reported in patients with T-cell lymphoma, one of whom had CDKN2A loss. A squamous non-small cell lung (NSCLC) cancer patient with CDKN2A and CDKN2B loss achieved 22% reduction in tumor burden at 4 weeks per RECIST 1.1 criteria. In addition, clinical benefit was reported in two patients with endometrial cancer and one each with ovarian and pancreatic cancers. The primary objectives of the 065-101 study in the Phase 1 dose escalation stage are to determine maximum tolerated dose (MTD) and/or RP2D and in the Phase 2, Proof of Concept stage to evaluate preliminary efficacy of fadraciclib as measured by overall response rate (ORR). The secondary objectives in dose escalation are to assess safety and tolerability, pharmacokinetics, and ORR, while in Phase 2, Proof of Concept, to assess safety and tolerability, evaluate disease control rate (DCR), duration of response (DOR), progression free survival (PFS), and overall survival (OS). The study is utilizing a Simon two-stage optimal design to evaluate clinical activity. Exploratory objectives include investigation of clinical pharmacodynamics (PD) and pharmacogenomics (PGx). The Phase 2, part of the study is ongoing and two dose expansion cohorts are enrolling patients with mechanistically relevant biomarkers, including CDKN2A and/or CDKN2B mutation or deletion or T-cell lymphoma. Cohort 8 prospectively enrolled 12 patients with known CDKNAB genetic alterations between April and September 2024. The rationale was to further evaluate observations of clinical activity in Phase 1 patients with known CDKN2A or CDKN2B genetic alterations. Cohort 6 is enrolling patients with T-cell Lymphoma with two patients treated so far. The rationale was to further evaluate observations of partial response (PR) in 2/3 Phase 1 patients with T-cell lymphoma. Certain T-Cell lymphomas are known to harbor CDKN2A genetic alterations. All patients were treated with oral fadraciclib 100mg BID, M-F, week 1-4 in 28-day cycles which was the Recommended Phase 2 dose (RP2D). Table of Contents Interim data from the Phase 2 was presented as a poster at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain in October, 2024. The data showed that fadraciclib was well tolerated in Cohort 8. Most common drug-related adverse events included diarrhea, nausea, vomiting and were similar to those seen at this dose in Phase 1. There were no Grade 3 or higher treatment-emergent adverse events in the Phase 2 study thus far, consistent with the Phase 1 data. The majority of patients (12/14) had ECOG performance status of 1 and median number of prior therapies was 3. In Cohort 8, four patients had pancreatic cancer, and one each cholangiocarcinoma, duodenal, melanoma, cervical, laryngeal, ovarian, squamous cell cancer with unknown primary (CUP) and thymus cancer. Out of six patients evaluable for efficacy, two achieved stable disease; a melanoma patient whose treatment duration was 125 days and a squamous cell CUP patient who achieved 11% tumor shrinkage in the sum of all lesions on first scan with treatment duration of over 85 days (ongoing). Two additional patients with ovarian and laryngeal cancer are ongoing but have not had their first scan yet. The most common molecular characteristics of Cohort 8 patients were loss of function or deletion of CDKN2A and/or CDKN2B tumor suppressor genes. Other pharmacogenomic observations included CDKN2A/B, KRAS and/or TP53 mutations. Fadraciclib tablets can be given orally with repeat dosing which has led to transient suppression of anti-apoptosis proteins with generally good tolerability and no Grade 3 or higher hematological toxicity in the first cycle. We believe that fadraciclib's inhibition of CDK2 and CDK9 may be superior to inhibiting either CDK2 or CDK9 alone. Plogoseritib Phase 1/2 Study In Advanced Solid Tumors and Lymphoma (140-101; NCT#05358379) This open-label Phase 1/2 registration-directed study uses a streamlined design and initially seeks to determine the RP2D for single-agent oral plogoseritib in a dose

increase in cash used by operating activities was primarily the result of a decrease in net loss of \$9.1 million, brought about by a reduction in clinical trial supply and non-clinical activities, offset by a change in working capital of \$2.9 million. Investing activities Net cash used by investing activities remained inconsequential for each of the nine months ended September 30, 2024 and 2023 and consisted of IT-related capital expenditure in 2023.

Table of Contents

Financing activities Net cash provided by financing activities was \$6.2 million for the nine months ended September 30, 2024 as a direct result of receiving approximately \$6.2 million, net of expenses, from the issuance of common stock and warrants under a Securities Purchase Agreement with an institutional investor. Net cash used in financing activities was \$0.2 million for the nine months ended September 30, 2023 as a result of dividend payments of approximately \$0.2 million to the holders of our 6% Preferred Stock.

Funding Requirements and Going Concern We do not currently have sufficient funds to complete development and commercialization of any of our drug candidates. Current business and capital market risks could have a detrimental effect on the availability of sources of funding and our ability to access them in the future, which may delay or impede our progress of advancing our drugs currently in the clinical pipeline to approval by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for commercialization. Additionally, we plan to continue to evaluate in-licensing and acquisition opportunities to gain access to new drugs or drug targets that would fit with our strategy. Any such transaction would likely increase our funding needs in the future.

Our future funding requirements will depend on many factors, including but not limited to:

- the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities;
- the costs associated with establishing manufacturing and commercialization capabilities;
- the costs of acquiring or investing in businesses, product candidates and technologies;
- the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
- the costs and timing of seeking and obtaining FDA and EMA approvals;
- the effect of competing technological and market developments; and
- the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter.

Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. Although we are not reliant on institutional credit finance and therefore not subject to debt covenant compliance requirements or potential withdrawal of credit by banks, we are reliant on the availability of funds and activity in equity markets. We do not know whether additional funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or make changes to our operating plan, which may include ceasing operations altogether and/or filing for bankruptcy. In addition, we may have to partner one or more of our product candidate programs at an earlier stage of development, which would lower the economic value of those programs to us.

Since our inception, we have relied primarily on the proceeds from sales of common and preferred equity securities to finance our operations and internal growth. Additional funding has come through research and development tax credits, government grants, the sale of product rights, interest on investments, licensing revenue, royalty income, and a limited amount of product revenue from operations discontinued in September 2012. As discussed in Note 2 of the Notes to the Consolidated Financial Statements accompanying this Quarterly Report on Form 10-Q, under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the 26 Table of Contents financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. Our history of losses, our negative cash flows from operations, our liquidity resources currently on hand, and our dependence on the ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in our assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q. We are currently investigating ways to raise additional capital through private equity financing or by entering into a strategic transaction. In the event that we are not able to secure funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy. In such event, our stockholders may lose their entire investment in our company.

Results of Operations

Three and Nine Months Ended September 30, 2024 and 2023

Revenues We recognized \$10,000 and \$43,000 of revenue for the three and nine months ended September 30, 2024, respectively. This revenue is related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center. Revenues recognized for the three and nine months ended September 30, 2023 were approximately \$16,000 and \$389,000 respectively. The future We expect to completely fulfill our obligations under this agreement by the fourth quarter of 2024. The associated clinical manufacturing costs are presented as a component of research and development expenses.

Research and Development Expenses From our inception, we have focused on drug discovery and development programs, with a particular emphasis on orally available anticancer agents, and our research and development expenses have represented costs incurred to discover and develop novel small molecule therapeutics, including clinical trial costs for IND applications and Phase I/II studies. We have also incurred costs in the advancement of product candidates toward clinical and preclinical trials and the development of in-house research to advance our biomarker program and technology platforms. We expense all research and development costs as they are incurred. Research and development expenses primarily include:

- Clinical trial and regulatory-related costs;
- Payroll and personnel-related expenses, including consultants and contract research organizations;
- Preclinical studies, supplies and materials;
- Technology license costs;
- Stock-based compensation; and
- Rent and facility expenses for our offices.

Table of Contents

The following table provides information with respect to our research and development expenditures for the three and nine months ended September 30, 2024 and 2023 (in \$000s except percentages).

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Transcriptional Regulation (fadracilic)	\$884k	\$3,554k	(2,670)	(75)
Anti-mitotic (plogosertib)	\$4,128k	\$15,683k	(61)	(116)
Other research and development expenses	\$50k	\$142k	(135)	(65)
Total research and development expenses	\$5,062k	\$18,379k	\$(192)	\$(451)
Research and development expenses represented 56% and 76% of our operating expenses for the nine months ended September 30, 2024 and 2023 respectively.				

Research and development expenses decreased by \$9.9 million from \$15.6 million for the nine months ended September 30, 2023 to \$5.2 million for the nine months ended September 30, 2024. Expenditure for the transcriptional regulation program decreased by \$6.6 million relative to the respective comparative period, primarily due to decreases in manufacturing and non-clinical expenditure. Research and development expenses relating to plogosertib decreased by \$2.7 million relative to the respective comparative period due to decreases in manufacturing and non-clinical expenditure. The future We anticipate that overall research and development expenses for the year ended December 31, 2024 will decrease compared to the year ended December 31, 2023 as we do not expect to incur further manufacturing or preclinical costs. Expenditure will be primarily clinical trial costs related to our fadracilic Phase I/II study in advanced solid tumors and lymphomas.

General and Administrative Expenses General and administrative expenses include costs for administrative personnel, legal and other professional expenses and general corporate expenses. The following table summarizes the general and administrative expenses for the three and nine months ended September 30, 2024 and 2023 (in \$000s except percentages).

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Total general and administrative expenses	\$1,237k	\$3,688k	\$(24)	\$(444)
Total general and administrative expenses represented 44% and 24% of our operating expenses for the nine months ended September 30, 2024 and 2023 respectively.				

General and administrative expenses decreased by approximately \$0.3 million from \$4.8 million for the nine months ended September 30, 2023 to \$4.5 million for the nine months ended September 30, 2024, due largely to reduction in stock compensation expense.

Table of Contents

The future We expect general and administrative expenditures for the year ended December 31, 2024 to be lower than our expenditures for the year ended December 31, 2023, due to management efforts to lower costs across all departments.

Other (expense) income, net The following table summarizes other (expense) income, net for the three and nine months ended September 30, 2024 and 2023 (in \$000 except percentages).

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023							
Foreign exchange gains (losses)	\$2	\$104	\$(98)	\$(6)							
Interest (expense) income	\$(8)	\$(50)	\$(42)	\$(18)							
Other income (expense), net	\$(9)	\$(52)	\$(5)	\$(2)							
Total other (expense) income, net	\$(10)	\$(156)	\$(145)	\$(26)							
Total other income decreased by \$195,000 from \$235,000 for the nine months ended September 30, 2023 to \$40,000 for the nine months ended September 30, 2024. Other income for the nine months ended September 30, 2024 relates to royalties receivable under a December 2005 Asset Purchase Agreement, or APA, whereby Xcyte Therapies, Inc., or Xcyte (a business acquired by us in March 2006) sold certain assets and intellectual property to ThermoFisher Scientific Company, or TSC (formerly Invitrogen Corporation) through the APA and other related agreements. The assets and technology were not part of our product development plan following the transaction between Xcyte and Cyclacel in March 2006. Accordingly, we presented \$52,000 and \$50,000 as other income arising from royalties from the APA during each of the nine months ended September 30, 2024 and 2023 respectively. Foreign exchange gains (losses) Foreign exchange gains increased by \$64,000, from a loss of \$58,000 for the nine months ended September 30, 2023, to a gain of \$6,000 for the nine months ended September 30, 2024. The future Other income (expense), net for the year ended December 31, 2024, will continue to be impacted by changes in foreign exchange rates and the receipt of income under the APA. As we are not in control of sales made by TSC, we are unable to estimate the level and timing of income under the APA, if any. Because the nature of funding advanced through intercompany loans is that of a long-term investment, unrealized foreign exchange gains and losses on such funding will be recognized in other comprehensive income until repayment of the intercompany loan becomes foreseeable. Foreign exchange gains and losses relating to intercompany operating expenditure, which is expected to be settled in the foreseeable future, will be recognized within the statement of operations. Income Tax Benefit Credit is taken for research and development tax credits, which are claimed from the United Kingdom revenue and customs authority, or HMRC, in respect of qualifying research and development costs incurred. <p>Table of Contents</p> <p>The following table summarizes total income tax benefit for the three and nine months ended September 30, 2024 and 2023 (in \$000s except percentages).</p> <table border="1"><thead><tr><th></th><th>Three Months Ended September 30, 2024</th><th>Nine Months Ended September 30, 2024</th><th>Three Months Ended September 30, 2023</th><th>Nine Months Ended September 30, 2023</th></tr></thead><tbody><tr><td>Total income tax benefit</td><td>\$210k</td><td>\$668k</td><td>\$(69)</td><td>\$(1,976)</td></tr><tr><td>Total income tax benefit, decreased by approximately \$0.6 million, from \$2.6 million for the nine months ended September 30, 2023 to \$2.0 million for the nine months ended September 30, 2024. The level of tax credits recoverable is linked directly to qualifying research and development expenditure incurred in any one year and the availability of trading losses. The future We expect to continue to be eligible to receive United Kingdom research and development tax credits for the year ended December 31, 2024 and will continue to elect to receive payment of the tax credit. The amount of tax credits we will receive is entirely dependent on the amount of eligible expenses we incur and could be restricted by any future cap introduced by HMRC. Beyond 2024, we cannot be certain of our eligibility to receive this tax credit or if eligible, the amount that may be received, as a result of any future changes by HMRC to the eligibility criteria.<p>Table of Contents</p><p>Critical Accounting Policies and Estimates</p><p>Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023 and Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. There have been no material changes to our critical accounting policies during the nine months ended September 30, 2024.</p><p>Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, we are not required to provide information in response to this item.</p><p>Item 4. Controls and Procedures Under the supervision and with the participation of our management, including our chief executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of September 30, 2024, of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as</p></td></tr></tbody></table>		Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023	Total income tax benefit	\$210k	\$668k	\$(69)	\$(1,976)	Total income tax benefit, decreased by approximately \$0.6 million, from \$2.6 million for the nine months ended September 30, 2023 to \$2.0 million for the nine months ended September 30, 2024. The level of tax credits recoverable is linked directly to qualifying research and development expenditure incurred in any one year and the availability of trading losses. The future We expect to continue to be eligible to receive United Kingdom research and development tax credits for the year ended December 31, 2024 and will continue to elect to receive payment of the tax credit. The amount of tax credits we will receive is entirely dependent on the amount of eligible expenses we incur and could be restricted by any future cap introduced by HMRC. Beyond 2024, we cannot be certain of our eligibility to receive this tax credit or if eligible, the amount that may be received, as a result of any future changes by HMRC to the eligibility criteria. <p>Table of Contents</p> <p>Critical Accounting Policies and Estimates</p> <p>Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023 and Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. There have been no material changes to our critical accounting policies during the nine months ended September 30, 2024.</p> <p>Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, we are not required to provide information in response to this item.</p> <p>Item 4. Controls and Procedures Under the supervision and with the participation of our management, including our chief executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of September 30, 2024, of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as</p>
	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023							
Total income tax benefit	\$210k	\$668k	\$(69)	\$(1,976)							
Total income tax benefit, decreased by approximately \$0.6 million, from \$2.6 million for the nine months ended September 30, 2023 to \$2.0 million for the nine months ended September 30, 2024. The level of tax credits recoverable is linked directly to qualifying research and development expenditure incurred in any one year and the availability of trading losses. The future We expect to continue to be eligible to receive United Kingdom research and development tax credits for the year ended December 31, 2024 and will continue to elect to receive payment of the tax credit. The amount of tax credits we will receive is entirely dependent on the amount of eligible expenses we incur and could be restricted by any future cap introduced by HMRC. Beyond 2024, we cannot be certain of our eligibility to receive this tax credit or if eligible, the amount that may be received, as a result of any future changes by HMRC to the eligibility criteria. <p>Table of Contents</p> <p>Critical Accounting Policies and Estimates</p> <p>Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form 10-K for the year ended December 31, 2023 and Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. There have been no material changes to our critical accounting policies during the nine months ended September 30, 2024.</p> <p>Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, we are not required to provide information in response to this item.</p> <p>Item 4. Controls and Procedures Under the supervision and with the participation of our management, including our chief executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of September 30, 2024, of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as</p>											

[illegible]

[illegible]

[The following text contains extremely dense, non-readable symbols and characters, likely representing corrupted or encrypted data.]

[illegible]

link:calculationLink link:definitionLink 99902002—Disclosure—Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 999030403—Disclosure—Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 999030503—Disclosure—Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 999030703—Disclosure—Accrued and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 999030803—Disclosure—Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 999030903—Disclosure—Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 999031003—Disclosure—Stockholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 999040201—Disclosure—Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 999040301—Disclosure—Revenue (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 999040401—Disclosure—Net Loss Per Common Share—Schedule of Company's Potential Anti-Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 999040801—Disclosure—Leases—Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 999040901—Disclosure—Stock Based Compensation—Schedule of Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 999040902—Disclosure—Stock Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 999040903—Disclosure—Stock Based Compensation—Schedule of Fair Value of the Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 999040904—Disclosure—Stock Based Compensation—Schedule of Share Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 999040905—Disclosure—Stock Based Compensation—Schedule of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 999041001—Disclosure—Stockholders Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 999041002—Disclosure—Stockholders Equity—Amounts allocated to each instruments (Details) link:presentationLink link:calculationLink link:definitionLink 999041003—Disclosure—Stockholders Equity—Valuation assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 999041101—Disclosure—Subsequent Events—Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 995210601—Disclosure—Non Current Assets link:presentationLink link:calculationLink link:definitionLink 999040601—Disclosure—Non Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink EX-101-CAL 9 cyce-20240930-cal.xml EX-101-CAL EX-101-DEF 10 cyce-20240930-def.xml EX-101-DEF EX-101-LAB 11 cyce-20240930-lab.xml EX-101-LAB Document and Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Common Stock Preferred Stock Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag CONSOLIDATED BALANCE SHEETS Condensed Balance Sheet Statement [Table] 6% Convertible Exchangeable Preferred Stock Series A Convertible Preferred Stock Series B Convertible Preferred Stock Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Operating Lease, Right of Use Asset Right of use lease asset Deposits Assets, Noncurrent Non-current deposits Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued and other current liabilities Accrued and other current liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liability Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity (deficit): Preferred Stock, Value, issued Preferred stock, value Common Stock, Value, Issued Common stock, \$0.001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 2,152,202 shares issued and outstanding at September 30, 2024 and 1,058,892 shares issued and outstanding at December 31, 2023 Additional Paid in Capital Additional paid in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Stockholder's Equity Deficit Balance Balance Total stockholders' equity (deficit) Liabilities and Equity Total liabilities and stockholders' equity (deficit) Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Dividend Rate, Percentage Preferred stock, dividend rate (in percent) Dividend rate on convertible exchangeable preferred stock (in percent) Preferred Stock, Liquidation Preference, Value Preferred stock, liquidation-preference value (in dollars) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Statement [Table] Product and Service [Axis] Product and Service [Domain] Clinical trial supply revenue, Clinical Trial Supply [Member] Clinical trial supply Equity Components [Axis] Equity Component [Domain] Represents redeemable common shareholders Redeemable Common Stock [member] Redeemable common shareholders Revenues [Abstract] Revenues: Revenue from Contract with Customer, Including Assessed Tax Revenues Revenue Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development Selling, General and Administrative Expense General and administrative Operating Expenses, Total Total operating expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other (expense) income: Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange gains (losses) Amount before accretion (amortization) of purchase discount (premium) of interest income expense on nonoperating securities: Investment Interest income Expenses Interest (expense) income Other Nonoperating Income (Expense) Other income (expense), net Nonoperating Income (Expense) Total other (expense) income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total Loss before taxes Income Tax Expense (Benefit) Income tax benefit Net loss Net loss Loss for the period Preferred Stock Dividends, Income Statement Impact Dividend on convertible exchangeable preferred shares Net Income (Loss) Available to Common Stockholders, Diluted, Total Net loss applicable to common shareholders Net Loss per Common Share Basic and diluted earnings per common share: Earnings Per Share, Basic Net loss per share—basic Earnings Per Share, Diluted Net loss per share—diluted CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Translation adjustment Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax. If the entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. It includes gain (loss) on foreign exchange on intercompany loans. Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax Unrealized foreign exchange on intercompany loans Unrealized foreign exchange gain (loss) on intercompany loans Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total Comprehensive loss CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Additional Paid in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Shares, Issued Balance (in shares) Balance (in shares) The value of stock issued during the period upon conversion of pre-funded warrants in an offering, for issuance costs: Stock Issued During Period, Value, Upon Conversion Of Pre-Funded Warrants In An Offering, Issuance Costs Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering Number of shares issued during the period upon conversion of pre-funded warrants in an offering for issuance costs. Stock Issued During Period, Shares, Upon Conversion Of Pre-Funded Warrants In An Offering, Issuance Costs Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering (in shares) The value of stock issued during the period upon conversion of pre-funded warrants in an offering, net of issuance costs. Stock Issued During Period, Value, Upon Conversion Of Pre-Funded Warrants In An Offering, Net Of Issuance Costs Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses Number of shares issued during the period upon conversion of pre-funded warrants in an offering net of issuance costs Stock Issued During Period, Shares, Upon Conversion Of Pre-Funded Warrants In An Offering, Net Of Issuance Costs Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses (in shares) Represents amount related to Issue of common stock on At Market Issuance sales agreement. Stock Issued During Period, Value, At Market Issuance Sales Agreement Issue of common stock in At Market Issuance sales agreement, net of expenses Represents shares related to Issue of common stock on At Market Issuance sales agreement. Stock Issued During Period, Shares, At Market Issuance Sales Agreement Issue of common stock in At Market Issuance sales agreement, net of expenses (in shares) Stock Issued During Period, Shares, New Issues Number of shares issued (in shares) Adjustment to retained earnings for the increase in carrying amount of redeemable common stock that is classified as temporary equity. Increase in Carrying Amount of Redeemable Common Stock Reclassification of redeemable common stock Number of shares of stock reclassified to temporary equity during the period. Reclassification of redeemable common stock, Shares Reclassification of redeemable common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Series B Preferred stock conversions (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Expenses related to Securities Purchase Agreement In Private Placement Number of shares issued as a result of the exercise of warrants. Stock Issued During Period Shares Stock Warrants Exercised Warrant Exercises (in shares) Exercise of pre-funded warrants (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Stock-based compensation (in shares) Adjustments To Additional Paid In Capital Preferred Stock Conversion Preferred stock dividends CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation Share-based Compensation Stock-based compensation Changes In Lease Liability Changes in lease liability Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable and Other Operating Liabilities Accounts payable, accrued and other current liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property, plant and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: The cash inflow from issuance of common stock and warrant exercises, net of issuance costs. Proceeds from Issuance of Common Stock and Warrant Exercises, Net of Issuance Costs Proceeds from issuing common stock and pre-funded warrants, net Payments of Ordinary Dividends, Preferred Stock and Preference Stock Payment of preferred stock dividend Net Cash Provided by (Used in) Financing Activities Net cash provided by (used) in financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Supplemental Cash Flow Elements [Abstract] Cash received during the period for: Proceeds from Interest Received Interest Proceeds from Income Tax Refunds Research & development tax credits Income Taxes Paid, Net [Abstract] Cash paid during the period for: Income Taxes Paid, Net Taxes Non-cash financing activities: Non-cash financing activities: Represents amount of accrual of preferred stock dividends. Accrual Of Preferred Stock Dividends Accrual of preferred stock dividends Company Overview Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Company Overview Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Revenue Revenue from Contract with Customer [Text Block] Revenue Earnings Per Share [Text Block] Net Loss per Common Share Prepaid Expenses and Other Current Assets This element represent as Prepaid Expenses and Other Current Assets. Prepaid Expenses and Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets N/A Non-Current Assets Entire disclosure for non-current assets. Non-Current Assets [Text Block] Non-Current Assets Accrued and Other Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued and Other Liabilities Leases Lessee, Operating Leases [Text Block] Leases Stock-based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Based Compensation Stockholders Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders Equity Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Represents policy disclosure related to Going Concern. Going Concern [Policy Text Block] Going Concern Represent recently issued accounting pronouncements. Recently Issued Accounting Pronouncements [Policy Text Block] Recently Issued Accounting Pronouncements Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency and Currency Translation Lessee, Leases [Policy Text Block] Leases Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Basic and Diluted Net Loss Per Share Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued and Other Liabilities Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Stock Based Compensation Expense Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Fair Value of the Stock Options Granted Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share Option Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Restricted Stock Units Activity Schedule of Stock by Class [Table] Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to april 2024, securities purchase agreement. April 2024, Securities Purchase Agreement [Member] April 2024 Securities Purchase Agreement December 2023 Securities Purchase Agreement December 2023 Securities Purchase Agreement [Member] December 2023 Securities Purchase Agreement Class of Stock [Line Items] Tabular disclosure of each instruments issued in an offering and their classification as part of shareholders equity. Schedule of Instruments Issued in an Offering and their Classification Under Shareholders Equity [Table Text Block] Schedule of fair values of instruments issued in an offering Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of fair value of warrants valuation assumption Substantial Doubt about Going Concern, within One Year [true-false] Substantial Doubt about Going Concern, within One Year Other Comprehensive Income (Loss), Tax Tax on other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassifications out of other comprehensive income (loss) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock options Restricted Stock Units (RSUs) Information of common stock warrant. Common Stock Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total shares excluded from calculation Total shares excluded from calculation Prepaid Expenses and Other Current Assets [Abstract] Deferred Income Taxes and Other Tax Receivable, Current Research and development tax credit receivable Represents the amount of current prepayments and value added tax receivable. Prepayments And Value Added Tax Receivable Current Prepayments and VAT receivable Other Assets, Current Other current assets Represents the value of deposits held by a third-party but considered an asset to the Company. Deposits Held By Related Party Clinical trial deposits held by a contract research organization Represents the carrying value, as of the balance sheet date, of obligations incurred through that date and payable arising from research and development transactions: Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research and Development Costs Current Accrued research and development Accrued Professional Fees, Current Accrued legal and professional fees Other Accrued Liabilities, Current Other current liabilities Geographical [Axis] Geographical [Domain] Berkeley Heights Facility [Member] Berkeley Heights Facility [Member] Berkeley Heights facility Represents information pertaining to Dundee, Scotland. Dundee facility Operating Lease, Expense Operating lease expense Operating Lease, Payments Operating lease, payments Operating Lease, Weighted Average Remaining Lease Term Remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Discount rate lease liability Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract] Operating Lease Obligation Lessee,

Operating Lease, Liability, Payments, Remainder of Fiscal Year2024 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months2025 Amount of Lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).Lessee Operating Lease Liability Payments Due After Year TwoThereafter Lessee, Operating Lease, Liability, Payments, DueTotal future minimum lease obligation Lessee, Operating Lease, Liability, Undiscounted Excess AmountLess discount Operating Lease, LiabilityTotal Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] General and administrative Research and development Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Allocated Share-based Compensation ExpenseStock-based compensation costs before income taxes Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Information about plan name.2018 Equity Incentive Plan (the "2018 Plan") [Member]2018 Plan Represents information pertaining to inducement equity incentive plan 2020.Inducement Equity Incentive Plan 2020 [Member]Inducement Plan Scenario [Axis] Scenario, Unspecified [Domain] Options Vesting On Third Anniversary Of Grant.Options Vesting On Third Anniversary Of Grant [Member]Options Vesting On Third Anniversary Of Grant Range [Axis] Range [Domain] Minimum Maximum Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares AuthorizedNumber of authorized shares Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares AuthorizedNumber of additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for GrantNumber of shares reserved for issuance Share-based Compensation Arrangement by Share-based Payment Award, Expiration PeriodLife of stock option awards granted Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting PeriodStock awards vesting period Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, GrossGrantedOptions granted (in shares) Represents the grant date fair value of options granted during the reporting period.Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Grant Date Fair ValueOptions granted, grant date fair value Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock OptionsRemaining unrecognized compensation cost of non-vested stock options Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for RecognitionWeighted average remaining requisite service period of recognition of unrecognized compensation cost Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in PeriodOptions exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in PeriodGrantedRestricted Stock Units, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueRestricted stock units, grant date fair valueRestricted stock units, grant date fair value Share Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service PeriodVesting period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodCancelled/forfeitedShares forfeited The number of additional equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period, AdditionsAdditional shares forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueGranted Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected TermExpected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest RateRisk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility RateVolatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend RateExpected dividend yield over expected term Share Based Compensation Arrangement By Share-Based Payment Award Options Grants In Period Weighted Average Grant Date Cumulative Fair Value.Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Cumulative Fair ValueResulting weighted average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]Number of Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, NumberOptions outstandingOptions outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in PeriodCancelled/forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning BalanceUnvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, NumberVested and exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]Weighted Average Exercise Price Per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise PriceOptions outstandingOptions outstanding Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceGranted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise PriceExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise PriceCancelled/forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price, Beginning BalanceUnvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise PriceVested and exercisable Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]Weighted Average Remaining Contractual Term (Years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermOptions outstanding Weighted average remaining contractual term for unvested options, in "PnYnMnDtHnHnMnS" format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days.Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Remaining Contractual TermUnvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual TermVested and exercisable Number of Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, NumberRestricted Stock Units outstanding, Ending balanceRestricted Stock Units outstanding, Beginning balance The number of unvested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Unvested, NumberUnvested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in PeriodVested Weighted Average Grant Date Value Per Share N/A.Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Remaining Term [Abstract]Weighted Average Remaining Term Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual TermsRestricted stock units, Weighted average remaining term Weighted average remaining contractual term for equity-based awards excluding options, unvested, in "PnYnMnDtHnHnMnS" format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days.Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Unvested, Weighted Average Remaining Contractual TermsUnvested Weighted average remaining contractual term for equity-based awards excluding options, vested and exercisable, in "PnYnMnDtHnHnMnS" format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days.Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Exercisable, Weighted Average Remaining Contractual TermsVested Counterparty Name [Axis] Counterparty Name [Domain] Cantor Fitzgerald & Co. [Member]Cantor Fitzgerald & Co. [Member]Cantor Fitzgerald & Co. Co-Placement Agents [Member]Co-Placement Agents [Member]Co-Placement Agents Represents information pertaining to Roth Capital Partners, LLCRoth Capital Partners, LLC [Member]Roth Capital Partners, LLC Represents information pertaining to Ladenburg Thalmann & Co. Inc.Ladenburg Thalmann & Co. Inc [Member]Ladenburg Thalmann & Co. Inc Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Pre-funded warrantsPre Funded Warrants [Member]Pre Funded Warrants Placement Agent WarrantsPlacement Agent Warrants [Member]Placement Agent Warrants Represents information pertaining to pre-funded warrants and common warrants.Pre Funded Warrants and Common Warrants [Member]Pre-funded warrants and common warrants Represents information pertaining to series A warrants.Series A Warrants [Member]Series A warrants Represents information pertaining to series B warrants.Series B Warrants [Member]Series B Warrants Represents information relating to August 2021 Controlled Equity Offering Sales Agreement.August 2021 Controlled Equity Offering Sales Agreement [Member]August 2021 Controlled Equity Offering Sales Agreement December 2023 Private PlacementDecember 2023 Private Placement [Member]December 2023 Private Placement December 2020 Warrants December 2020 Warrants [Member]December 2020 Warrants Represent information pertains to December 2020 Warrants.December 2020 Warrants [Member]December 2020 Warrants Represent information pertains to April 2024 Warrants.April 2024 Warrants [Member]April 2024 Warrants December 2023 Insider Private PlacementDecember 2023 Insider Private Placement [Member]December 2023 Insider Private Placement December 2023 Placement Agency AgreementDecember 2023 Placement Agency Agreement [Member]December 2023 Placement Agency Agreement Title of Individual [Axis] Relationship to Entity [Domain] Chief Executive Officer [Member]Chief Executive Officer Chief Financial Officer And Chief Operating OfficerChief Financial Officer And Chief Operating Officer [Member]Chief Financial Officer and Chief Operating Officer Proceeds from further issuance of shareAggregate offering price Class of Warrant or Right, Number of Securities Called by Warrants or RightsWarrants to purchase shares Number of warrants or rights exercisable.Class Of Warrant Or Rights, ExercisableExercisable warrants Sale of Stock, Number of Shares Issued in TransactionNumber of share sold under the sales agreement Warrants and Rights Outstanding, TermWarrant outstanding Term Warrants and Rights OutstandingAggregate fair value Warrants Class of Warrant or Right, Exercise Price of Warrants or RightsWarrants, exercise price per share The gross amount of proceeds from issuance of common stock.Proceeds from issuance of Common Stock, GrossProceeds from issuance of common stock, gross Amount of Shares reclassified to outside equity.Reclassification of Common Stock, ValueAggregate purchase price Shares Issued, Price Per ShareShare issue price per share Class of Warrant or Right, Number of Securities Called by Each Warrant or RightNumber of warrant to purchase each share of our common stock Percentage of outstanding common stock Percentage Of Outstanding Common StockPercentage of outstanding common stock Proceeds from Issuance or Sale of EquityGross proceeds Percentage of outstanding common stock at the election of purchaser, immediately following the consummation of the public offering.Percentage of Outstanding Common Stock, at Election of PurchaserOutstanding common stock at election of purchaser Class of Warrant or Right, OutstandingWarrants outstanding Represents total proceeds received life-to-date through the sale of stock Aggregate Proceeds From Sale Of StockTotal gross proceeds received Number of warrants or rights exercised during the period.Class of Warrant or Right, ExercisedWarrants exercised Preferred Stock, Convertible, Conversion RatioPreferred stock conversion ratio Convertible Preferred Stock, Shares Issued upon ConversionNumber of common shares issued upon conversion Conversion of Stock, Shares ConvertedNumber of shares converted Represents the number of securities equivalent price per share called by each warrant.Number Of Securities Equivalent Price Per Share Called By Each Warrant Or RightPrice per share used to determine number of shares of common stock Convertible Preferred Stock, Conversion PriceConversion price of convertible preferred stock Represents the percentage of conversion price.Convertible Preferred Stock, Conversion PercentageConversion percentage Share Price The number of consecutive trading days used as the measurement period in determining whether specified triggers are met which would allow the entity to require the conversion of all or part of outstanding preferred stock.Conversion Trigger, Measurement PeriodMeasurement period of consecutive trading days used in determining whether specified triggers are met which would allow the entity to require the conversion of all or part of outstanding preferred stock Percentage by which the weighted average price of common stock during the measurement period exceeds the initial conversion price which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted.Conversion Trigger, Percentage of Weighted Average Common Stock Price During Measurement Period in Excess of Initial Conversion PricePercentage by which the weighted average price of common stock during the measurement period exceeds the initial conversion price which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted.Threshold amount of daily trading volume on each trading day during the measurement period which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted.Conversion Trigger, Threshold of Daily Trading Volume During Measurement PeriodThreshold amount of daily trading volume on each trading day during the measurement period which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted Notice period from the holder to increase the percentage of ownership of outstanding common stock after exercise of warrants Notice Period from Holder to Increase Ownership PercentageNotice period from the holder to increase the percentage of ownership of outstanding common stock after exercise of warrants Number of fractional shares issued during period.Stock Issued During Period, Shares, FractionalFractional shares issued Shares reclassified to outside equity.Reclassification of Common Stock, SharesReclassified shares The number of shares of reclassified common stock for which no proceeds were received.Reclassification Of Common Stock, Shares, No Proceeds ReceivedReclassified shares for which no proceeds were received Represents the percentage of blocker provision.Convertible Preferred Stock, Conversion Percentage, Blocker ProvisionPercentage of blocker provision Preferred Stock, Liquidation Preference Per ShareLiquidation preference (in dollars per share) Dividends PayableAccrued and unpaid dividends Common Stock, Capital Shares Reserved for Future IssuanceShares reserved for future issuance upon conversion Represents the percentage of the closing sales price of the entity's common stock for at least 20 days within 30 trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the preferred stock to be convertible.Preferred Stock Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion PricePercentage of closing sales price of common stock that conversion price must exceed in order for preferred stock to be convertible Represents the number of trading days within a period of 30 consecutive trading days the closing price of the entity's common stock must exceed the applicable price in order for the preferred stock to be convertible.Preferred Stock Conversion Obligation Common Stock Closing Sales Price Number of Trading DaysNumber of trading days within 30 trading days in which the closing price of common stock must exceed conversion price for preferred stock to be convertible Represents the number of trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the preferred stock to be convertible.Preferred Stock Conversion Obligation Number of Trading DaysNumber of trading days during which closing price of common stock must exceed conversion price for at least 20 days in order for the preferred stock to be convertible Represents the number of trading days within 30-day trading period required to be ended prior to notice of automatic conversion.Preferred Stock Conversion Obligation Thirty Day Trading Period Ending within Number of Trading Days Prior to Notice of Automatic ConversionNumber of trading days prior to notice of automatic conversion Preferred Stock, Redemption Price Per ShareRedemption price per share (in dollars per share) Represents the unit of measurement in dollars which establishes the exchange rate of the preferred stock into debt.Preferred Stock Exchange Rate Principal Amount of Notes Used in CalculationDebt principal amount per share, basis for exchange (in dollars per share) Debt Instrument, TermDebt instrument, term Cash placement fee as a percentage of gross proceeds raised in offerings.Cash Placement Fee PercentageCash placement fee, percentage of gross proceeds raised Management fee as a percentage of gross proceeds raised in offerings.Management fee Percentage to the Aggregate Gross ProceedsManagement fee percentage Compensation amount as a percentage of the aggregate gross proceeds raised in the offering.Compensation Percentage to the Aggregate Gross ProceedsPercentage of compensation raised Professional FeesPlacement agent fees Regular Warrants warrantsRegular Warrants [Member]Regular Warrants Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Price Volatility [Member]Expected volatility Measurement Input, Expected Term [Member]Contractual term Measurement Input, Risk Free Interest Rate [Member]Risk free interest rate Measurement Input, Expected Dividend Rate [Member]Expected dividend yield Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement InputWarrants and rights outstanding Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent event Subsequent Event [Line Items] EX-101.PRE-12-cycc-20240930_pre.xml EX-101.PRE XML 14-R1.htm IDEA: XBRL DOCUMENT

Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	000-50626
Entity Registrant Name	Cyclacel Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	91-1707622
Entity Address, Address Line One	200 Connell Drive
Entity Address, Address Line Two	Suite 1500
Entity Address, City or Town	Berkeley Heights
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07922
City Area Code	908
Local Phone Number	517-7330
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	6,287,205
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001130166
Amendment Flag	false

Common Stock	
Document Information [Line Items]	
Title of 12(b) Security	Common Stock, par value \$0.001 per share
Trading Symbol	CYCC
Security Exchange Name	NASDAQ
Preferred Stock	

Document Information [Line Items]	
Title of 12(b) Security	Preferred Stock, \$0.001 par value
Trading Symbol	CYCCP
Security Exchange Name	NASDAQ

XML 15 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD (\$) \$ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	\$ 2,982	\$ 3,378
Prepaid expenses and other current assets	1,931	4,066
Total current assets	4,913	7,444
Property and equipment, net	4	9
Right-of-use lease asset	51	93
Non-current deposits	413	1,259
Total assets	5,381	8,805
Current liabilities:		
Accounts payable	4,126	3,543
Accrued and other current liabilities	2,225	4,618
Total current liabilities	6,351	8,161
Lease liability	0	37
Total liabilities	6,351	8,198
Stockholders' equity (deficit):		
Common stock, \$0.001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 2,152,202 shares issued and outstanding at September 30, 2024 and 1,058,892 shares issued and outstanding at December 31, 2023	2	1
Additional paid-in capital	436,503	429,796
Accumulated other comprehensive loss	(1,033)	(908)
Accumulated deficit	(436,442)	(428,282)
Total stockholders' equity (deficit)	(970)	607
Total liabilities and stockholders' equity (deficit)	5,381	8,805
6% Convertible Exchangeable Preferred Stock		
Stockholders' equity (deficit):		
Preferred stock, value	0	0
Series A Convertible Preferred Stock		
Stockholders' equity (deficit):		
Preferred stock, value	0	0
Series B Convertible Preferred Stock		
Stockholders' equity (deficit):		
Preferred stock, value	\$ 0	\$ 0

XML 16 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD (\$)	9 Months Ended Sep. 30, 2024	12 Months Ended Dec. 31, 2023
Preferred stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Dividend rate on convertible exchangeable preferred stock (in percent)	6.00%	
Common stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,152,202	1,058,892
Common stock, shares outstanding	2,152,202	1,058,892
6% Convertible Exchangeable Preferred Stock		
Preferred stock, shares issued	335,273	335,273
Preferred stock, shares outstanding	335,273	335,273
Dividend rate on convertible exchangeable preferred stock (in percent)	6.00%	6.00%
Preferred stock, liquidation preference value (in dollars)	\$ 4,157,385	\$ 4,157,385
Series A Convertible Preferred Stock		
Preferred stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Preferred stock, shares issued	264	264
Preferred stock, shares outstanding	264	264
Series B Convertible Preferred Stock		
Preferred stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Preferred stock, shares issued	0	119,000
Preferred stock, shares outstanding	0	119,000

XML 17 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED	3 Months Ended	9 Months Ended
--------------	----------------	----------------

STATEMENTS OF OPERATIONS - USD (\$)	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:					
Revenues	\$ 10,000		\$ 16,000	\$ 43,000	\$ 389,000
Operating expenses:					
Research and development	950,000		5,236,000	5,775,000	15,637,000
General and administrative	1,237,000		1,625,000	4,444,000	4,845,000
Total operating expenses	2,187,000		6,861,000	10,219,000	20,482,000
Operating loss	(2,177,000)		(6,845,000)	(10,176,000)	(20,093,000)
Other (expense) income:					
Foreign exchange gains (losses)	2,000		104,000	6,000	(58,000)
Interest (expense) income	8,000		50,000	(18,000)	243,000
Other income (expense), net			(9,000)	52,000	50,000
Total other (expense) income, net	10,000		145,000	40,000	235,000
Loss before taxes	(2,167,000)		(6,700,000)	(10,136,000)	(19,858,000)
Income tax benefit	210,000		668,000	1,976,000	2,574,000
Net loss	(1,957,000)	\$ (3,257,000)	(6,032,000)	(8,160,000)	(17,284,000)
Dividend on convertible exchangeable preferred shares			(50,000)		(151,000)
Net loss applicable to common shareholders	\$ (1,957,000)		\$ (6,082,000)	\$ (8,160,000)	\$ (17,435,000)
Redeemable common shareholders					
Basic and diluted earnings per common share:					
Net loss per share - basic			\$ (0.48)		\$ (1.39)
Net loss per share - diluted	\$ 0.00		(0.48)	\$ 0.00	(1.39)
Common Stock					
Basic and diluted earnings per common share:					
Net loss per share - basic	\$ (0.18)		(0.48)	(2.04)	(1.39)
Net loss per share - diluted		\$ (0.18)	\$ (0.48)	\$ (2.04)	\$ (1.39)
Clinical trial supply					
Revenues:					
Revenues	\$ 10,000		\$ 16,000	\$ 43,000	\$ 389,000

XML 18 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD (\$) \$ in Thousands	3 Months Ended	9 Months Ended		
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS				
Net loss	\$ (1,957)	\$ (6,032)	\$ (8,160)	\$ (17,284)
Translation adjustment	(14,586)	8,571	(12,967)	(2,050)
Unrealized foreign exchange gain (loss) on intercompany loans	14,468	(8,642)	12,842	2,198
Comprehensive loss	\$ (2,075)	\$ (6,103)	\$ (8,285)	\$ (17,136)

XML 19 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) - USD (\$) \$ in Thousands		Preferred Stock	Common Stock	Additional Paid- in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2022			\$ 1	\$ 422,981	\$ (1,316)	\$ (405,727)	\$ 15,939
Balance (in shares) at Dec. 31, 2022	573,282	628,139					
Stock-based compensation				401			401
Preferred stock dividends				(50)			(50)
Unrealized foreign exchange on intercompany loans					5,263		5,263
Translation adjustment					(5,171)		(5,171)
Loss for the period						(5,804)	(5,804)
Balance at Mar. 31, 2023			\$ 1	423,332	(1,224)	(411,531)	10,578
Balance (in shares) at Mar. 31, 2023	573,282	628,139					
Balance at Dec. 31, 2022			\$ 1	422,981	(1,316)	(405,727)	15,939
Balance (in shares) at Dec. 31, 2022	573,282	628,139					
Unrealized foreign exchange on intercompany loans							2,198
Translation adjustment							(2,050)
Loss for the period							(17,284)
Balance at Sep. 30, 2023			\$ 1	428,475	(1,168)	(423,011)	4,297
Balance (in shares) at Sep. 30, 2023	573,282	842,854					
Balance at Mar. 31, 2023			\$ 1	423,332	(1,224)	(411,531)	10,578
Balance (in shares) at Mar. 31, 2023	573,282	628,139					
Issue of common stock in At Market Issuance sales agreement, net of expenses				1,105			1,105
Issue of common stock in At Market Issuance sales agreement, net of expenses (in shares)			53,213				
Stock-based compensation				359			359
Preferred stock dividends				(50)			(50)
Unrealized foreign exchange on intercompany loans					5,577		5,577
Translation adjustment					(5,450)		(5,450)
Loss for the period						(5,448)	(5,448)
Balance at Jun. 30, 2023			\$ 1	424,746	(1,097)	(416,979)	6,671
Balance (in shares) at Jun. 30, 2023	573,282	681,352					
Reclassification of redeemable common stock				3,389			3,389
Reclassification of redeemable common stock (in shares)			154,593				
Stock-based compensation				390			390
Stock-based compensation (in shares)			6,909				
Preferred stock dividends				(50)			(50)
Unrealized foreign exchange on intercompany loans					(8,642)		(8,642)
Translation adjustment					8,571		8,571
Loss for the period						(6,032)	(6,032)
Balance at Sep. 30, 2023			\$ 1	428,475	(1,168)	(423,011)	4,297
Balance (in shares) at Sep. 30, 2023	573,282	842,854					
Balance at Dec. 31, 2023			\$ 1	429,796	(908)	(428,282)	607
Balance (in shares) at Dec. 31, 2023	454,537	1,058,892					
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering				(80)			(80)
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering (in shares)			219,700				
Series B Preferred stock conversions (in shares)		(119,000)	39,667				
Stock-based compensation				203			203
Unrealized foreign exchange on intercompany loans					(2,130)		(2,130)
Translation adjustment					2,140		2,140
Loss for the period						(2,946)	(2,946)
Balance at Mar. 31, 2024			\$ 1	429,919	(898)	(431,228)	(2,206)
Balance (in shares) at Mar. 31, 2024	335,537	1,318,259					

Balance at Dec. 31, 2023		\$ 1	429,796	(908)	(428,282)	607
Balance (in shares) at Dec. 31, 2023	454,537	1,058,892				
Unrealized foreign exchange on intercompany loans						12,842
Translation adjustment						(12,967)
Loss for the period						(8,160)
Balance at Sep. 30, 2024		\$ 2	436,503	(1,033)	(436,442)	(970)
Balance (in shares) at Sep. 30, 2024	335,537	2,152,204				
Balance at Mar. 31, 2024		\$ 1	429,919	(898)	(431,228)	(2,206)
Balance (in shares) at Mar. 31, 2024	335,537	1,318,259				
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses		\$ 1	6,289			6,290
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses (in shares)		486,945				
Stock-based compensation			189			189
Unrealized foreign exchange on intercompany loans				504		504
Translation adjustment				(521)		(521)
Loss for the period					(3,257)	(3,257)
Balance at Jun. 30, 2024		\$ 2	436,397	(915)	(434,485)	999
Balance (in shares) at Jun. 30, 2024	335,537	1,805,204				
Expenses related to Securities Purchase Agreement In Private Placement			(1)			(1)
Exercise of pre-funded warrants (in shares)		347,000				
Stock-based compensation			107			107
Unrealized foreign exchange on intercompany loans				14,468		14,468
Translation adjustment				(14,586)		(14,586)
Loss for the period					(1,957)	(1,957)
Balance at Sep. 30, 2024		\$ 2	\$ 436,503	\$ (1,033)	\$ (436,442)	\$ (970)
Balance (in shares) at Sep. 30, 2024	335,537	2,152,204				

XML-20-R7.htm IDEA: XBRL DOCUMENT

	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD (\$)		
\$ in Thousands		
Operating activities:		
Net loss	\$ (8,160)	\$ (17,284)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	5	23
Stock-based compensation	499	1,151
Changes in lease liability	(37)	(55)
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	3,129	3,364
Accounts payable, accrued and other current liabilities	(2,070)	599
Net cash used in operating activities	(6,634)	(12,202)
Investing activities:		
Purchase of property, plant and equipment	0	(6)
Net cash used in investing activities	0	(6)
Financing activities:		
Proceeds from issuing common stock and pre-funded warrants, net	6,209	0
Payment of preferred stock dividend	0	(151)
Net cash provided by (used) in financing activities	6,209	(151)
Effect of exchange rate changes on cash and cash equivalents	29	(42)
Net increase (decrease) in cash and cash equivalents	(396)	(12,401)
Cash and cash equivalents, beginning of period	3,378	18,345
Cash and cash equivalents, end of period	2,982	5,944
Cash received during the period for:		
Interest	59	243
Research & development tax credits	3,715	4,846
Cash paid during the period for:		
Taxes	2	2
Non cash financing activities:		
Accrual of preferred stock dividends	\$ 0	\$ 50

XML-21-R8.htm IDEA: XBRL DOCUMENT

Company Overview		9 Months Ended Sep. 30, 2024	
Company Overview Company Overview			
1.	Company Overview		
Nature of Operations			
Cyclacel Pharmaceuticals, Inc. ("Cyclacel" or the "Company") is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis control biology. Cyclacel is a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient's overall survival.			
Through September 30, 2024, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.			

XML-22-R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2024

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated balance sheet as of September 30, 2024, the consolidated statements of operations, comprehensive loss, and stockholders’ equity (deficit) for the three and nine months ended September 30, 2024 and 2023 and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2024. The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of September 30, 2024, and the results of operations, comprehensive loss, and changes in stockholders’ equity (deficit) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024, have been made. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 that are included in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2024.

Going Concern

Pursuant to the requirements of Accounting Standard Codification (ASC) 205-40, *Presentation of Financial Statements-Going Concern*, management is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern for one year after the date that these financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipts of potential funding

from future equity or debt issuances or by entering into partnership agreements cannot be considered probable at this time because these plans are not entirely within the Company’s control nor have they been approved by the Board of Directors as of the date of these consolidated financial statements.

Based on the Company’s current operating plan, it is anticipated that cash and cash equivalents of \$3.0 million as of September 30, 2024, will allow it to meet its liquidity requirements into the fourth quarter of 2024. The Company’s history of losses, negative cash flows from operations, liquidity resources currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.

On August 26, 2024, the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company was not in compliance with the Nasdaq Listing Rule 5550(b) (1) (the “Equity Rule”) because the Company reported stockholders’ equity of less than \$2.5 million as of June 30, 2024. The notice from the Staff further stated that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”), the Company’s securities would be subject to delisting. As of September 30, 2024, the Company has a stockholders equity deficit of approximately \$0.97 million which is not in compliance with the Equity Rule. On October 15, 2024, the Company met with the Panel regarding the Company’s potential delisting from Nasdaq as a result of its violation of the Equity Rule. On October 22, 2024, the Company received the Panel’s decision which granted the Company until December 24, 2024 to regain compliance with the Equity Rule and all applicable criteria for continued listing on Nasdaq. If the Company is unable to regain compliance with the listing standards of the Nasdaq Capital Market by December 24, 2024, the Company’s securities may be delisted from Nasdaq.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business.

Recently Issued Accounting Pronouncements

The FASB has issued ASU 2023-07, “Segment Reporting (Topic 280)”. This standard will require all public entities – even those like the Company that have a single reportable segment – to disclose additional information about the title and position of the Chief Operating Decision Maker (“CODM”), the measure or measures of segment profit and loss used by the CODM in assessing segment performance and deciding how to allocate resources, an explanation of how the CODM uses the reported measure(s) in assessing segment performance, significant segment expenses that are regularly provided to the CODM, and a reconciliation of segment profit and loss to the closest consolidated totals prepared under United States GAAP. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 will not change the way in which reportable segments are determined. However, the Company is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.

The FASB has issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This standard will require all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation of that information.

Fair Value of Financial Instruments

Financial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.

Comprehensive Income (Loss)

All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three and nine months ended September 30, 2024 and 2023.

Foreign Currency and Currency Translation

Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable future.

The assets and liabilities of the Company’s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that are of a long-term-investment nature, are recorded in other comprehensive loss.

Leases

The Company accounts for lease contracts in accordance with ASC 842. As of September 30, 2024, the Company’s outstanding leases are classified as operating leases.

The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company’s obligation to make lease payments under the lease. As the Company’s leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company’s credit risk.

The Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:

- The lease payments due in any optional period;
- Penalties for failure to exercise (or not exercise) the option;
- Market factors, such as the availability of similar assets and current rental rates for such assets;
- The nature of the underlying leased asset and its importance to the Company’s operations; and
- The remaining useful lives of any related leasehold improvements.

Lease expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.

The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.

Revenue Recognition

When the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, *Revenue from Contracts with Customers* (“ASC 606”):

- (1) identify the contract with a customer;
- (2) identify the performance obligations in the contract;
- (3) determine the transaction price;
- (4) allocate the transaction price to the performance obligations in the contract; and
- (5) recognize revenue when, or as, the Company satisfies a performance obligation.

The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers:

- Whether achievement of a development milestone is highly susceptible to factors outside the entity’s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies;
- Whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;
- Whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and
- The complexity and inherent uncertainty underlying the achievement of the milestone.

The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.

The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.

The Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.

Grant revenue received from organizations that are not the Company’s customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses.

XML 23 R10.htm IDEA: XBRL DOCUMENT

Revenue		9 Months Ended Sep. 30, 2024	
Revenue			
Revenue	3.	Revenue	
The Company recognized \$10,000 and \$43,000 of revenue for the three and nine months ended September 30, 2024 respectively. This revenue is related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center. Revenues recognized for the three and nine months ended September 30, 2023 were \$16,000 and \$389,000 respectively.			

XML 24 R11.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share		9 Months Ended Sep. 30, 2024	
Net Loss per Common Share			
Net Loss per Common Share	4.	Net Loss per Common Share	
The Company calculates net loss per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net loss per common share was determined by dividing net loss			

applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period.

The following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months ended September 30, 2024 and 2023, as the result would be anti-dilutive:

	September 30, 2024	September 30, 2023
Stock options	118,989	145,446
Restricted Stock Units	39,747	34,798
6% convertible exchangeable preferred stock	6	6
Series A preferred stock	440	440
Series B preferred stock	—	79,248
Common stock warrants	10,871,577	215,625
Total shares excluded from calculation	11,030,759	475,563

XML 25 R12.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

9 Months Ended
Sep. 30, 2024

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in \$000s):

	September 30, 2024	December 31, 2023
Research and development tax credit receivable	\$ 1,248	\$ 2,933
Prepayments and VAT receivable	374	792
Other current assets	309	341
	\$ 1,931	\$ 4,066

XML 26 R13.htm IDEA: XBRL DOCUMENT

Non-Current Assets

Non-Current Assets

Non-Current Assets

6. Non-Current Assets

As of September 30, 2024, the Company had non-current assets of \$0.4 million, which is primarily comprised of deposits held by a contract research organization in relation to the Company's clinical trials.

XML 27 R14.htm IDEA: XBRL DOCUMENT

Accrued and Other Liabilities

9 Months Ended
Sep. 30, 2024

Accrued and Other Liabilities

Accrued and Other Liabilities

7. Accrued and Other Liabilities

Accrued and other current liabilities consisted of the following (in \$000s):

	September 30, 2024	December 31, 2023
Accrued research and development	\$ 1,616	\$ 3,668
Accrued legal and professional fees	277	570
Other current liabilities	332	380
	\$ 2,225	\$ 4,618

XML 28 R15.htm IDEA: XBRL DOCUMENT

Leases

Leases

Leases

8. Leases

The Company currently has an operating lease liability relating to its facilities in Berkeley Heights, New Jersey.

For the nine months ended September 30, 2024 and 2023, the Company recognized operating lease expenses of \$57,178 and \$55,982 respectively, including \$9,097 and \$7,902 respectively relating to a short term lease for offices in Dundee, Scotland. Cash payments made during the nine months ended September 30, 2024 and 2023 totaled \$38,058 and \$55,245, respectively, and were presented within cash outflows from operating activities. The remaining lease term as of September 30, 2024 is approximately 0.8 years for the Berkeley Heights facility. The discount rate used by the Company in determining the lease liability was 12%.

Remaining lease payments for both facilities are as follows (in \$000s):

2024	\$ 16
2025	38
Thereafter	—
Total future minimum lease obligation	\$ 54
Less discount	(3)
Total	\$ 51

XML 29 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

Stock-Based Compensation

Stock-Based Compensation

Stock-Based Compensation

9. Stock Based Compensation

ASC 718 requires compensation expense associated with share-based awards to be recognized over the requisite service period which, for the Company, is the period between the grant date and the date the award vests or becomes exercisable. The Company recognizes all share-based awards under the straight-line attribution method, assuming that all granted awards will vest. Forfeitures are recognized in the periods when they occur.

Stock based compensation has been reported within expense line items on the consolidated statement of operations for the three and nine months ended September 30, 2024 and 2023 as shown in the following table (in \$000s):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
General and administrative	\$ 101	\$ 279	\$ 421	\$ 801
Research and development	6	111	78	350
Stock-based compensation costs	\$ 107	\$ 390	\$ 499	\$ 1,151

2018 Plan

In May 2018, the Company's stockholders approved the 2018 Equity Incentive Plan (the "2018 Plan"), under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The 2018 Plan replaced the 2015 Equity Incentive Plan (the "2015 Plan").

The 2018 Plan allows for various types of award grants, including stock options and restricted stock units.

On June 21, 2024, the Company's stockholders approved an additional 160,000 shares of common stock that may be issued under the 2018 Plan. On June 13, 2023, the Company's stockholders approved an additional 60,000 shares of common stock that may be issued under the 2018 Plan. As of June 30, 2024, the Company has reserved approximately 204,000 shares of the Company's common stock under the 2018 Plan for future issuances. Stock option awards granted under the Company's equity incentive plans have a maximum life of 10 years and generally vest over a one to four-year period from the date of grant.

2020 Inducement Equity Incentive Plan

In October 2020, the Inducement Equity Incentive Plan (the "Inducement Plan"), became effective. Under the Inducement Plan, Cyclacel may make equity incentive grants to new senior level Employees (persons to whom the Company may issue securities without stockholder approval). The Inducement Plan allows for the issuance of up to 13,333 shares of the Company's common stock (or the equivalent of such number). As of September 30, 2024, 8,000 shares under the Inducement Plan have been issued, leaving a remaining reserve of 5,333 shares.

Option Grants and Exercises

There were 12,500 options granted during the nine months ended September 30, 2024, all issued under the 2018 Plan. These options had a grant date fair value of \$1.77 per option. There were 43,342 options granted during the nine months ended September 30, 2023. These options had a grant date fair value ranging between \$6.32-\$10.98 per option.

All of the options granted during the nine months ended September 30, 2024 shall vest six months from their date of grant. Of the options granted during the nine months ended September 30, 2023, 25,633 awards shall vest on the third anniversary of their date of grant, or earlier if either of the certain performance conditions are met relating to enrollment goals for various clinical studies. The Company has assumed that these awards will vest after three years as satisfaction of the performance conditions is not probable at this time.

The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the following assumptions:

	Nine months ended September 30, 2024	Nine months ended September 30, 2023
Expected term (years)	6	5 - 6

Risk free interest rate	3.995%	3.660% - 4.050%
Volatility	93%	89% - 92%
Expected dividend yield over expected term	0.00%	0.00%
Resulting weighted average grant date fair value	\$1.77	\$6.63

There were no stock options exercised during each of the nine months ended September 30, 2024 and 2023, respectively. The Company does not expect to be able to benefit from the deduction for stock option exercises that may occur because the company has tax loss carryforwards from prior periods that would be expected to offset any potential taxable income.

As of September 30, 2024, the total remaining unrecognized compensation cost related to the non-vested awards with service conditions amounted to approximately \$0.2 million, which will be amortized over the weighted-average remaining requisite service period of 1.45 years.

Outstanding Options

A summary of the share option activity and related information is as follows:

	Number of Options Outstanding	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (\$'000)
Options outstanding at December 31, 2023	142,796	\$ 50.20	7.96	\$ —
Granted	12,500	\$ 2.28	—	\$ —
Exercised	—	\$ —	—	\$ —
Cancelled/forfeited	(36,307)	\$ 51.78	—	\$ —
Options outstanding at September 30, 2024	118,989	\$ 44.31	7.46	\$ —
Unvested at September 30, 2024	20,273	\$ 14.00	8.53	\$ —
Vested and exercisable at September 30, 2024	98,716	\$ 50.54	7.24	\$ —

Restricted Stock Units

The Company issued 12,500 restricted stock units during the nine months ended September 30, 2024. These restricted stock units vest monthly over a six-month service period. These restricted stock units were valued at \$2.28 at the date of grant, which was equivalent to the market price of a share of the Company’s common stock on that date.

A total of 17,133 restricted stock units issued in January 2023 vest on the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met. A three-year vesting assumption was applied to these restricted stock units as satisfaction of the performance conditions is not probable at this time. Each of these restricted stock units was valued at \$13.50 at the date of grant, which was equivalent to the market price of a share of the Company’s common stock on that date. During 2023, 300 of these restricted stock units were forfeited as the recipient voluntarily terminated employment with the Company. Through September 30, 2024, an additional 7,077 of these restricted stock units have been forfeited due to the holders’ termination of employment with the Company.

Summarized information for restricted stock units as of September 30, 2024 is as follows:

	Restricted Stock Units	Weighted Average Remaining Term
Restricted Stock Units outstanding at December 31, 2023	34,498	8.96 years
Granted	12,500	
Cancelled/forfeited	(7,251)	
Restricted Stock Units outstanding at September 30, 2024	39,747	8.55 years
Unvested at September 30, 2024	10,278	8.31 years
Vested at September 30, 2024	29,469	8.64 years

XML 30 R17.htm IDEA XBRL DOCUMENT

Stockholders Equity

Stockholders Equity

10. Stockholders Equity

April 2024 Securities Purchase Agreement

On April 30, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 145,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase up to 4,823,945 shares of common stock (the “Pre-Funded Warrants”), (iii) series A warrants to purchase up to 4,968,945 shares of common stock (the “Series A Warrants”), and (iv) series B warrants to purchase up to 4,968,945 shares of common stock (the “Series B Warrants” and together with the Series A Warrants, the “Common Warrants”). The purchase price of each share of common stock and associated Common Warrants was \$1.61 and the purchase price of each Pre-Funded Warrant and associated Common Warrants was \$1.6099.

The Common Warrants are exercisable immediately upon issuance at an exercise price of \$1.36 per share. The Series A Warrants will expire five and one-half years from the date of issuance and the Series B Warrants will expire eighteen months from the date of issuance. The Pre-Funded Warrants are exercisable immediately upon issuance at an exercise price of \$0.0001 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any portion of such warrants to the extent that the holder would own more than 4.99% (or, at the election of the holder 9.99%) of the Company’s outstanding common stock immediately after exercise.

In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of April 30, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the securities issued in the Private Placement.

The Private Placement closed on May 2, 2024. The gross proceeds to the Company from the Private Placement were approximately \$8.0 million, before deducting placement agent fees and estimated offering expenses payable by the Company.

H.C. Wainwright & Co., LLC (“Wainwright”) acted as the Company’s exclusive placement agent in connection with the Private Placement, pursuant to that certain engagement letter, dated as of April 29, 2024, between the Company and Wainwright (as amended, the “Engagement Letter”). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to 7.0% of the aggregate gross proceeds of the Private Placement and (ii) a management fee of 1.0% of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued to Wainwright or its designees warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 298,137 shares of Common Stock at an exercise price equal to \$2.0125 per share. The Placement Agent Warrants are exercisable immediately upon issuance and have a term of exercise equal to five and a half years from the date of issuance.

In connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained in an engagement letter entered into on March 14, 2024, in an amount equal to 7.0% of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate Ladenburg Thalmann & Co. Inc, pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in an amount equal to 8.0% of the aggregate proceeds of the Private Placement.

Each of the instruments issued in the Private Placement have been classified and recorded as part of shareholders’ equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective instruments as follows:

	Allocated Amount
Common shares	\$72,108
Prefunded warrants	2,398,831
Common warrants	3,819,274
Net proceeds	\$6,290,213

The aggregate fair value of the Placement Agent Warrants was \$609,179. These have been accounted for as a direct cost of the Private Placement, resulting in no net effect to overall shareholders’ equity (deficit).

In determining the fair values of the Pre-Funded Warrants, Common Warrants, and Placement Agent Warrants, the Company used a Black-Scholes Option Pricing model with the following assumptions:

	Pre-Funded Warrants	Common Warrants	Placement Agent Warrants
Expected volatility	100%	103% - 121%	103%
Contractual term	1 year	1½ - 5½ years	5½ years
Risk-free interest rate	5.51%	4.57% - 5.51%	4.57%
Expected dividend yield	0%	0%	0%

The fair value of the common shares was determined using the closing price of the Company’s common stock as of May 2, 2024, which is the date that the Private Placement closed.

December 2023 Registered Direct Offering Securities Purchase Agreement

On December 21, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (“Purchasers”). Pursuant to the Securities Purchase Agreement, the Company agreed to sell in a registered direct offering (“Registered Direct Offering”) 168,500 shares (“Shares”) of the Company’s common stock, \$0.001 par value per share (“Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 219,700 shares of Common Stock. The Pre-Funded Warrants have an exercise price of \$0.001 per share and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share is being sold at an offering price of \$3.315 and each Pre-Funded Warrant is being sold at an offering price of \$3.314 (equal to the purchase price per Share minus the exercise price of the Pre-Funded Warrant). The Pre-Funded Warrants have been included in the calculation of basic and diluted loss per share for all periods outstanding.

Pursuant to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the “Offerings”), the Company also agreed to issue to the Purchasers unregistered warrants (“Common Warrants”) to purchase up to 388,200 shares of Common Stock. Each Common Warrant has an exercise price of \$3.19 per share, is exercisable immediately following their original issuance and will expire seven years from the original issuance date. The closing of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately \$1.0 million, after deducting placement agent fees and other offering expenses payable by the Company.

On December 21, 2023, in a separate concurrent insider private placement (the “Insider Private Placement”), the Company also entered into a Securities Purchase Agreement with certain of its executive officers (the “Insider Securities Purchase Agreement”) pursuant to which the Company agreed to sell in a private placement (i) 6,070 shares of Common Stock and warrants to purchase 6,070 shares of Common Stock on the same terms as the Common Warrants issued to the Purchasers in the Offerings to Spiro Rombotis, the Company’s Chief Executive Officer, and (ii) 1,886 shares of Common Stock and

warrants to purchase 1,886 shares of Common Stock on the same terms as the Common Warrants issued to the Purchasers in the Offerings to Paul McBarron, the Company’s Executive Vice President- Finance, Chief Financial Officer and Chief Operating Officer. Each such share of Common Stock and accompanying warrant was sold at a purchase price of \$3.315, which was the same purchase price for the Shares sold in the Registered Direct Offering.

Ladenburg Thalmann & Co. Inc. (the “Placement Agent”) acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the “Placement Agency Agreement”), dated December 21, 2023, by and between the Company and the Placement Agent.

Pursuant to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to 8.0% of the aggregate gross proceeds raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions, the Company also agreed to reimburse all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with the Offerings, including but not limited to legal fees, up to a maximum of \$85,000. In addition, the Placement Agent also received warrants that have substantially the same terms as the Warrants issued in the concurrent private placement to the Purchasers in the Offerings to purchase that number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Prefunded Warrants sold in the Offerings, or an aggregate of 23,769 shares of Common Stock, at an exercise price of \$4.14375 per share (the “Placement Agent Warrants”). The Placement Agent Warrants will be exercisable immediately following the date of issuance and will expire five years from issuance. The Placement Agency Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The Company has agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and liabilities arising from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to payments that the Placement Agent may be required to make in respect of those liabilities.

Each of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders’ equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective instruments as follows:



The aggregate fair value of the Placement Agent Warrants was \$47,000. These have been accounted for as a direct cost of the Offerings and Inside Private Placement, resulting in no net effect to overall shareholders’ equity (deficit).

In determining the fair values of the Pre-Funded Warrants, Regular Warrants, and Placement Agent Warrants, the Company used a Black-Scholes Option Pricing model with the following assumptions:



The fair value of the common shares was determined using the closing price of the Company’s common stock as of December 26, 2023, which is the date that the Offerings and the Insider Private Placement closed.

August 2021 Controlled Equity Offering Sales Agreement

On August 12, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to \$50.0 million through Cantor as the sales agent. Cantor could sell the Company’s common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of the Securities Act.

On August 12, 2022, the Company became aware that the shelf registration statement on Form S-3 (file number 333-231923) (the “Registration Statement”) associated with this Sales Agreement had expired on June 21, 2022. Prior to becoming aware of the expiration, the Company sold an aggregate of 132,473 shares of its common stock at the market price, following the expiration of the Registration Statement and through August 12, 2022, for aggregate proceeds of approximately \$2,721,187. There was no sale of shares post August 12, 2022. The sale of these shares was subject to potential rescission rights by certain shareholders. As a result of these potential rescission rights, the Company reclassified 207,807 shares (including 75,333 shares sold for which the Company did not receive any proceeds), with an aggregate purchase price of \$4,494,496 of its common as stock outside stockholders’ equity (deficit) through the expiration date of those rescission rights in August 2023. These shares were treated as issued and outstanding for purposes of calculating basic and diluted loss per share in the three and nine months ended September 30, 2023. The rescission rights for these shares have lapsed and the shares were reclassified back to permanent equity. There have been no claims or demands to exercise such rights.

On August 15, 2022, due to expiry of the Registration Statement, the Sales Agreement was mutually terminated. A total of 218,738 shares, for gross proceeds of approximately \$7.6 million, had been sold pursuant to the Sales Agreement.

Warrants

April 2024 Warrants

As of September 30, 2024, warrants to purchase a total of 14,718,027 shares of common stock issued pursuant to a securities purchase agreement in a April 2024 financing transaction (the “April 2024 Securities Purchase Agreement”) remained outstanding. A total of 15,059,972 warrants were issued in pursuant to the April 2024 Securities Purchase Agreement. This consisted of i) pre-funded warrants to purchase 4,823,945 of common stock, exercisable immediately from the date of issuance, and with no expiry date, at an exercise price of \$0.0001 per warrant share, ii) series A warrants to purchase up to 4,968,945 shares of common stock, exercisable immediately from the date of issuance for a period of five and a half years after the date of issuance, at an exercise price of \$1.36 per warrant share, iii) series B warrants to purchase up to 4,968,945 shares of common stock, exercisable immediately from the date of issuance for a period of eighteen months after the date of issuance, at an exercise price of \$1.36 per warrant share. A further 298,137 warrants issued in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a period of five and a half years after the date of issuance, at an exercise price of \$2.0125 per warrant share.

A total of 688,945 pre-funded warrants were exercised during the nine months ended September 30, 2024.

December 2023 Warrants

As of September 30, 2024, warrants to purchase a total of 419,925 shares of common stock issued pursuant to a securities purchase agreement in a December 2023 financing transaction remained outstanding. A total of 396,156 warrants, including 7,956 warrants issued in a concurrent private placement, are exercisable immediately from the date of issuance for a period of seven years after the date of issuance, at an exercise price of \$3.19 per warrant share. A further 23,769 warrants issued in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a period of five years after the date of issuance, at an exercise price of \$4.14375 per warrant share.

There were no exercises of these warrants during the nine months ended September 30, 2024.

December 2020 Warrants

As of September 30, 2024, warrants to purchase 44,657 shares of common stock issued pursuant to a securities purchase agreement in a December 2020 financing transaction remained outstanding (the “December 2020 Securities Purchase Agreement”). Each warrant shall be exercisable beginning on the 12-month anniversary of the date of issuance for a period of five years after the date of issuance, at an exercise price of \$61.95 per warrant share. The exercise price of the warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the warrants. The warrants may be exercised on a “cashless” basis.

There were no exercises of these warrants during the nine months ended September 30, 2024 or September 30, 2023.

April 2020 Warrants

As of September 30, 2024, 146,000 warrants issued pursuant to a securities purchase agreement in connection with an April 2020 equity financing remained outstanding, each with an exercise price of \$75.00. The common warrants are immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company’s common stock. The common warrants were issued separately from the common stock and were eligible for transfer immediately after issuance. A common warrant to purchase one share of common stock was issued for every share of common stock purchased in this offering.

The common warrants are exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice accompanied by payment in full for the number of shares of the Company’s common stock purchased upon such exercise (except in the case of a cashless exercise). A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s common warrants up to 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. No fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, the Company will round down to the next whole share.

There were no exercises of these warrants during the nine months ended September 30, 2024 or September 30, 2023.

Series B Preferred Stock

A total of 237,745 shares of the Company’s Series B Preferred Stock were issued pursuant to a December 2020 Securities Purchase Agreement. Each share of Series B Preferred Stock was initially convertible into one third (1/3) share of common stock (the “Conversion Shares”), subject to adjustment in accordance with the Certificate of Designation.

Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Certificate of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, (e) pay certain dividends or (f) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. The Purchaser may convert shares of Series B Preferred Stock through a conversion into shares of common stock if and solely to the extent that such conversion would not result in the Purchaser beneficially owning in excess of 9.99% of then-outstanding common stock or aggregate voting power of the Company (such limitation, the “Ownership Limitation”) and any portion in excess of such limitation will remain outstanding as Series B Preferred Stock.

During the year ended December 31, 2023, 118,745 shares of Series B Preferred Stock were converted, at the option of the holder, into 39,582 shares of common stock. During the nine months ended September 30, 2024, the remaining 119,000 shares of Series B Preferred Stock were converted, at the option of the holder, into 39,667 shares of common stock.

Series A Preferred Stock

A total of 8,872 shares of the Company’s Series A Preferred Stock were issued in a July 2017 Underwritten Public Offering. Each share of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing \$1,000 by the initial conversion price of \$600.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.

As of September 30, 2024 and December 31, 2023, 264 shares of the Series A Preferred Stock remain issued and outstanding. The 264 shares of Series A Preferred Stock issued and outstanding at September 30, 2024, are convertible into 440 shares of common stock.

In the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company’s ability to repurchase shares of Series A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and

there are no sinking fund provisions applicable to Series A Preferred Stock.

Subject to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder of the Series A Preferred Stock to convert all or part of such holder's Series A Preferred Stock in the event that (i) the volume weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds 300% of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds \$500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of Series A Preferred Stock to convert all or part of such holder's Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock.

The Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution.

6% Convertible Exchangeable Preferred Stock

As of September 30, 2024, there were 335,273 shares of the Company's 6% Convertible Exchangeable Preferred Stock (the "6% Preferred Stock") issued and outstanding at an issue price of \$10.00 per share. Dividends on the 6% Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the 6% Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company's board of directors and must come from funds that are legally available for dividend payments. The 6% Preferred Stock has a liquidation preference of \$10.00 per share, plus accrued and unpaid dividends. As of September 30, 2024, there were no accrued and unpaid dividends.

The Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company's common stock has exceeded \$888,300, which is 150% of the conversion price of the 6% Preferred Stock, for at least 20 trading days during any 30 day trading period, ending within five trading days prior to notice of automatic conversion.

The 6% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.

The Company may, at its option, redeem the 6% Preferred Stock in whole or in part, out of funds legally available at the redemption price of \$10.00 per share.

The 6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November 1, 2005 (the "Exchange Date") for the Company's 6% Convertible Subordinated Debentures (the "Debentures") at the rate of \$10.00 principal amount of Debentures for each share of 6% Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have substantially similar terms to those of the 6% Preferred Stock. No such exchanges have taken place to date.

XML 31 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

Subsequent Events
Subsequent Events

11. Subsequent Events

Dividends on 6% Preferred Stock

On September 4, 2024, the board of directors of the Company passed a resolution to suspend payment of the quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock scheduled for November 1, 2024. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis.

On October 15, 2024, 200,000 shares of the Company's 6% Convertible Exchangeable Preferred Stock was converted into 3 shares of common stock.

As of October 23, 2024, all of the remaining 4,135,000 pre-funded warrants pursuant to the April 2024 Securities Purchase Agreement were fully exercised.

XML 32 R19.htm IDEA: XBRL DOCUMENT

Pay vs Performance
Disclosure - USD (\$)
\$ in Thousands

Pay vs Performance Disclosure

Net Income (Loss)

XML 33 R20.htm IDEA: XBRL DOCUMENT

Insider Trading
Arrangements

Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted

Non-Rule 10b5-1 Arrangement Adopted

Rule 10b5-1 Arrangement Terminated

Non-Rule 10b5-1 Arrangement Terminated

XML 34 R21.htm IDEA: XBRL DOCUMENT

Summary of
Significant
Accounting Policies
(Policies)

Summary of
Significant
Accounting Policies
Basis of Presentation

Basis of Presentation

The consolidated balance sheet as of September 30, 2024, the consolidated statements of operations, comprehensive loss, and stockholders' equity (deficit) for the three and nine months ended September 30, 2024 and 2023 and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on March 21, 2024. The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of September 30, 2024, and the results of operations, comprehensive loss, and changes in stockholders' equity (deficit) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024, have been made. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 that are included in the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2024.

Going Concern

Going Concern

Pursuant to the requirements of Accounting Standard Codification (ASC) 205-40, *Presentation of Financial Statements-Going Concern*, management is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern for one year after the date that these financial statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered probable at this time because these plans are not entirely within the Company's control nor have they been approved by the Board of Directors as of the date of these consolidated financial statements.

Based on the Company's current operating plan, it is anticipated that cash and cash equivalents of \$3.0 million as of September 30, 2024, will allow it to meet its liquidity requirements into the fourth quarter of 2024. The Company's history of losses, negative cash flows from operations, liquidity resources currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.

On August 26, 2024, the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") determined that the Company was not in compliance with the Nasdaq Listing Rule 5550(b) (1) (the "Equity Rule") because the Company reported stockholders' equity of less than \$2.5 million as of June 30, 2024. The notice from the Staff further stated that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the "Panel"), the Company's securities would be subject to delisting. As of September 30, 2024, the Company has a stockholders equity deficit of approximately \$0.97 million which is not in compliance with the Equity Rule. On October 15, 2024, the Company met with the Panel regarding the Company's potential delisting from Nasdaq as a result of its violation of the Equity Rule. On October 22, 2024, the Company received the Panel's decision which granted the Company until December 24, 2024 to regain compliance with the Equity Rule and all applicable criteria for continued listing on Nasdaq. If the Company is unable to regain compliance with the listing standards of the Nasdaq Capital Market by December 24, 2024, the Company's securities may be delisted from Nasdaq.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business.

Recently Issued
Accounting
Pronouncements

Recently Issued Accounting Pronouncements

The FASB has issued ASU 2023-07, "Segment Reporting (Topic 280)". This standard will require all public entities - even those like the Company that have a single reportable segment - to disclose additional information about the title and position of the Chief Operating Decision Maker ("CODM"), the measure or measures of segment profit and loss used by the CODM in assessing segment performance and deciding how to allocate resources, an explanation of how the CODM uses the reported measure(s) in assessing segment performance, significant segment expenses that are regularly provided to the CODM, and a reconciliation of segment profit and loss to the closest consolidated totals prepared under United States GAAP. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 will not change the way in which reportable segments are determined. However, the Company is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.

The FASB has issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This standard will require all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation of that information.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Financial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.

Comprehensive Income (Loss)

Comprehensive Income (Loss)

All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three and nine months ended September 30, 2024 and 2023.

Foreign Currency and Currency Translation

Foreign Currency and Currency Translation

Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable future.

The assets and liabilities of the Company's international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans for which settlement is not planned or anticipated in the foreseeable future and that are of a long-term-investment nature, are recorded in other comprehensive loss.

Leases

Leases

The Company accounts for lease contracts in accordance with ASC 842. As of September 30, 2024, the Company's outstanding leases are classified as operating leases.

The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company's obligation to make lease payments under the lease. As the Company's leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company's credit risk.

The Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:

- The lease payments due in any optional period;
- Penalties for failure to exercise (or not exercise) the option;
- Market factors, such as the availability of similar assets and current rental rates for such assets;
- The nature of the underlying leased asset and its importance to the Company's operations; and
- The remaining useful lives of any related leasehold improvements.

Lease expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.

The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.

Revenue Recognition

Revenue Recognition

When the Company enters into contracts with customers, the Company recognizes revenue using the five step-model provided in ASC 606, *Revenue from Contracts with Customers* ("ASC 606"):

- (1) identify the contract with a customer;
- (2) identify the performance obligations in the contract;
- (3) determine the transaction price;
- (4) allocate the transaction price to the performance obligations in the contract; and
- (5) recognize revenue when, or as, the Company satisfies a performance obligation.

The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers:

- Whether achievement of a development milestone is highly susceptible to factors outside the entity's influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies;
- Whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;
- Whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and
- The complexity and inherent uncertainty underlying the achievement of the milestone.

The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.

The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.

The Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.

Grant revenue received from organizations that are not the Company's customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses.

XML 35 R22.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

9 Months Ended Sep. 30, 2024

Net Loss per Common Share

Schedule of Basic and Diluted Net Loss Per Share

	September 30, 2024	September 30, 2023
Stock options	118,989	145,446
Restricted Stock Units	39,747	34,798
6% convertible exchangeable preferred stock	6	6
Series A preferred stock	440	440
Series B preferred stock	—	79,248
Common stock warrants	10,871,577	215,625
Total shares excluded from calculation	11,030,759	475,563

XML 36 R23.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

9 Months Ended Sep. 30, 2024

Prepaid Expenses and Other Current Assets

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following (in \$000s):

	September 30, 2024	December 31, 2023
Research and development tax credit receivable	\$ 1,248	\$ 2,933
Prepayments and VAT receivable	374	792
Other current assets	309	341
	\$ 1,931	\$ 4,066

XML 37 R24.htm IDEA: XBRL DOCUMENT

Accrued and Other Liabilities (Tables)

9 Months Ended Sep. 30, 2024

Accrued and Other Liabilities

Schedule of Accrued and Other Liabilities

Accrued and other current liabilities consisted of the following (in \$000s):

	September 30, 2024	December 31, 2023
Accrued research and development	\$ 1,616	\$ 3,668
Accrued legal and professional fees	277	570
Other current liabilities	332	380
	\$ 2,225	\$ 4,618

XML 38 R25.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended Sep. 30, 2024

Leases

Schedule of the Company's Contractual Obligations and Commitments Relating to its Facilities Leases

Remaining lease payments for both facilities are as follows (in \$000s):

2024	\$ 16
2025	38
Thereafter	—
Total future minimum lease obligation	\$ 54

XML-39-R26.htm IDEA: XBRL DOCUMENT	Less discount	(3)
	Total	\$ 51

Stock-Based Compensation (Tables)

9 Months Ended Sep. 30, 2024

Stock-Based Compensation Schedule of Stock Based Compensation Expense

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
General and administrative	\$ 101	\$ 279	\$ 421	\$ 801
Research and development	6	\$ 111	78	350
Stock-based compensation costs	\$ 107	\$ 390	\$ 499	\$ 1,151

Schedule of Fair Value of the Stock Options Granted

	Nine months ended September 30, 2024	Nine months ended September 30, 2023
Expected term (years)	6	5 - 6
Risk free interest rate	3.995%	3.660% - 4.050%
Volatility	93%	89% - 92%
Expected dividend yield over expected term	0.00%	0.00%
Resulting weighted average grant date fair value	\$1.77	\$6.63

Schedule of Share Option Activity

A summary of the share option activity and related information is as follows:

	Number of Options Outstanding	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (\$000)
Options outstanding at December 31, 2023	142,796	\$ 50.20	7.96	\$ —
Granted	12,500	\$ 2.28	—	\$ —
Exercised	—	\$ —	—	\$ —
Cancelled/forfeited	(36,307)	\$ 51.78	—	\$ —
Options outstanding at September 30, 2024	118,989	\$ 44.31	7.46	\$ —
Unvested at September 30, 2024	20,273	\$ 14.00	8.53	\$ —
Vested and exercisable at September 30, 2024	98,716	\$ 50.54	7.24	\$ —

Schedule of Restricted Stock Units Activity

	Restricted Stock Units	Weighted Average Remaining Term
Restricted Stock Units outstanding at December 31, 2023	34,498	8.96 years
Granted	12,500	
Cancelled/forfeited	(7,251)	
Restricted Stock Units outstanding at September 30, 2024	39,747	8.55 years
Unvested at September 30, 2024	10,278	8.31 years
Vested at September 30, 2024	29,469	8.64 years

XML-40-R27.htm IDEA: XBRL DOCUMENT

Stockholders Equity (Tables)

9 Months Ended Sep. 30, 2024

April 2024 Securities Purchase Agreement

Class of Stock [Line Items]

Schedule of fair values of instruments issued in an offering

	Allocated Amount
Common shares	\$72,108
Prefunded warrants	2,398,831
Common warrants	3,819,274
Net proceeds	\$6,290,213

Schedule of fair value of warrants valuation assumption

	Pre-Funded Warrants	Common Warrants	Placement Agent Warrants
Expected volatility	100%	103% - 121%	103%
Contractual term	1 year	1½ - 5½ years	5½ years
Risk-free interest rate	5.51%	4.57% - 5.51%	4.57%
Expected dividend yield	0%	0%	0%

December 2023 Securities Purchase Agreement

Class of Stock [Line Items]

Schedule of fair values of instruments issued in an offering



Schedule of fair value of warrants valuation assumption



XML-41-R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Narrative) (Details) - USD (\$) \$ in Thousands

9 Months Ended

Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022

Summary of Significant Accounting Policies

Cash and cash equivalents

\$ 2,982

\$ 3,378

Substantial Doubt about Going Concern, within One Year

true

Stockholder's Equity Deficit

\$ 970

\$ (4,297)

\$ (999)

\$ 2,206

\$ (607)

\$ (6,671)

\$ (10,578)

\$ (15,939)

Tax on other comprehensive income (loss)

0

Reclassifications out of other comprehensive income (loss)

\$ 0

\$ 0

XML-42-R29.htm IDEA: XBRL DOCUMENT

Revenue (Narrative) (Details) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023

Revenue

Revenue

\$ 10,000

\$ 16,000

\$ 43,000

\$ 389,000

XML-43-R30.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share - Schedule of Company's Potential Anti Dilutive Securities (Details) - shares

9 Months Ended

Sep. 30, 2024 Sep. 30, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total shares excluded from calculation

11,030,759

475,563

Preferred stock, dividend rate (in percent)

6.00%

Employee Stock Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total shares excluded from calculation

118,989

145,446

Restricted Stock Units (RSUs)

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]										
Total shares excluded from calculation				39,747		34,798				
6% Convertible Exchangeable Preferred Stock										
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]										
Total shares excluded from calculation				6		6				
Preferred stock, dividend rate (in percent)				6.00%						
Series A Convertible Preferred Stock										
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]										
Total shares excluded from calculation				440		440				
Series B Convertible Preferred Stock										
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]										
Total shares excluded from calculation				0		79,248				
Common Stock Warrants										
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]										
Total shares excluded from calculation				10,871,577		215,625				
XML 44 R31.htm IDEA: XBRL DOCUMENT										
<div>Prepaid Expenses and Other Current Assets</div> <div>- Schedule of Prepaid Expenses and Other Current Assets</div> <div>(Details) - USD (\$)</div> <div>\$ in Thousands</div>										
Sep. 30, 2024 Dec. 31, 2023										
Prepaid Expenses and Other Current Assets [Abstract]										
Research and development tax credit receivable				\$ 1,248		\$ 2,933				
Prepayments and VAT receivable				374		792				
Other current assets				309		341				
Prepaid expenses and other current assets				\$ 1,931		\$ 4,066				
XML 45 R32.htm IDEA: XBRL DOCUMENT										
<div>Non-Current Assets</div> <div>(Details)</div> <div>\$ in Millions</div>										
Sep. 30, 2024										
USD (\$)										
Non-Current Assets										
Clinical trial deposits held by a contract research organization \$ 0.4										
XML 46 R33.htm IDEA: XBRL DOCUMENT										
<div>Accrued and Other Liabilities - Schedule of accrued and other current liabilities</div> <div>(Details) - USD (\$)</div> <div>\$ in Thousands</div>										
Sep. 30, 2024 Dec. 31, 2023										
Accrued and Other Liabilities										
Accrued research and development				\$ 1,616		\$ 3,668				
Accrued legal and professional fees				277		570				
Other current liabilities				332		380				
Accrued and other current liabilities				\$ 2,225		\$ 4,618				
XML 47 R34.htm IDEA: XBRL DOCUMENT										
<div>Leases - Narrative</div> <div>(Details) - USD (\$)</div> <div>Sep. 30, 2024 Sep. 30, 2023</div> <div>9 Months Ended</div>										
Operating lease expense				\$ 57,178		\$ 55,982				
Operating lease, payments				\$ 38,058		55,245				
Discount rate lease liability				12.00%						
Berkeley Heights facility										
Remaining lease term				1 month 6 days						
Dundee facility										
Operating lease expense				\$ 9,097		\$ 7,902				
XML 48 R35.htm IDEA: XBRL DOCUMENT										
<div>Leases - Future Minimum Lease Payments (Details)</div> <div>\$ in Thousands</div> <div>Sep. 30, 2024</div> <div>USD (\$)</div>										
Operating Lease Obligation										
2024				\$ 16						
2025				38						
Thereafter				0						
Total future minimum lease obligation				54						
Less discount				(3)						
Total				\$ 51						
XML 49 R36.htm IDEA: XBRL DOCUMENT										
<div>Stock-Based Compensation - Schedule of Stock Based Compensation Expense (Details) - USD (\$)</div> <div>\$ in Thousands</div>										
3 Months Ended 9 Months Ended										
Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023										
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]										
Stock-based compensation costs before income taxes				\$ 107		\$ 390		\$ 499		\$ 1,151
General and administrative										
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]										
Stock-based compensation costs before income taxes				101		279		421		801
Research and development										
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]										
Stock-based compensation costs before income taxes				\$ 6		\$ 111		\$ 78		\$ 350
XML 50 R37.htm IDEA: XBRL DOCUMENT										
<div>Stock-Based Compensation (Narrative) (Details) - USD (\$)</div> <div>\$ / shares in Units, \$ in Millions</div>										
1 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 21 Months Ended										
Jun. 21, 2024 Jun. 13, 2023 Jan. 31, 2023 Jun. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Sep. 30, 2024 Oct. 31, 2020										
Stock-based compensation										
Remaining unrecognized compensation cost of non-vested stock options						\$ 0.2				\$ 0.2
Weighted-average remaining requisite service period of recognition of unrecognized compensation cost						1 year 5 months 12 days				
Stock options										
Stock-based compensation										
Stock awards vesting period						6 months				
Options granted (in shares)						12,500		43,342		
Options granted, grant date fair value						\$ 1.77				
Options exercised (in shares)										0
Vesting period						3 years				

Stock options Minimum				
Stock-based compensation				
Options granted, grant date fair value		\$ 6.32		
Stock options Maximum				
Stock-based compensation				
Options granted, grant date fair value		\$ 10.98		
Stock options Options Vesting On Third Anniversary Of Grant				
Stock-based compensation				
Options granted (in shares)		25,633		
Restricted Stock Units (RSUs)				
Stock-based compensation				
Stock awards vesting period		3 years		
Restricted Stock Units, Granted		17,133	12,500	
Restricted stock units, grant date fair value		\$ 13.50		
Vesting period			6 months	
Shares forfeited			7,251	300
Additional shares forfeited			7,077	
Granted			\$ 2.28	
2018 Plan				
Stock-based compensation				
Number of additional shares authorized		160,000	60,000	
Number of shares reserved for issuance			204,000	
Life of stock option awards granted			10 years	
2018 Plan Minimum				
Stock-based compensation				
Stock awards vesting period			1 year	
2018 Plan Maximum				
Stock-based compensation				
Stock awards vesting period			4 years	
Inducement Plan				
Stock-based compensation				
Number of authorized shares			8,000	8,000
Number of shares reserved for issuance			5,333	5,333
XML 51 R38.htm IDEA: XBRL DOCUMENT				
Stock-Based Compensation - Schedule of Fair Value of the Stock Options Granted (Details) - Stock options - \$ / shares		9 Months Ended		
		Sep. 30, 2024 Sep. 30, 2023		
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]				
Expected term (years)		6 years		
Risk free interest rate		3.995%		
Volatility		93.00%		
Expected dividend yield over expected term		0.00%		
Resulting weighted average grant date fair value		\$ 1.77 \$ 6.63		
Minimum				
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]				
Expected term (years)		5 years		
Risk free interest rate		3.66%		
Volatility		89.00%		
Maximum				
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]				
Expected term (years)		6 years		
Risk free interest rate		4.05%		
Volatility		92.00%		
XML 52 R39.htm IDEA: XBRL DOCUMENT				
Stock-Based Compensation - Schedule of Share Option Activity (Details) - \$ / shares		9 Months Ended		
		Sep. 30, 2024 Sep. 30, 2023		
Weighted Average Remaining Contractual Term (Years)				
Options outstanding		7 years 11 months 15 days		
Stock options				
Number of Options Outstanding				
Options outstanding		142,796		
Granted		12,500 43,342		
Cancelled/forfeited		(36,307)		
Options outstanding		118,989		
Unvested		20,273		
Vested and exercisable		98,716		
Weighted Average Exercise Price Per Share				
Options outstanding		\$ 50.20		
Granted		2.28		
Exercised		0		
Cancelled/forfeited (in dollars per share)		51.78		
Options outstanding		44.31		
Unvested		14.00		
Vested and exercisable		\$ 50.54		
Weighted Average Remaining Contractual Term (Years)				
Options outstanding		7 years 5 months 15 days		
Unvested		8 years 6 months 10 days		
Vested and exercisable		7 years 2 months 26 days		
XML 53 R40.htm IDEA: XBRL DOCUMENT				
Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) - \$ / shares		1 Months Ended	9 Months Ended	12 Months Ended
		Jan. 31, 2023	Sep. 30, 2024	Dec. 31, 2023
Number of Options Outstanding				
Restricted Stock Units outstanding, Beginning balance		34,498		
Granted		17,133	12,500	
Cancelled/forfeited			(7,251)	(300)
Restricted Stock Units outstanding, Ending balance		39,747 34,498		
Unvested		10,278		
Vested		29,469		

Weighted Average Grant Date Value Per Share

Restricted stock units, grant date fair value

\$ 13.50

Granted

\$ 2.28

Weighted Average Remaining Term

Restricted stock units. Weighted average remaining term

8 years 6 months 18 days 8 years 11 months 15 days

Unvested

8 years 3 months 21 days

Vested

8 years 7 months 20 days

~~XML 54 R41.htm IDEA: XBRL DOCUMENT~~

								1 Months Ended	9 Months Ended	12 Months Ended						
Stockholders Equity (Narrative) (Details)	Sep. 04, 2024	May 02, 2024 USD (\$)	Apr. 30, 2024 \$/ shares	Dec. 21, 2023 USD (\$) \$/ shares	Aug. 15, 2022 USD (\$) shares	Aug. 12, 2022 USD (\$) shares	Aug. 12, 2021 USD (\$)	Jul. 31, 2017 \$/ shares	Sep. 30, 2024 USD (\$) \$/ shares	Sep. 30, 2023 shares	Dec. 31, 2023 \$/ shares	Apr. 29, 2024 \$/ shares	Mar. 14, 2024	Dec. 26, 2023 USD (\$)	Oct. 30, 2023	Dec. 31, 2020 shares
Class of Stock [Line Items]																
Common stock, par value (in dollars per share) \$ / shares									\$ 0.001		\$ 0.001					
Gross proceeds \$		\$ 8,000,000.0														
Dividend rate on convertible exchangeable preferred stock (in percent)									6.00%							
Common stock, shares authorized									100,000,000		100,000,000					
Cash placement fee, percentage of gross proceeds raised												7.00%				
Management fee percentage												1.00%				
December 2023 Private Placement																
Class of Stock [Line Items]																
Warrants to purchase shares									419,925							
Exercisable warrants									396,156							
Warrant outstanding Term									7 years							
Warrants, exercise price per share \$ / shares									\$ 3.19							
December 2020 Warrants																
Class of Stock [Line Items]																
Warrants to purchase shares									44,657							
Warrant outstanding Term									5 years							
Warrants, exercise price per share \$ / shares									\$ 61.95							
Warrants exercised									0	0						
April 2024 Warrants																
Class of Stock [Line Items]																
Warrants to purchase shares									14,718,027							
Exercisable warrants									15,059,972							
December 2023 Insider Private Placement																
Class of Stock [Line Items]																
Share issue price per share \$ / shares				\$ 3.315												
December 2023 Placement Agency Agreement																
Class of Stock [Line Items]																
Exercisable warrants									23,769							
Warrant outstanding Term									5 years							
Warrants, exercise price per share \$ / shares									\$ 4.14375							
Warrants exercised									0							
Cash placement fee, percentage of gross proceeds raised				8.00%												
April 2024 Securities Purchase Agreement																
Class of Stock [Line Items]																
Number of shares issued (in shares)			145,000													
Common Stock Warrants December 2023 Private Placement																
Class of Stock [Line Items]																
Warrants to purchase shares				388,200												
Warrant outstanding Term				7 years												
Warrants, exercise price per share \$ / shares				\$ 3.19												
Total gross proceeds received \$														\$ 1,000,000.0		
Common Stock Warrants December 2023 Insider Private Placement Chief Executive Officer																
Class of Stock [Line Items]																
Warrants to purchase shares				6,070												
Common Stock Warrants December 2023 Insider Private Placement Chief Financial Officer and Chief Operating Officer																
Class of Stock [Line Items]																
Warrants to purchase shares				1,886												
Common Stock Warrants April 2024 Securities Purchase Agreement																
Class of Stock [Line Items]																
Warrants, exercise price per share \$ / shares			\$ 1.36													
Pre-Funded Warrants December 2023 Securities Purchase Agreement																
Class of Stock [Line Items]																
Warrants to purchase shares				219,700												
Warrants, exercise price per share \$ / shares				\$ 0.001												

Share issue price per share \$ / shares	\$ 3.314	
Pre-Funded Warrants April 2024 Warrants		
Class of Stock [Line Items]		
Exercisable warrants		4,823,945
Warrants, exercise price per share \$ / shares		\$ 0.0001
Warrants exercised		688,945
Pre-Funded Warrants April 2024 Securities Purchase Agreement		
Class of Stock [Line Items]		
Warrants to purchase shares	4,823,945	
Warrants, exercise price per share \$ / shares	\$ 0.0001	
Placement Agent Warrants		
Class of Stock [Line Items]		
Warrants to purchase shares		298,137
Warrant outstanding Term		5 years 6 months
		\$ 2.0125
Warrants, exercise price per share \$ / shares		
Placement Agent Warrants December 2023 Securities Purchase Agreement		
Class of Stock [Line Items]		
Aggregate fair value Warrants \$		\$ 47,000
Placement Agent Warrants December 2023 Private Placement		
Class of Stock [Line Items]		
Exercisable warrants		7,956
Placement Agent Warrants April 2024 Warrants		
Class of Stock [Line Items]		
Exercisable warrants		298,137
Warrant outstanding Term		5 years 6 months
		\$ 2.0125
Warrants, exercise price per share \$ / shares		
Placement Agent Warrants December 2023 Placement Agency Agreement		
Class of Stock [Line Items]		
Warrants to purchase shares	23,769	
Warrant outstanding Term	5 years	
Warrants, exercise price per share \$ / shares	\$ 4.14375	
Percentage of outstanding common stock	6.00%	
Placement Agent Warrants April 2024 Securities Purchase Agreement		
Class of Stock [Line Items]		
Aggregate fair value Warrants \$		\$ 609,179
Pre-funded warrants and common warrants April 2024 Securities Purchase Agreement		
Class of Stock [Line Items]		
Share issue price per share \$ / shares	\$ 1.6099	
Series A warrants		
Class of Stock [Line Items]		
Warrant outstanding Term	5 years 6 months	
Series A warrants April 2024 Warrants		
Class of Stock [Line Items]		
Warrants to purchase shares		4,968,945
Warrant outstanding Term		5 years 6 months
		\$ 1.36
Warrants, exercise price per share \$ / shares		
Series A warrants April 2024 Securities Purchase Agreement		
Class of Stock [Line Items]		
Warrants to purchase shares	4,968,945	
Series B Warrants April 2024 Warrants		
Class of Stock [Line Items]		
Warrants to purchase shares		4,968,945
Warrant outstanding Term		18 months
Warrants, exercise price per share \$ / shares		\$ 1.36
Series B Warrants April 2024 Securities Purchase Agreement		
Class of Stock [Line Items]		
Warrants to purchase shares	4,968,945	
Warrant outstanding Term	18 months	
Maximum December 2023 Placement Agency Agreement		
Class of Stock [Line Items]		
Placement agent fees \$	\$ 85,000	
Cantor Fitzgerald & Co.		
Class of Stock [Line Items]		
Aggregate offering price \$		\$ 50,000,000.0
Number of share sold under the sales agreement	218,738	
Proceeds from issuance of common stock, gross \$	\$ 7,600,000	
Cantor Fitzgerald & Co. August 2021 Controlled Equity Offering		

Sales Agreement

Class of Stock [Line Items]

Number of share sold under the sales agreement	132,473
Aggregate purchase price \$	\$ 4,494,496
Total gross proceeds received \$	\$ 2,721,187
Reclassified shares	207,807
Reclassified shares for which no proceeds were received	75,333

Co-Placement Agents

Class of Stock [Line Items]

Warrant Exercises (in shares)	0	0
Warrants, exercise price per share \$ / shares	\$ 75.00	
Number of warrant to purchase each share of our common stock	1	
Warrants outstanding	146,000	
Fractional shares issued	0	
Co-Placement Agents Common Stock Warrants		

Class of Stock [Line Items]

Percentage of outstanding common stock	4.99%
Outstanding common stock at election of purchaser	9.99%
Notice period from the holder to increase the percentage of ownership of outstanding common stock after exercise of warrants	61 day
Co-Placement Agents Common Stock Warrants April 2024 Securities Purchase Agreement	

Class of Stock [Line Items]

Percentage of outstanding common stock	4.99%
Outstanding common stock at election of purchaser	9.99%
Roth Capital Partners, LLC	

Class of Stock [Line Items]

Percentage of compensation raised		7.00%
Ladenburg Thalmann & Co. Inc		

Class of Stock [Line Items]

Percentage of compensation raised		8.00%
6% Convertible Exchangeable Preferred Stock		

Class of Stock [Line Items]

Preferred stock, shares issued	335,273	335,273
Preferred stock, shares outstanding	335,273	335,273
Share issue price per share \$ / shares	\$ 10.00	
Share Price \$ / shares	\$ 888,300	
Dividend rate on convertible exchangeable preferred stock (in percent)	6.00%	6.00%
Liquidation preference (in dollars per share) \$ / shares	\$ 10.00	
Accrued and unpaid dividends \$	\$ 0	
Percentage of closing sales price of common stock that conversion price must exceed in order for preferred stock to be convertible	150.00%	
Number of trading days within 30 trading days in which the closing price of common stock must exceed conversion price for preferred stock to be convertible	20 days	
Number of trading days during which closing price of common stock must exceed conversion price for at least 20 days in order for the preferred stock to be convertible	30 days	
Number of trading days prior to notice of automatic conversion	5 days	
Redemption price per share (in dollars per share) \$ / shares	\$ 10.00	
Debt principal amount per share, basis for exchange (in dollars per share) \$ / shares	\$ 10.00	
Debt instrument, term	25 years	
Series A Convertible Preferred Stock		

Class of Stock [Line Items]

Preferred stock, shares issued	8,872	264	264
Preferred stock, shares outstanding		264	264
Conversion of Stock, Shares Converted		440	
Price per share used to determine number of shares of common stock \$ / shares	\$ 1,000		
Conversion price of convertible preferred stock \$ / shares	\$ 600.00		
Conversion percentage	9.99%		
Measurement period of consecutive trading days used in determining whether specified triggers are met which would allow the entity to require the conversion of all or part of outstanding preferred stock		30 days	

Percentage of blocker provision	4.99%			
Series A Convertible Preferred Stock Minimum				
Class of Stock [Line Items]				
Percentage by which the weighted average price of common stock during the measurement period exceeds the initial conversion price which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted	300.00%			
Series A Convertible Preferred Stock Maximum				
Class of Stock [Line Items]				
Threshold amount of daily trading volume on each trading day during the measurement period which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted \$	\$ 500,000			
Series B Convertible Preferred Stock				
Class of Stock [Line Items]				
Preferred stock, shares issued	0	119,000		237,745
Preferred stock, shares outstanding	0	119,000		
Outstanding common stock at election of purchaser	9.99%			
Preferred stock conversion ratio	0.33			
Number of common shares issued upon conversion		39,582		
Conversion of Stock, Shares Converted	119,000	118,745		
Shares reserved for future issuance upon conversion	39,667			
Common Stock December 2023 Securities Purchase Agreement				
Class of Stock [Line Items]				
Common stock, par value (in dollars per share) \$ / shares	\$ 0.001			
Share issue price per share \$ / shares	\$ 3.315			
Common stock, shares authorized	168,500			
Common Stock December 2023 Insider Private Placement Chief Executive Officer				
Class of Stock [Line Items]				
Common stock, shares authorized	6,070			
Common Stock December 2023 Insider Private Placement Chief Financial Officer and Chief Operating Officer				
Class of Stock [Line Items]				
Common stock, shares authorized	1,886			
Common Stock April 2024 Securities Purchase Agreement				
Class of Stock [Line Items]				
Share issue price per share \$ / shares	\$ 1.61			
XML-55-R42.htm IDEA: XBRL DOCUMENT				
Stockholders Equity - Amounts allocated to each instruments (Details) - USD (\$)	3 Months Ended 9 Months Ended			
	Mar. 31, 2024	Sep. 30, 2024		
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering	\$ (80,000)			
April 2024 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		\$ 6,290,213		
December 2023 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		1,049,000		
Common Stock Warrants April 2024 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		3,819,274		
Regular Warrants [Member] December 2023 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		470,000		
Pre-Funded Warrants April 2024 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		2,398,831		
Pre-Funded Warrants December 2023 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		321,000		
Common Stock April 2024 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		72,108		
Common Stock December 2023 Securities Purchase Agreement				
Class of Stock [Line Items]				
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering		\$ 258,000		
XML-56-R43.htm IDEA: XBRL DOCUMENT				
Stockholders Equity - Valuation assumptions (Details)	Sep. 30, 2024	Dec. 31, 2023		
	Y			
	M			
Expected volatility Pre-Funded Warrants April 2024 Securities Purchase Agreement				
Fair Value Measurement Inputs and Valuation Techniques [Line Items]				
Warrants and rights outstanding	1			
Expected volatility Pre-Funded Warrants December 2023 Securities Purchase Agreement				
Fair Value Measurement Inputs and Valuation Techniques [Line Items]				
Warrants and rights outstanding	1.34			
Expected volatility Regular Warrants December 2023 Securities Purchase Agreement				
Fair Value Measurement Inputs and Valuation Techniques [Line Items]				

Warrants and rights outstanding Expected volatility Placement Agent Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.96				
Warrants and rights outstanding Expected volatility Placement Agent Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	1.03				
Warrants and rights outstanding Expected volatility Minimum Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.99				
Warrants and rights outstanding Expected volatility Minimum Common Stock Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items]	89	87			
Warrants and rights outstanding Expected volatility Maximum Fair Value Measurement Inputs and Valuation Techniques [Line Items]	1.03				
Warrants and rights outstanding Expected volatility Maximum Common Stock Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items]	92	93			
Warrants and rights outstanding Contractual term Pre-Funded Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	1.21				
Warrants and rights outstanding Contractual term Pre-Funded Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	1				
Warrants and rights outstanding M Contractual term Regular Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	1				
Warrants and rights outstanding Contractual term Placement Agent Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	7				
Warrants and rights outstanding Contractual term Placement Agent Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	5.5				
Warrants and rights outstanding Contractual term Minimum Common Stock Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items]	5				
Warrants and rights outstanding Contractual term Maximum Common Stock Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items]	1.5				
Warrants and rights outstanding Risk-free interest rate Pre-Funded Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	5.5				
Warrants and rights outstanding Risk-free interest rate Pre-Funded Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0551				
Warrants and rights outstanding Risk-free interest rate Regular Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0553				
Warrants and rights outstanding Risk-free interest rate Placement Agent Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0391				
Warrants and rights outstanding Risk-free interest rate Placement Agent Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0457				
Warrants and rights outstanding Risk-free interest rate Minimum Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0389				
Warrants and rights outstanding Risk-free interest rate Minimum Common Stock Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items]	3.660	1.370			
Warrants and rights outstanding Risk-free interest rate Maximum Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0457				
Warrants and rights outstanding Risk-free interest rate Maximum Common Stock Warrants Fair Value Measurement Inputs and Valuation Techniques [Line Items]	4.050	3.605			
Warrants and rights outstanding Expected dividend yield Common Stock Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.0551				
Warrants and rights outstanding Expected dividend yield Pre-Funded Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0				
Warrants and rights outstanding Expected dividend yield Pre-Funded Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0				
Warrants and rights outstanding Expected dividend yield Regular Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.00				
Warrants and rights outstanding Expected dividend yield Placement Agent Warrants April 2024 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0.00				
Warrants and rights outstanding Expected dividend yield Placement Agent Warrants December 2023 Securities Purchase Agreement Fair Value Measurement Inputs and Valuation Techniques [Line Items]	0				
Warrants and rights outstanding XML 57-R44.htm IDEA XBRL DOCUMENT	0.00				
Subsequent Events - Narrative (Details)	Oct. 23, 2024	Oct. 15, 2024	9 Months Ended 12 Months Ended		
	shares	shares	Sep. 04, 2024	Sep. 30, 2024	Dec. 31, 2023
Subsequent Event [Line Items] Preferred stock, dividend rate (in percent) Subsequent event Pre-Funded Warrants Subsequent Event [Line Items]				6.00%	
Warrants exercised 6% Convertible Exchangeable Preferred Stock Subsequent Event [Line Items]	4,135,000				
Preferred stock, dividend rate (in percent)			6.00%	6.00%	6.00%

Subsequent Event [Line Items]

200,000

6.00%

3

[illegible]

[illegible]

[illegible]

[illegible]

0(KHR%5T)\$=6HFF(KD^J)Z2N/2F:IM(^(^RD2O_NA^Y&VKO:~#3@=6CJ71MM2M0DUR6VZ^N^:HU/U/UY^JS:%A>H/88+GG(D.H^959QOQ2IKO)(P0^<~&*M
M^0^0BF+<N)PWKE75%T@9+<GHG(H1&8Z^M^OH!=<(&TG;OG^IW+<WL+<W%JKL^M^<1=SP^O/E#F)H:HC>HFROD:1^1012^<9R/M&7^+W.19_>=<N^49#<+Z?
\$1JZE^5M^R^+F>U969T0^<T@>#/\$!^<9K^M^<13K^<=4RM^OML^A2PSC7K^<1E>^3QOQZ^NANFYV70K5\$%HMSJDB^ACT^M^+M^+QDSM^+T^H^4B^<P^<N^<P^<G^<I<E
TEB287:75#<@<UO^TSWZU^<@>NG^MU^H^<1VGY<R^<@>B1E%<UO^I5^<Z^XQW^<1^H1^70^<G12ZGEQOMHJW^2^MD1>^ZXIVUJ61VY^<9^M3^<V^TK@<ADQJY<BAKGI^BR73+SY^HT
M73^<#1^2921P@<MPNYIM^<3A^<122YEJH^<12VCG^MNFAT^<M261>^TS^<06DE^<MJHN^<5P^<+<1PDDP^<D^<RT^<+<@>M^<5^<40B^<U^<F^<EQA:<@<T(0^<7^<AD)OJGL6^<M^<6^<KX^<
WX&^<PUA9^<MPQ2^<@<JBT^<RA^<ZF7OJ4P^<J^<7L^<@<ZAQ^<KY^<O6^<#0^<R16^<1^<H^<R^<F7^<UO^<ML^<@<2^<E^<H\$K^<EXV^<CH^<+<2H^<G^<LYTB^<T^<F10B^<BNA^<EV^<LU^<HU^<9^<2^<H^<A^<M^<M5MR0#1^<D
Z4^<M0^<WM0^<Y^<16^<HDM^<RA^<WINS^<ZW^<U^<M8^<~<K^<W^<+<P7^<UH^<7^<F2^<FA^<7^<VBR^<T^<UO^K^<MPC^<3^<29^<O1^<GJ^<H^<L^<T^<E9^<M^<F61B^<N^<9GT^<E^<FEN^<ERW^<J0X^<+<1^<+<P1R^<@<I@^<?^<A8H^<
Q^<IN^<2^<A^<1^<E^<M2^<WZ9^<C1\$P^<KJ^<16Q\$^<H^<W^<HY^<TN^<+<CQX^<IZ^<TOO^<X^<FE^<E\$^<WE^<J^<W^<Z^<S^<7^<+<9^<M6^<T^<CDO^<S^<6Q^<O^<U^<T^<S1^<3^<Y^<B^<+<B8R^<+<2^<P^<T^<P^<O^<Z^<3^<6^<1^<H^<L^<+<3^<S^<U^<Z^<
M^<0^<T^<+<1^<@<U^<1^<5^<~<0^<V^<1^<N^<P^<1^<+<10^<M^<+<6^<5^<4^<F^<1^<+<1^<H^<3^<H^<1^<M^<X^<+<G^<1^<A^<1^<7^<+<1^<H^<R^<D^<+<20^<1^<2^<Z^<N^<+<Z^<C^<6^<E^<M^<E^<A^<1^<F^<F^<+<1^<D^<D^<+<1^<H^<+<J^<+<D^<W^<Z^<U^<S^<D^<
QFQ<~<#^<M^<E^<0^<B^<A^<0^<+<0^<V^<1^<E^<T^<X^<2^<Q^<#^<@<10^<M^<+<P^<E^<S^<+<O^<S^<P^<+<1^<H^<H^<+<8^<P^<+<G^<E^<A^<1^<U^<Z^<5^<1^<R^<D^<+<1^<H^<R^<F^<G^<I^<V^<R^<T^<O^<9^<M^<A^<W^<+<U^<+<6^<M^<N^<B^<U^<+<W^<E^<+<H^<E^<N^<8^<
2X\$9^<165^<D^<H^<8^<R^<3^<X^<U^<+<5^<F^<L^<2^<P^<G^<E^<B^<A^<+<@<C^<A^<E^<H^<M^<4^<+<M^<+<U^<N^<H^<U^<A^<O^<1^<H^<L^<R^<U^<+<K^<I^<G^<K^<7^<6^<+<1^<7^<+<1^<H^<B^<L^<T^<+<V^<Z^<H^<A^<+<3^<W^<Z^<+<5^<W^<M^<7^<9^<C^<H^<+<9^<+<J^<F^<W^<Z^<0^<1^<D^<1^<G^<+<2^<
D\$A^<W^<O^<J^<+<1^<4^<+<6^<V^<H^<+<@<Y^<M^<5^<B^<Y^<X^<B^<A^<I^<+<X^<V^<I^<O^<A^<7^<F^<I^<O^<M^<+<G^<+<1^<P^<+<W^<L^<Y^<+<8^<P^<+<1^<Y^<+<2^<F^<A^<+<1^<G^<+<H^<S^<O^<F^<93^<62^<+<J^<H^<Y^<D^<Z^<3^<C^<U^<5^<X^<K^<H^<O^<O^<+<2^<V^<H^<O^<K^<Y^<C^<W^<75^<V^<+<6^<+<H^<W^<E^<V^<1^<G^<+<K^<O^<Z^<R^<P^<4?
13^<+<1^<V^<M^<9^<C^<1^<6^<+<1^<N^<L^<S^<+<T^<+<G^<1^<M^<+<T^<H^<S^<O^<C^<3^<B^<0^<+<M^<+<N^<4^<9^<A^<D^<L^<W^<L^<O^<+<I^<M^<6^<+<1^<Y^<+<S^<+<S^<+<F^<C^<O^<L^<S^<P^<O^<M^<V^<I^<+<O^<P^<9^<G^<+<G^<W^<+<J^<H^<+<1^<H^<+<1^<+<L^<+<K^<O^<+<4^<+<B^<+<B^<+<
1E1O^<B^<W^<D^<I^<K^<2^<M^<3^<S^<C^<N^<E^<N^<1^<O^<+<G^<2^<N^<E^<L^<K^<8^<I^<R^<C^<5^<S^<L^<+<1^<T^<5^<M^<+<9^<L^<H^<C^<N^<+<A^<M^<+<9^<+<S^<+<4^<M^<+<X^<+<R^<+<2^<+<E^<+<J^<V^<+<+<S^<4331^<1^<H^<E^<D^<+<E^<9^<R^<O^<5^<B^<F^<B^<+<3^<M^<

M:KG*ON8SOY8J180W\1)W6WB362L6*15X(O@f-G;L#B/97L2B)XS8-19U-ML7HI""B;E=A#WZQZ430+W4V>Y? MYLW-W%'5\$W21A1-R--?4FX>#1#3(OJ-
J-9-FN3ZJ/SX3ETS;@24B#2 MJJY3YVF(O?3-TIG@1T5TGW1-CJG;H/UZ3YH?SA-S=&B ET-?477W-MO1-KZ3/RRRHJ@EU0DYJHIG A#16(XB+<C13(+@4Y0-@V;1GJM-IP\$A)
M@HNB>=H4<=O1P2Z5FB;J2@G6G;U46DU1T1.OY;7\$+8-M* OXQO<1 NWWYJ2J3(C7Q)O2=P1\$;#N-M*2;84FI@ZOH2A2572@B7UVY5\$Y25OX"
(C1SBV<=7Z2J1@EB1-B#IK-Z2M1>N(TN@ABM2W#B7BM7NZX?#1"8JH4QZB9V+5TS;>#1LK-GVYR:@A;J\$;G15EOQ.P.=ZX.M2.L4.L:0D^WGX?
H:=YVZM+RO\$;,,BCV|=AC%OW,+4T"V-?,"U\$K4>Y-M39P1?R=4JB@BYN^MZP1L4&7V14+;N+5Z#DT%(3WC%MD6-S<&.,EWF^B-
M=S974_KC@W.G1=1\$1T"U;7C60@IOBXZN_1?8P53K1H81+1=UN\$?>GM-MF/5>3?3170411<=<O?E%="1Q1K?;UB-V9>W0FL+J6HK4^"8Z-"H<3 MEZ\$3-P0/
U818+1%MF8Z304M2=A1#M->T>X836<.,8H0D.M+X+3+JEM1YXP19>0-M-WR9-2.VL-M.B;1L453B9#Z.RTB.G\$)OCW\$B8RU.53)2^..8V?>DPJFBW0CWEL3=AA6I
MLTENM2-JX1;=1-Q1=N-2.BJ>=?7?XP.M5W6GNS#;/ROUQ.B2)NFMU#1?CIG&K1-G;U-VS2ID-DHX^OO@W6H5?Y2J MVK9?F?U04?F03\$W6.W1>?PCM+
1(H?7M)+>J1CEYFDA\$;F1_KZ-M57G1F2B8W0E(O?31)4F9Y;2\$S?UGK;V12.26^1(G;U)Z87+Z.GEUS17W<=3?O)ENH54T+>1"0YXFGV1P544@A>&A433F4^A^M.4%JA
fWHV#4C6<2.MD1'=7IDJ@8021>1?1P1-0@?SUF#>= #F056.OW:3-MUB6F\$=5M.P.\$9!\$8Q<-F;-HZ?1L150^60#;UC<^SGKG@=,;^A^K:1Y
M0HGPD&J2PK6XN\$;HHV;8Y5NH(N?#X1O)=M0A.YDYJUVHXJH72BR^M2@<P^8ATU6O;,,#NO7Y+Q13V1Z-IM>0AVT0.Q?0R-5@<6N>ME>NJ6FI(16MHJ^1@0H?>PU
K.N.B7A.OB-MPVYD@<PVDVBXKW10-M?>2IT5M20;2.MM.TIU+<=>.Q?5T7B-0#2@A.0@A1A ONGPI_4497676^NNA0.FVPE(C16P^KH+E@K1E4Y<M^MZR20.MJ+>+>
UBZHB3579L?1?V1GCL;TBF#KD?F@JTMJ6C@MXJH1DVQ MURBE01M\$;106Y1K(1244-SWP>1E- D3FAE+?A7#Q<=M7GCH; >?5T4Y^PYONOD+ODI@5DXP?/804H4M1J1.OH&E2?
Z(K1OHL@_1PO-MACINA_X#1..YWX8#0.07U1XZ&W^07AR-A.K_G8HG40W1#12L6%01=>#M9;0K(R<G^G&U1736@>5?7 MPS1?1VDFE1EG;01#1<K@F>FD1J;6XZ7?
M1HJUJHTS3/1OD>09YGGIRGE?DOWF>T9?21.K#;H5?YZL.M#9;9?)QS-W0M\$G-INN1SM(WG@^J4.M\$=^T3?^H8<+W%M(A;13H/Z%3ITKMXS7<0%0/WL&HWT H47^=06K?
018<M<=>X0X^70H4H+0YIEK1"06BETC#0#X5_A1?<=>K5D1O&W1W;Z9Y_?3Y31LWK-M?C?>.,GDW9(NHJ=GSFCD?SPPR531W)TUCO2UEH^<^1)9\$5^YUV1^9Z-MG1>1+>N+>
1Y^OOJFY1^6Y1+VHE\$<@VH1>=>1U.H1.\$P33?E/L1H?6U-M1W^11P21E76?U@1A1=^D^G+O10<@TF;.,(419Y;V^..XH1E<11<^>?>0-0XJ1<.;
M_#88RXB18C\$@03N3?511HN"_.O@BHLH@1P1^1H^K<=1U@ELHX470YK.MO.Z.#;#J0E15NS6LKM1M3D\$>1(6VEZ^ULIUG.S-PO'G.\$S\$X_U(3^5D>YZ=1O=;+E/;#F=V
M'6H1Y51N0.37#1=<=H7X.S;B9(G\$=8Y4X.AH)1<1MXG11_?2^1.M_2E=M0CA1T1.K1_1YVNGC0#81RN.R1G&Z1P65)O.EBZ5R05(1N1B2.RH.P4;20-M.B;10J/GW^9T5OKI
M\$OYCH1%+Z^X#3-1C7NIS46DU1+B"0#1.M>RP= GLBP+J.C_/DKJ#Y4VD7D(M.EJ#X\$;^5X-P.%3.99;#141C)Z0;\$-13@.MJH&1\$6#=-7026CG7>N!\$T18-
>^YJUC0P51^4P1<@108GF87F.G.H\$4VA>=>K7Y-M.U1<= W&1^K1C-L6W>1RA4+<#?>FJ02\$%1^>O+D&8MWF0\$&BEU172^4EJ1#R-MX20FM1P-/1-E\$=51\$BRHIEZDQCO+4LY/2M%
15H1U-619.CV)FEL1.M99N2NR6G&\$;U1X21E(YW?233)1<1_5PS2N@.WNT\$N#;DYV-1^>#0#;SD1_V1UT-M_Y?0PWSH+JA^XN9WNTV+JA^XN20J22-PZTZNCGRJO8C?_YHFE1
M&\$<^YMK.M.7NZV01Y^1FKZTSID6<^64^6AH-MY6;1.H1KJ1<=>=>24.GH<BW05Y9G691M110^>=ED+IHSZ-W^XKND70.LNW-M.G4NX9T9(NGLLZ1-KSFQOM;V1>77.8WP2?1F^K
MZIH:5+>(BR1<=>536UQZMD\$WJ2G18X\$4VTA.W1D)6231E15W&9/1B1%5M;V1N.CD44F\$4+1^62&T.O%O^>XZDC-M_K^?&8M_K^?&8J8JEN-9611/E1=8T^02L@1&R-
1\$;FJ1#R0L&ZPIVA\$(M.#O(C5U42%2H_E6D,+5Y-X8ZM@5TX3^C@Q;YCH#1\$FW_RS<#9#>+443-M%*0/BS1CBS1<X9YZ+W1^E?WF\$HBB1_T>=#M\$?&G.X\$5OHU-
3ME^G.C.UO MU_/M&S#O^BOGTMI19&MK5.9365.ZR16;4R5>O1HC?1M1CXHFE^C@QG04.M.&@/Y4X-1W^9 MY-
9P.ND1Z3.D80HSF+R661)YEOE5QD1&#Y1A15914+1\$P15BH2.M^F6T5J;J4G1^V;C=KXU16^BAIE3X&@RB3;3QDT=K+K1>S_Y;3.TL@_MKYZ%2ZIK8>1(70X9^1K=LU@P^K^+
(97T1>G-WX^K^<QOT^>ZB5A1^YK^<Q2-M3MD.M%F61+>R;1Y48ZVXK-R&+<AQ914+1>OH@>0P2ODMLESUF0R4SIH.MDZN.F23TDXW1T>1/5E-@O-M.L=1.EVE1#Z2%+MI?
#Y1&3?&Z=>#H1= M9JMG6.#YV1T?Z.M^<2^5%1>.,#801PYGH4M9W2118233WYTS\$G7FE5Y92.14KPZ.Z?OKP.&#?0CHZ16P/AC00\$5#91@U7\$A(3302)2_/O4>?1%-
A;1G;H)19\$;0#1M4(K&X1NGY^A;29%;.YY.V.K/=&Z.K1;KX>Y1(@.MAB=O1_?ZEUU^?PGME0F7850V^1JRIMR>3+U6W1&1<1;BDFFX\$S-MC
R3\$P#@.N^M^ONPK?H7Z6TSH1?>W>W1<@Q23>P<1? MJK16&#&1C21A>@2PZ539X6K&1&VO^AMJHJ?PM>W4;SF(O^1.W31SF.MF1P1B^LXG+Q+>5.G1@4&F1;90SQ
MM^B0?7\$M>62ZT;2B1EY1S.ME1YD1D@<49C>1%1H_15_.(624.9E1&1<L;R^N-1)B+1(R1K)E?G%?M.FE1#0H?#&6;K81#^VK+1S08IE16F1465YX21^=Z^WZ3=NB.M^LS;C&
MTR^T(R)E.DFK4+1D^N1U1WB6CB_?RH15MH&W-M.V1P1-1U1U;KLFK1&R1GYKA&NOH1?71+1J6M+K33F576+1MQ_6=1W^C9P1Z?E;KA81&K8MM55<5KYIN(GC15F)A6#3Y.LD1O@TGO.
M6R1V4ADW^G<Q1@<VYV_1E.FR01Y_1M%1@1W1Z>1T.Z-203ID0?E(W1B)D-M.D&T326K6&G&G?_1JF4>=13F1U?2KM6PS?<FV1MJBW&AS&CEH1M1+M+C?%<=>
=M1/G1^XZ=H1TF=>=>1^>E3-(R1E^@R%#B?T>@OY_A1ZO.TFZPOAVP<=<0JWC2RW.MK91%1W;N-Q3#KY080R+6>=>S^YOY%<^QOP-R/F3H17A819W.P(+^\$A<MKL;GIT^1^1
Y1)63>=K1P0+1D.P.KYX^1(W1V@>0JMP(MPN1+1;H11.M0.21Z48-S^?F1P+BBH&4M136;1E1V64F_1D_K\$A<1.MGH1P_AQP2>@>0D0;A.V71=^P.E@<FTCP?73C.MSHK&ZH9
/EF@R1M3.1P1MVS+1Q1T@H21@PHH1SD0?>Z^X&2E1V^O<=W-Z7%K1?1QW1AYPTFH.M^29>2@#>1TQ;0YK8W^XJ1<(<#E1MA1E019+506>52P.O+O9R<4.0#B09N?^FH.MB?
H776R&K&3A1Q^1#6D.1DQZK72KR9G6K809E3>YA+HLQ.O1F-H@+F.E1R<@C.MN-W^1L\$N+OPHW-KEK1D1SHH6\$;U154&Z4Q1F1W1%12%\$>.X66RO>=>YBLU
M1OHUEPL8<(R5PB&B<CE5X1H41HHVS)R1?>09Y?3@18B1&Z.E1R^W<=O.M.W1Z131T3C41A^=VM>#>.F1M1B1B4>Q1R46FUX91UP5>=>?1%FO?
7L1UM&8510M^M7%0.LW-MKE1#1+2V^@1^1)HMES0_P&D3;D21W&FPMXQ+814C<*>10\$;8C(+Y_P.#^Y1OC.M7TO.CBL1FY
?1Z;1L1V/RP&\$&X&5<Z(O)N1D\$5(BE\$TA191X)MW017TAP1M0B1B^1B@<1X&1E1W>DK\$X&1UBTB@ELCD15^YD1^69T\$@>=BT9Y1>=DYT=1-UP2B-5.AF6FS1QDS2-7M4S
MC5="8K2@C4G13+1^UNKGD0\$5NHLG315V-T\$U.L-HC1%>1Z-NAM3G1VC.M3J>=>6G/C90B1V<1G;GT^R1D1_9P60@H(K04161^UN10N2A75).ELB(O1+1E
M1B01<W1W16=1S1Y191214>+>1S_0XMTH0\$XNE0U_@>@1S0QW.MN1=0V=>B/S1^1N1Y2RZ<14810AWP1@<@B1D&P1\$PDN11;H11012.L.MZR
1^&H1X3^HFO41X1OT0W11?P.M+1W11^?0@Y11^H1ED^C)1B&@15N;U(TH4Y1&13180).H11^92L(SO+1M1C.M1Y21J>31AMOV1Y+1ZDGH<
AOH&KY07>/O\$5\$F1+>\$Y1W8MS17L\$X2>+11TBGYK00X^XU&S2@.MPH^X^+Y-E-Y\$RM-2FHN%15^?+90M81Z16G/@EB1>81^12#1+O
M1#BKZ7M.MV<=<W%142H=11FUWR8-LV146UR+13&FR41Y6D8N13M1^1+GUVN^8W-M0;13DD1<@KF+Z>=>?05#8933RRQ<4)Y\$%Y4LO1>1=1=+@OCN%G<^@CH
M-Z#21A-WD7^0#H<@197>0EK7M25XLAU4KMN=11QF1382?1F53H0.01?M.K\$095148D-C4V1W3UN^<ZL1TB1DZ71^1)P1SAW0-77KZW9V9.3%N
M_T2N141X13Y1+1A1B&3BZ180_M2UL#5=514S1811_1.WOBBPY>08^01M0K1LXN1K1H1+1%>T7=>C>R6+SM^VJQ;=>#1H<W+1F+O1G1P;GPO+1ZXN&10.Q.M^XJ
C1M17X&6&1Z_G>1EGU4O1\$S_K-GW2E13C7U1Z?>O6F65KB7K8-M^O@Q1E5^?2_1?0W(D1.M^Y8+Z1E7E2Q1X1VP&EUD\$3B7BS1^1H1VDP-A2BD<OPR<PBB<3(CU
M1T7Z<1)64+^9.T6ELOPU.SAG^#QCH71K_7\$DFQ166DN%11>G41FH30F.MZ5-\$=K/U4XW19O.SN.YM1&4U6EY.9^W&=ZY1N-8W%1LG.O=6XDZAS^Y<OB-M^E0#
Q035EM&X14R11+1^C0E19W1V1V<=>51Y1T515L CC77CM^KGUVH#M-MWTF\$317GB151^1P<_U1M?P?G-VO^1M@13FK.#U5K15<9J\$;2#67.Y1L@M!
(?>51%K8#AX108R.DV\$@L\$;VER&05F1M@>MEGF>19151R(3G-A-M_1B7@7M^VSD^Q.FP?Z1G;VE7E.67L1U0&^ZH
MT^A511DPN@L1H4M^E9&K<A^V1^1TAEH13(61+1>?71&8091?E2\$YHL1Z55G1?W8015Y7FC.M-ZS(1R4^O1G6CC5M701H_VHBPT21ZK61U@A^?F4QZOT1BFC1^<A13
M6^5U1Z121^21S181;H10^FMA=<GD018.R)E@>.G3F#H?N1Z<=R(5<108H01E?O1Q@3AA00M&8?7;C100H1R5D.MC0121S21@<1PD177G91Y1>94>?^V41G1?2&8;H=O<
MO/C5NVE1X11%9130C.R5L00+1=6VO^C+GHL4OWH1.PU6MD8&8192W-^9.M^L8\$XS(B^LEMO+HX5(\$?>10^6&U1%1H01L1T1=1L1#(0RA1NDG1?2
Y41CGG33K2NK(\$W^SO&GP_01J6<^P1-80+MDL1E8L-X1AM1+Q1MU1G.C.O?^?F.CC#7Y?NM191A+V459F1XJ1S1^12B-M551V1E3&F0K^?0R:QX0R1U_11^10WAP3.P33Z6-
FG4O1U>3.K12K.M.M?=<1E131Y1Y1YR=<@1P&VZ1M.#82P1@>.UHL1E61Y1MX1O&.56L17L>=<5^V1L%61G(XDC19YKX#1LOR1HK;71<+&3ZPDM@<OW-MJ129B&?
S61B9^1WWSY1G15>Z<9(5<1HEN;2<=>S1L&K<A^1Y3W110EF1016\$>=&15EA2?R14^N1H+Z4G71BFZ.M^M^M^ZP141+BYK7M2.F1#^9V3HDF1101^O1H1H801K&K43^?8V1Y
M1(M158K1)=D1=9151T0F1W1^>X&YK1V10F91L1L1<=&GS&F7H\$?FA11.M.S00V&Y181N41Z1APF8M1K1^VBSB-CQ^4.O.MK?137D1SD1^12L0.F1H^<O130.H14XCB1R1<
@.YV1WTZPQZ8YFM3+15ZB.M@1V1&F&S+1)2.Z>9PA^W^_GU=<#N0J3N-VW%10+1B1G1KW1P234OYD81>U^EN1TSV1G(1^O2=NN78.R151VH>S1>4)S1^TZ1O1+PZG1=1
M1J>1T6B1+13?H82^0R3V1#1Y1C8R91.MW41=1@H%N=M.3100PQ1461G1V1-M61^7X\$;BV1L1QCMM1^U1B=>0.6S1G5JMW1L.U01.6R51Z1Q-ODT^FEN1?
M1AF253.K110NRMLC\$Z>1U1Z871MGH+19%1HUV.R1+UT1.GDX-2=>S1(11^M614H1M5A>N7Z.O1M58.YCMVYNOR%1ZRG7566A.U&H7<5D4C>1AP^D1.Y1S1M&
1HHG>O<L&6K11Z1>1<O11E1>17O1S1.933H61AHEGSD1DUBGPAV15L1E=>#&2QO1^1UHM1NM1P1G1MPG1L19<OZ^11A132.OK#C.O&Q1P1Q909K1YU1=516615ZT.FQH
M0\$FDH15+1IMX1>1L1K1E1A>1U1J1501_103^?=>1515;1M9W+1(9.1%FQ<=M^M^6K9D1X1E-4Z1A5C\$<
#*YS9S=#B;Z;GL1^1VC=>#S<8>^U<KBYU1MK1ZEH50AR&7Q0C01J1T111TT1DP@G&O.M1<4@MXYVUWNW+1QF1DNRX1@IM.S1@_ZM1(%M88Y7\$A)1\$=HK0_&TF1)DN:6\$UC
M179BH@8K#8X<@9: MZC1OM_?131(0C%MSK#1Z=S?&P&1M10RABLA7M1A61DQX1TTFV9?>=S1^23V1W.F1JK#8^11P1S7-1SD1Y.XC6#1+>MR>13P:61#1\$S<+<
B.01%Q37V1@<M9T.X(6-->1@33<B1WU0P@M.M9T\$X(6-->1@33<#B1WU0B@M9T1X(W1#>@EG10417>=1+1WJF3
M1\$CU117464.51Y1XM<1T>12>O.91^H1Z1_RAXU1GKR73Y1YKEXNN1M11^K1_K7#151W11<1NB02Y1>1^KPK1E51=>18301^1ML1E11B1K1W1+U06@<1(GPW3A.P11
SA1H1KA21?>1H1>?7HE1W>C1O1M41Z191\$P1A1@15G1Y441UNX11H1=674CND80&8?7;C100H1R5D.MC0121S21@<1PD177G91Y1>94>?^V41G1?2&8;H=O<
(R0D2XP1R1&2>UF4;FTO?90^KG.RNE6V.M2F8RV1=01RHK#1361F5AM72T.YU2>&W6@1ST^R&\$R6G4C8R2?T.F11M80XBUD&G\$P9B>1L(1519E56;O'S8B^1
104>CM1^180^AV79CZU9Y-M4_1X;H\$5W15Z824L1F11BMX31D1^5&U102FM1.MRSUBC&#R-SU1)MO<+>1^6W1W92<1G>1@E^F1?1L@16D?K1O1Y1M1
100LXEW11L(H1V1V1-MUM1A1BBK51+>9^MEV1@11^1V69>=>GC36015>7)502^5&A5F100_12ED1.M^S^Y1^10B8R6D(6<^>DM^PH^8&K(MOBB1.V1W41PNW1TV0Y+
1R151M+19R.WKMR1=U1SSK1<@<@Y131M4K1H1W1-K1F^E?C>=>445T.N.OYV%0X11T6L&4MULCRWM1=Z3FM^U?7.M^Y1SV1T^81)815.N1V21C1E1XQ082<X1HP<1^>9<G
M1W6C1(O1^>1T>@17.M&K<36770@C0N\$1#6.S1GU-2C1R91D31@H1.M05125AG6.LZ1MR1C21^?3^W9<=>1(W2911V1G1%5GLN1#M6G1UM11D1P51^1R1B>1#N1M1^FS&1?2
R7#F1H1Z<1^1%4A&S<P.6\$+>1\$SW1RG1Z?2#2N-1&1291L1A1V<OY.M%321H1B.W1G1U6^Q3D1J1+K22DGF8211^MZJ0LL>1@%+N^1Z^5C1+7BH7N1H
M1^F^ZDA1U10CDE4W4NU\$N21U1TE818.251H1\$R1D121@<D.U1C1?71V1O1M9H1?1U>1=181G1PV16DX1?1M6Z1K^6K5.G1G15121R1V1^1KP29Z13
MGMSA<DX1M\$>70>1@1KHK110W1V1(2R^?1>1D^<8<^1J1Y95102WD.M=NC1G1C1T1?<=>S1W5128BK1E8^MW1E1911X1A131TH791O1&F28C+18&H1
MT3E191O19175101U15M5HB81D1E701DQ&H&H556.FC1P1K1H208141TV^1F.MD81MF1K1M1B1P1J47N>1=1L1^3V3G114D21=CUD1V1V1>1^&S<=Q1M220141O1.W2101_191
613=>#ZU<@11W&1T191P1)UD&EA-DC<=>101A1M1<=>=>H^<H1B00180C1&G1^FPZ<^00.020V1L1M1^<1E2510&X1.MU14XK179G&61Y1+OB1.R34&=>Q9&L9K1@11OPO1K^_N1
1A1F>W1U1.FH#<6.M@<@M7^N7ZRG1FVYK8ENP+10L3PEAF112%0QC1N1UK15NR6&YUK137^?33L.M1-9XNP=UA21=1Z=8Y0E.C1YK1ETD91@31@GR1M1K1^+K10CD0W1M4K
M&41.H1M08+61N1Z1_UX1(+1=1D1P1+W^W1V>UA1AN\$A1R^11^5@OP92DX14H060.M@DZDCA1EO7P41M1C1T1-219UW+M\$;Q5K15RZ1OB.O1Z%>1HH1C>=>@C1
MDQ@PZ1G=>1E19F6=>3#1F1R.N1G0<=>OH4^1A1R1S1X11X1E1Y1T231P.MG6(AW1)^W1=13NSX1NH1W1TE911^20APDA1E12181O1Y1DU\$1=1J1F2151
MG2KT3122H@1B^BHM14O11>1>GR>=>51Y1R1A1M1@161T6181H141HDFG9\$;9#M&1M^Y1ZD1^X1J1T<1^910L51U1M1#<=>1X1E11A1>=2B13.C1&53391HSW1C
M41T1FU1731GGH0_ZAKR1W1G1S+PAT131=>@S1H10@MP11_2XOXHTM1^UMUT1CC2_K1(1T1Z1OW1D1NS1FX01C1K1A15EE7H1M1M^1TE.WC1&K1M^&#G1^<K@U=2
HB1B0V>N.C.<=>1Y1+1PZ\$;VNO1E1H1YH1K1OM1M51M1W1N6>N1D1^?1H4Q?0^>0&KH6M1KEFS1=H1Q1N11QV2\$NC1N1(1_KZ2-MX31A1F1E1Z1N1&1&1W
M1W1YBB1-31F%31M7Z1U1<3Z71.M1M1LC1^1=1?WP^CWZ131U801^JFD1CE.M1#N-GXP1KE1R1V^N6E1X1E61LZ1O13^5C1&#E>R.91T1J1O1<D<=>R.M8O1Q-
1R1S^V1N1B.V^V\$E1G1A0Z15PHE1Y21%1L<1&586ZSRV1R19YK1M1O1771Z1HR1M1H1JSZ1PYR1=>6^5414U1JM1K1@QX55G8H1L1+UDP81O1^
ML0UD1=>1A1SF1G1O1YK191A11S1=>1G101AK1^W08M19H31PZ1FL1R1B1E1K^#3<1UCN1.M11Y1D1>1Z1G1A1O1F1F1H1C1H18B21>Z7C6RL1&?
M1H1C1K1PX1#NV15284\$;B1IFX1RV1R1@21W0G1V171T1^1AK618Z1+H&M1YH&S1^G7K1O1B21MY1TY0D1L1M1^1AHD1M1O1J0E1F1CP151P1=SK1Z8M3AB1-1K6Z7Z0VKW1
M7#67@OEQX=&O@IRV111<@<QKK=&O181@11Y1Y1E11CM1_MV\$1Y151R1#1^1DZ1Z191R171WU@8P1Q1A1W1W1F1(L1H1"8Z2^YH&C1P11^1WE1M1M1R16P1Z1Y1U1N1A1^9-
1^Y212FY3<6CWICK1?1WD1U47D1S161JGWH1+1H1^XMP1H143&1165UMK1=1HK#7.5.M1O<@S1HT1^H191Y168UZP170151ENK1P&Z1^1BE^<1T7103?D1W@1
M1JQ2VH065M.C1B1SAVDP102U.O1P1PH1Y1&1&105Y7&7AC08100&KH3R&Z1U_1C1ZP4^9\$<M1+P=>#G1CNI151^1LH.61G16>31_2Y18U1O1^1C1^1A7>D1P1E17F1=UVX61
1M1@10141U1P1Z1H3&>=<691S1Q1MPG1C@M2P11^11^1H1R^87\$1X1J1TUSA.M11P^C1195ED12K18Y1N1W31<1^QO1L1+>QEL1^1E1E1Q21R3JH1A1CW1+G1MIN?
(1<5C1G1K1C1^1UN1W14X1W1U15ZP1GH<=>1PH1NA1B6MA1^7EG1MGU11Y&M1B1AA1M14F1CTN1O1S1U&S1M21G1V19K10C1+>1Z81S1+51F151E1^
M^91.S5141W1^11T1K4E1P36&Y3B1+9NV1R61U9K141#_0&Q16R<=>SV1^11A81R1M1H131T1YH01L1SW12C92R1E12^2251#1^1V1#Z9>4K1S1=1ELL15-MTD1PAG1ON_@1XB3&N2C1P1B0B
X1+K4511Z1O1B1AWC&XP214161-F.O1M@A1R7&4&A1L21V18+KDJ<11&S1^1=1#1S.D<701C18X0T115E3C<91W1^1H1@1Z1ABA0?&K16U10DTKN3W13L1A1UGD@>51P11
<1;UXA1Z1O1P<@N1MK191M11G1G1O1Q1A8R51J1C&A0K1YA1=6K1+1^11^69K1C991L<@>6F3X1.D1M1G1^70P1B1Y1H1B1@VX1015B1HN1OM1^Y0.XSD1M1#SNX^0AM01-1RA1W1
M1^1170S1B1TMB10&03Y149Z0.4\$N&0?>5K1P1M1M166&80&K1NE6DE1D1Y3O&C1XB5&E1=23QC19S1&6Z1H8H1B1B1C1M1=1J1Z71Y19061#1+13V1C1>=>G21^1%7C1UB1
<1^1H2111A1=21M1.M10.M10^5%1B1Z1W1OYMP1CL1A1000D121K1^<=>X1=>#68151G1Q191G10N1H1Q191M1X1K19%1U1>M1Z1F18XRN1H1Y1Q1F1#1Z11H1YV69D1GM191V70.7.6MP125
MSY1M1W1X170@3YGVZ1W1#1\$1-(F1X1Y3R021P1^1ZC121N1A1O1S1C1Q1D1A1<N1M2F1?Z<=>1^1M1C2M1D1EX=>?1CMY1431A191A1_51W1+1P1H1O.620S1H1/POX1AW1MP11=OR11<@1Z191
1\$O1P1O13X15Y1Z1Y1W1A1#11NEBB011(NP=-01QO1UX1D111B1+1F1M1F1R5A1BQ\$1@-30A68N1^M-
M1P6QQUK6SUNG1E1#BQ1B1TB1R1Y4UL<=>0SQ%RZ1#>8S<101>WFOBUO1\$S1M1+>1X6191PYK=0Z1U51\$OG15%N48.0HC&Z3Z5B1WF1T^N1M1-M&Z1#1?2
MA4G19N1<1O41^2Y2G151U1XG1S10E1T11^HTT71Z^%1K187&11H19T1^0.030W1F1M1=51P1V17&A00H1Y1>OK1N11A1H1(W1M1H1AW20Z11O6J1M1<1^1ACEN119E1E11
M1L518H1818U191041YU1EK1D&51.N1COZNO1F1W1Z1B1D14CH1W16.624N1@N15H1M1-E1V1G1=>@P13GZG1Y1M1G1D1<1XZ1O111^1VE1J11X180010X71^1@31T7B1^V
MMG6=>15\$M1M1@UB=1D1215HTVGD1Y1%1#1K10741K1M1Z1C1Z1C1DDK1^DF16<1%1MXT1C3&W8U1Z12K1^1&Z12128K1X1W1+1P1OQ91P100.V12J
M1X&E4D19\$X37<R1=1SF09R0=>=""131715BD185)K1Y1+7^1Y21WE131DOED1M1L1V1Q1W

[illegible]

1.UXTK19K9C.EV&BW::1(1.1&)9%+::=XIOD[AMNCD]-1-BZ:P:=*7 M<7>19A7(HJ- R="3-L)%;^1+D"RI\$YW-GIPIX=- MC1&WHJ&>@0H.B5PT:7UWXS;K-ZN?>H0I92? <>B"WJHKRCQ321A-~%RY\$Q/52KS- N1Z05HLM-M.C9P-^F- JCR6BTG< MQ0B0EWY?E="H9>45H>+Q3F5GOVBKQOQ7KDB1JWCVCJ+H\$X FPN-1QH2 M#NUGDEN2+IGJ1GLB0W%T51\$ZQ6IEN3-Y-9>=>(HB5?7RPY2T-1@)(@FENY M1V+LW129R/(QV&>?V)T-UVIS%0K3P1U/30V73F7UFEN1ZD MCWV/ 1#&H11ZE.2%OR- H0YFZ/CHE1-RDX10YRML9-6"%>L-B=COC-^+>?Z15N-M-VK-^%0LL%<1?T1R 10X=T.O#3%SG2>#8;.QY-VH1SDIOX:~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~?PSJ-<% #411X&1@H31 411X&1@H31 MOY5M#0/(A1S%#)-A31O+U1V+1+L&5%NCGE7+VWZ>U9*2N-1H21(S1E2 M3TFV1P+19R1GA1F)79X9D2T:0.C8%7J1\$812 IV1A-8+1F(1F1TWIE M&NWA49&RG6R0I:W2M1BF+WM44VW&11J#;A^YEZ-M-M.K1.O71+1FM&9-M^PH1+R40HM&=^13CUC=CJOKM1XX@O93H1Q1F66PM1%)-%Q16C3^NDA:BUVEV M^ZZ43138%RA-M0-PUZ)\$?5W=>9C:H98<1B1*F1YY.7AA3B&F K-M>01/\$\$4HDN"8?^117<(TOXIX1^E:CA(ORD/QD^?7\$1E+R6J2/44A-AA@^M1\$C08?3.O0OK:"#B:49%- #313/2GTS1S(WB.9?S-MB2D+12:OM(PJ \$ MDDHR<?7&=17=X^D-UWB#~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

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

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|>0^M=%#MYK!%\$=003/1K\,C7E53ZWIA,BCLH|+>:INU<>S'I^CZ61Q.C:0NA%M(Tf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|>@R6QO@.K>BPWQ|KP?>LUT.M4DXUE"EG>C1|OI0Y=<M\$=732/C?>Z.YIHGG|F+HVLCS?>B%JEOWS8M.M<(P.P.WH8#)?I\$G<3S?EAAA?#)?EJA3L%#E59UQ>D+<+.VLY%5'N3K00U'5/0.MML.T3AK.4.2#H61H.M.2.O.DH\$#H?C?T%.S%CH1>1>90^UJHB<6T?S.WG.5YD?=>#F+HQO?<M.G&_4.YH8?H?I?P7.OIS(2.N.ZY.L34IU?<0N6HVN2L.NCJMDH?H.L.M8HJX?>Y0072E.HQ0L9.H.NPQO.WK|MG?>80HER?25.M5.<CH|MQ?77ENWZAR<D1/K\$>W6#FHH.109K.2.C/3.MC<@>D'M/ZMUW1L.E?N?<F33H|XTOJZ20FH.<?V.Z?>=>HPK4=>@<1.6XON1#<M.M(9'>5G<+I45&M.O1R0.FC4N.'4L'ON&*<4.M7Q2WQK.H?8.3.UJ?>YXWQ.P<=>MG?Y4:<+2.05'.N\$79B856B?<C?7H|FYK.MIK(NWC.#/G|<CL8?>#=>SGJEWKC.W.PG1.C.6&PPX.1L)<^6.T=>I^@D16#3?<M10.LN<9?Z.N.GOR.D.XZZZWD09?V.3X7C?S=\$=>H91:<@T0\$0MDN3.MY|EG#T^NFX.F75.TJ.M.J<=>F6L@PY.QIXI.K20T.TJ.O.IH+<=>5\$SFHV.M2.AU5X)>>@XLZ6MYKPF#H|H7R6F94.@V@<@16>=<=>?<GMIU.C.W@N<49Q.MFW@>9C89P?>0Q22?>9.R.<+TVS66126=H?WID?VYB.4QBWB=6+10Q/R.M.C<15?7TH@4P6B+>15=>2YH?TSK#R+>+K40KE@<3?PA#?Y@<7B0GA.<D<@>M039X%<W.W9.776ADSBMC2.<4Y<VQO9|E.L.R.YVO.XHS.YBV5KCMY.M|/C\$<L.6V5?DX.H.D.GFKWQ.O.DSAMV5W?OCBP+>Y42M.HGAI\$G?>MJ.P2A.K\$<+<48.U.O?YQF8.PTJ+<GK|<Z@<0I9U|3?>55.MZIS.GH|42KHBDI?Q.6AHJXK|<C.AJ+@IWL?>U'N'W'<C'>JTB+>+U.YHJHC?>SB|C@.MPMN250=FCIV#<+4&D)6\$<4Q?T02?7XO1=EI?>1.N=I?>9QB0?>J8+244GJ9.(EM.MIS.WJ|<N2FNZGJGJCA?>MZ5>("5XID.1KG1ZBL.VAI|96FI.B8?>HYIQT.O.HHGLT.OX?>V)LMF0U.T?OFI7IN<7.^N)ST&J.<I.T8Z|<?&.<0@>=1.L\$X|<?0TS>5.MU|<I.VTZ.D?>P0L^K|T<N'<2F^Y048L7EIB.MM|4.H^JXB>1.19C@>MPV.IDG601OT?>3?T.OKK.RI?>E0I.M02.AG<B+7X0\$N1.M9HJ3ISHHDSJF=I?>MF3@CRJ1\$>T.K|X1L04.D.6=>MOY?>P.JGOEMF40C<+>G>+E6.E.<61W&7W^C.GZ+4IWO>10.NB@?>H|MSH^NOX2|O.TBKUE.ZT\$8?<M.O?>1598800?2CV3RJY+<8+1.NIT8DNJ.L.ML.NHX9JX.2I@EISBN26@E!>D4DPI.Y?IFU.B+<G7.D@OR@IK8.M3UOWD?CZ?>BQ1(L.1.2\$SKYEV.O.A3.L5?F2FSO?80ZRL4+8.O3&E=32YRKT7RA.M9SAV49T^R?<g|3+M3.IXV+14?G>NOX3GA@>D7NR|+IM05ZSN4T0.BL^Q>+W3.M#C2**|GN\$&|X5IY.G2.E&K+L1L.MDZ5=>#D.(IB|K2K\$A|>A>.22=>X2|>P4YK0?>FZ6IY@<U.U<S>2?>B16D0.LMOH4+<O|K9H|<D.P.N?>ZT01=>XHIS.09)>#B>W3<0R9V?<Y<7>E#%<U1.M0UMPB<+76E?MVE.@>=>1UP5S.C?74Z%<K\$?7?>V>BOB&8?>S&3O.8^US\$MGA.XP1%F.#0@<U%N<0YD.DG.^4Z?<C|T3P=Z^N^R=ROA61TH=>Y.XW&B.M2KFF?<E=V1>0?<K\$S'A@<DP13>+>YQ4.'2.QOTE=CMCW>+>1^5UM^AM.K.G.M.C=LU+.B426K@L.XVIN8W^Z\$)>9.MJU0?4S:5I0.VKT^EG^Q|<@>MMHJN4.MAW.7FR0.4.Z.RZNU.T.7K#P.ZX.G|K@<CONRST?<T0X=>S2^AMS^X^P.6I@I.MRYN6EFMYOAZK|<XZE05V7W3?F\$4.2.L.GQUX&=>+TBVYU=>+K42ASL801.<@>W.R.O=56PIX.#D+>MVJ.L.MYVW?<CX\$7.O6^M<+<I.C3|>DOWK?>0.L2\$>@S.2W|>1=AX.N.#S+>MN=2?>T2FE>?>D7>@<L54\$Y?2^<@<IG&1RTH1>W7C8PGC<X^TP.2CP.0+>ID8.M344'.OO">4\$1R9I&3&S1DADG6.8XSFS5>0&4NNY.^00V.DRV=XIHHIDB.MN=QD?>S&COYH@<0)>E7C(5=6.%<6.N6?2?H20?>974Y|<@>M.HTF|8C.L;=>+>\$%f.3&5I^>M:Q1?>4A<=>=>E5W3?3&SD.M|P2(9)K\$<Q@<19^88^<S\$1WAL.MYH^<8EHOA=H28.7OFF.RI.Q?<5\$ZFBFO?>I2>TOH.3?>W+JF9J32M+HU.MWQ?7Z.W5858Z.E.H4C?<I1<6#?7E=>+>24.WXNJSW=0.5(E8A803J2?>Z?H|H&H8BY.OQW#6=J7?C.MIV.G<@<P|9L.2+1L?I?P%<6%<@<V.>@>N^>1257V.E#<U.7^9.<T#1|MKH|<+Q+ME01=MEGABE.Q|<I@P^H2INU.<_LWZ2Q.0+>G5H.KLRW61\$5.MU.'H|<+<CIG&M|HVR.C?2N

01-RT-67N-9(MOKRU4VDVHNGE6X2U+1A-AFFHWE-37-0Y#XD)6HC 0XA@+Y4 1M1VUHC1&B;V6<4E(H...NQXHF-IF=CR+I+9Y\$LSQ\$TYIO;S4B;
FGZLU_XL10/PX7K0M:CXCX+BGKW;A*6+D/EI/EH...@M...\$%>0<0?<RH1...@P>X<@JLKUIGY910Y)S8;M8;MO;ZS155AZU-D
...#1Z55=O4D/449P;P5THS\$80(H-M)=1-M-9N*2INC=03>0>1XIGADIM5XB@+016/RJX2W80>8D>4K6<+C...@MS\$B@7%J4C6W>1AGW#GEIDH@=-,F6N;V;CP+;
...&26J1@10K BP4?=-M1@QB+HX7E+M0&F86G#3+P+N3C5&M+P1/QO/P1FT= 2+X&S0;0WPVLZ MP&CCH#2P0P&ER=DW1...JK7Z+L&C#>...PRG&+<
1/1<1>UOK=UE/S1Z7E+M1D;ZS2\$>V\$1+2<?>19>XH92@/L 21GSP2>SKVYU+L+&KE#Z<+W1;BN9Q/L+P MMU5V3W16UO2=7%MG6(UA+98)R861GHHU-6V*6;C19;1"<5
K.V\$#%D%MY1G&TFID)D&IMJ...#W26L/GHX<JG;Y.3B*2>1W(>UE.F.R46;1P5 M#<@MV\$;AYSP-7ZND9JH V5N&GQ3)Q16%7:4618;..M&AS\$#>#4T/OKFEM
MTHU9R98HFMHGRAITJF@621K+BOJ/L GAG-GE5(HH?# M1A2>R7<1+U_YZA &UJCL'A"ND5"51V143M2;C1T#26;VH\$2L@<C)5YX% M@L(J)(K(L)<H&WUGT737HCX0
2M+1RO9UH4PMTH09Q9NZ;1M5JTL<MP.GG;@N8\$#>Z1Z)@PC>2OD 7+2D.O.M0&#%FXZ(JZ<E50>X);L&K;..M;H1M&EAD.PU7PB1J@D4K(R)S#YHDL Q< DBG<NE
2/2#9@X52VOL+Y VMY@MG.BX17+L>W>YX8M&N;N...+T2SSUJ0&#%#(WH1Z>B0+R7)FZ1HBB8AWR<G.A<..TL1+KU+<@>9+2HHFQ16W-8M)
(Z05;H+YKZ16GVYH+Y<0<=0<=XZ1L7V-DNK<KSEZ&#>C"U199...1M75=0+1RZ01+J6>58LCl6Z71>OGK<=>1RZTD/K;K1J=SHD215>D1A8>#<#
MR6NDBH1X5S68=+CR>7YK2Y+YAL&#>1J5D)K4%#2ER616+XP+U0A1QG9.MID&80EC=)C4L%9LYTA...=JXT.U;AHUATL;L.G561Q2DPDP<@=>K\$<+J&OP#;T2W MKY.A
F=GF0H;M1VP=+1Y+V\$M=M6R0R<0OEP.FH80=F141(MN15+LZIDG1F)D21>?@>TF<+E.3B1HRX;R618P#BXRYRO1;MLLYQ;F76+1M\$2>9DQ?<
1Q18>#9P=0G@+50H10LJK1V1N.TP...W71PV/>JZM+21X M2ZB&#>J.OXAKK18X1YC&#%SCU1R5D3<L271XU15P97.12@+>..D>8>C M6%7@1L1>6P7L>5\$5;
147UR+R&#%MC2>H.UV7JOKGIXY+K.Y.SF.M\$A=0%OTTO/ISO&#>C5=2KRB64R71R88MJ.GL68900M7&#>N1(HWFP7M1<@ M5RYPI@.K M5JUW>2M7K/G<P/CG...H30T
M4+6J.0G=Z-NSFW&M18Y<GTHFQI-R+HT>17EQ)9<7W+?..RU8K<L.O M*L#@>SNUUR<#<K3CU.W4M&R.NU@ 522ZJH1H905M@LDS&A1@ 1701M)JTS
0CK2"1L1<+IS.F&M1#ISSJ@>K 8X1H&VFI/H M1Z41+Q+U;P1;G@19W\$>T<C...#JHJ<TY.02H61?JMAA=C@H&A.5W.M+H&N1J K@ZIS@1V@#1
=>XCXN9Y=>@MDI&JG1UMG10S(BIC&R1+>B MOS?EYVTHK<JX<CPX17@#<+B1>Y13(ND9@YMLV.6.YZ7H1H2WCX% MYZ<LH>#>S1#1&F7LP@AC8P\$?<
2>W.NL@JK14JUTUS.XL&PVYU08<20LX00;1@JH1KON=>0PZV M2(QD>OS+L.G.D\$2GEZ2H.BZ?KEIN1.\$%1F72+@PRF.R=&E TF@<@G6;83.MR1L.W@#3\$0L
H3ROTGT2@JWHPW&#>L&FL7F0G/H14<4+Q1=>@Z=1F.M\$JN17Z+28<@LLT3L2>1@XKL<L=F4133+9>H1N.GM1F#R5L72KON&#>M70J(4A)01GT=M1=7*18P
M@>NRUT7ER28ZDUW157+BY1<16.960@>0EPI.OMN3061&M1=1A2%LR.M1>SNXF1.V3B6-K4%ZRR%4Z1>L&M1B190@1<4.%XJHG5L6<5(A/3E) M.26'9NCG>17*8K
B25>1#@>#AJNFSZ0?>3/1+TOD41@>20KX0.M9R=>HV&E2WJ=M(G@M.F54U@>1LMN9@1Z30J?L Q.H30VYU M1.A@A4HJ@K1
Q.51A1<@YUG/ID+D86YQ+1.MN0B<21KU.YK5<1+7+>M.EB1>@>C&DMMH19FO.EZB>Q#>Z7+@>1NMRE068%#F9.LW4GO=F1.1/H1N.MO<#X5'G"54-7@H
14KR<#>W0\$81.MKV1D861(38GU1Y+>E=>H>3>M191\$9QQO<@EP1.T85&3%<C\$SU@.Y.YJ>E=SP1N\$5Z@2GK1YU51<Q&S<3 M&C<+J\$S>C#ODW\$0GHS15177?<
9U21H=>S'4A37?T\$1&L>KDI>CCT3NB<@MOBX9H193;HOT\$EY3 9F&#>B#>UK5B20 M2E<#>L @HDEP34>H&WU<1=>1OW75A..TOO GDCN61E10>3TO9L1M4-M1G5K62
H&H&O&GJFE2V+15PF.95 &4.72B)H&#>BT<#KUT&E#>E@U>#>PG.M82=>1M>Z37#1L@93GL65Y+>1LND4FWL12AVY12FM%<K17)25.YIUU.C.T0C.M3R'MZP>BVYH1X
9.UT1>@85% OF&V&Q'U'M@>PL.M@>M1>8PTCB5<0/2N3+<2 RC0.Q&#>NV HZ15CN1W=>W:6.R'EGR15D.UH0S+<MX.N=7.R)@D1H<A1'>C1N>JRE5=>YOP9EJ
@D-T\$<#<D+ M SCG<#1#YFK1V<@PG051UEHJ.D4&AGF9ZU14IGS1#>2YV.#50A2O@G MXYU@>PMD'864<B=>F2PFDWD1=>#F3;A2F0H1RU.CK3\$A5F4.C 425EA#1W1+J
MD1B>3.MU<U&Z1YRAL1LB1BX1#>Y1+G1D.DW&K311WPC00R&#>L>L+<G1D8H6;H16XJXP6-H1C<+1.MT.XO.H2FK.H@<S%2Q2VYU<#>C6S%WLNZPB<Q1#48:41B)2P&
G.0L71L= M04MCEZ3D1YZ0&#>C.WMK9.C+16<12B'6'2ON?>1#>0&C<14H7+>A4+<+>M&XJTF1EN1J19#>9&SRXAF16#1WL5H1@U7UMZHL 42+>E8362B41T9M1HLO?<
-322%G1L.D%\$P2+AV0/LR<#>L5<61R.LD.%>@W61'G5.Y.4'MO.M8Y8T<H1B&B7:WDBW1S<E_FAE74-T(4G)HW&1R=86R'1=>1G5@>L6S.#1MPQ996V0P*9.9ZS31T63M1
<3N3+&1ADWG.OV)CL<1@PWN.M4-MH&#>APEM.MUR..366M+K1+UIS*XA'DN.BA&K(2<BZ80B1'<4>=>56Q2VL<CZ>?>MM1>M-0.78K1>+>1G-
T.X"=1+>TUA02AO+WN;X)YVW<#>H.L+Q1+ZNK87ZUZ(NB?>L70H1#>YX.G1B(CD"%>7.M@>G(3P1+1B1&2&AR)D.7H1B4BDQ.A<#>W&HJ1Y%>Q2R3.P9F<G.MA-WY=EV
F23D#>Q1019P&#>L6&D1U121DA2&#>P\$>L?>#>Z.BD)>@<C.MPZ1B6S501<V1G14H8<#>42VL.M\$H&B1#3CQ0'BD+>E4J31L1IRA.M1JY3<ZKZK3.YC&D(10891
1PH14H1DUY+WK.IAR<#>WQ'MHOT'PMWT.MR>JLS<55.DXONX3H1=N&E'WH&#>K1=>Z+H+SI<#>WOK.N'X&#>W1VY<Q'>MDH<@>XORIC<@>3ZKX1Y1931Q
KH0>#>+>86C2<GH=>M<#>MH3<0<1&R5+<#>3FWJ<3+1W31&A1J13=1Y<8J.MA19PH<8C6C@1%<@>SQ00D=>X6\$915U2FQ1W

MR7BDJ[1DOJ]>1C7Z<+QSC=1Q3Z0+U7D[B6PQ/PNY60L7GHIK>1X?>T0I M0:5XN?>7QDZ>KR:5WTC#D-PSXI 1Z:SWQ 3KB 389J0I?Q?FRM6MI(2QZ<MUZYI
M7B2D>BRVY1E:2:KW=1J4<+<C3Z<5_MXW7P<P<M&27YI03.SHJ<16 M0:1f0:25N?>7QDZ+52YU?AGVY-GIH7256A?>1C 3K8EN+>=VA Y79/CQR/E<L9
PR(\$S-LPDJDAH<C?QY33?>8KPI1C9T HQ3D\$B19P:1C TESU MP1A?>ZY-Y #9..\$9)M...JSWB?>ZKF+4<..0I?>H4.04?DYL&KZ-G?>L M+>A)=<C0>_H5
M5UXQ<<13>30/9EUA=>1XP>KH7FEKQF2?1A?M4Z2DYC7Y>BTB)C0>WT=MEUIBP8893<..\$80?>L+Y>ICFFI+HA/FKY 1?Y(TD?FYRLR2M?>K:K:ME.WRIFNCHRV?>
D:14+CW17:3PI<XHT12NIZM:OKU+61?>CHG-FN?>IY7Z Z MI>3F MYOYFC2<..&?>1<?>SIXWBA9HS 1?C +XP>ESK70RU8H?>H4?>T(YD?>EYLR 1?>M :>L?>5H1?>TF9VDPR6?>XZ1.F:>
A50<PZ1QE3?>C&P(PW6)<S:>7.S.N#>M?>7>N#>W60TGP29X1[5?>EVIT1.LGOX;D?>0A/H/L#ZOMA<6N2SY5?>IKKM4.ME!G<3JL51CY3?>LLS80>
68K0H?>P(W>LH/Y2?>YB\$M?>P)B8)& MX(17J 2(12+7G&+14C573FH&P+15R_@Y-ICE18<-RZM1G82<25?>I M
A:1SW+/D.S:IP>2YR8W:QC/R<C?>MJA>S>Y6HIS3Y(H854#<?>VYVHB-#Q&+>F.MOUX:7.69U=->Y">J?>319\$<C>QC&GV2JYV1<?>YXA#1L AY25.1\$>GVY)&
M%2<SW:UDF<7PC&Z<3\$2?>Q"

68:ILW26BXW?>=SGM?OQ?D?>L#F85988#M#MION92?WRIDZ(7H)JDPA-TMCZULW#C#P.OZ.PFN
M&Z1?<M0GU8?NCM5Y?W>=FJF65#KH'R'>+5:3RC=SQ<+F#BK47&N=>TZ6 MMUTC174NU2UCPA*LI>G9U:~J+BOB&-YSWF?I.6045764:SXM#+073JFFY
M0UKY?4IV.0ZV6?3?0FZ=ON(3HB1)9D8UE#<44UR3?P#KOI(=O)I\$W?D<8L M#S3D>3\$T6=9JW/7716~U#R M0~<8?LW-IXX.T97H%JX= M1CGYGMU\$3
M?<PND0M?P>I&ZMN2+&CEL?25IMD/G83>[HK&(M9F1.6&K&T1 MT~LFFK@TG60F (P8C3ZIDRSR24.S.YWB1(VK~>8H0)HQH1BP&U&XJ3H5+>R>+FX"MPW#UKZ"&IV(KS?
(K0:LDU.M#P3(K1RNRQ4B Z=YSK13Z1J9E(C?<PDBB1#ML#M81MY&WEHJZX#PH9(I~)JW6:RPEL08~1J9=12C8E:RQB8.FNA4408G-X 8 MDT?Q2"H<P?W2%>16KR
M-Q RON~NIE&LXV?U~>NFQHHHP Z KKG3RJYKHVY05.H#A6:2Z=XI:090:IH MDS65<9=;<K&RZZJ5?Q~) VULWIOZDHGUQ-0N9YU0L5&N&XSYQW~1BJ
M<94NM ZC:H0&XV(D#2F:K&7J@Z%>+1=L~>LNO=ACZY4>WY-CZ:GT2PIHE< M13+1 2ZRVOQ~1 M?M29?Y?>RO1FOAQQSIS-52&X/B?M(V5NSI&A)5H-T#>Q9~+&QI9Y
ML)Y#P-SI:<S"TE/C,S<P=I(=U&XLZQ:Q.T@0S>SH:~W2B#P>?~?4.N8. ME~4/5Q:~R.272~(P<@)J\$GD?~I~MADW/DHTLT@H&<3VH5U14"~O MO12.G#M 6DW>OQ6Q3%
<6JDXP3JWB3~8Q+R&A?73DC(H)~>|>KR&S~1VT?M~1HL981=IS.A:FK4ISJ2C M2~1=V6&ZWM\$S:M34ZJQU17TMM~X>X1V19E:0AX1~(1&XN1)S1U?O M\$INMX?~9~IXR2
M#W /0(N~<UJDH K&E#YK3>2K0H1+&DE4N1A9S81@C.9YVW2A~A1U?L M#7B~F.DXOT17?X~#1VPMV?1L.PHX ~C28J@~I1J9&15>~1M32GGL0H1U?~S& MS.N?+&YK5
85KHC?S NC~V1+LG+>U3Y8~1V~>S&P1>MV~B93?YB M&W&A&#?>1H6LG6:DNKN>#N19R>R~(JO:DPD&S95)DQ IAL<~1~<4 M440B8K&2%~1T7G# ?>1
1>3T+10E@IQ(14%~>UN:W+0=Q3?1T~<S&B0Y.M~)J#A ~<MXL+1@E7.D1~N3Y?2(1&3W4~23%HI#SW:R 3E7<5T.23%~7.8U.M#316 KDR7~>06=K4
~>THN/@8QOEJO@3B@Y\$V+~#OC< /3Z9X)33.VTHD M+O1 U\$77S)8\$B17~>D.H.(H>WRYHW1~>=B#KE/OQHYHRIX<~<CISGT-H MJO G4?DIA#UX~U9#/?TEN9:WG4X/XPF!
142UVEA?~<1&Q?ID)~<MNDUY M#VX5#1WY3~>M1+>OW0@<1H3N&2~1>Y4418W~1YGE# M3>826V~1@8?Q?UN.GK~3M9?MX3>EY=6D1D\$1OTI0DUY15T2Z~TYQ?
MNAWIH14PD0~1>1RAMD0~1>1KDDHP=>175L4FTYFLNFC>FJZC3N1~M=YIGIXE =@~(H)00Q<~7M9VFE~P~2.HW?>CWB2-DJ5ZUV(C#PKY~#1&F&F)
M0~>@EH\$J4BDCQ.100 MO44M1OCCGBHSX ~<8(NNJ+1JL1Y2Y)~) CSVW:A~H50BN?55~<U~10D>~M~<M~
Y4W7.1L7=GVZBDQOEL:LYHZZ~"X18 M#&#CJ@~GSJAZ+4JW.S#M)<6N80P5O7R#R#CAF&Z IWP(S1~1HYIZ?K7>~M#~63D=K3=PO3<1ZI(1M6)>1F8OGFA1;EM\$#HN 7&I
IQ=+UQ~>1W4%~1N2NY5(6.H0Q1C~>N1S5! MZMN.O-L1?RCVC4L TP@Q+2~5=.R6<C4WJE@Z~+8.W+~O~9IQ<12:"4.M
M.HLH?TGZ1Z42.0W105B1U@Z~7~8?D315AY#&@~UHL2SFOJ?Y?>P(XKT M2+5~>A~)~YVH~>JL2~1F2RY~+UJGZ?DF=BX\$B~21A.G~<KFQG.XF8?~M3)~R8>1@+75.B9
C&H8?~<A#H#M1K&F&D&P&W58E~MOJB-P6NK&IOCHH4~M1(SLGR SC=C/575V&W9&~<H&C(1650M~)~H~>1M~W~P~A2&70.1N03 M3P1E.DH(H
D>=>B.Y.YTPC~>1&5%~S2~5T1U~>IN M~%1%\$T AS1K1PHMU~"G8">8B)AYX1+4J7417~PTOT.726V4L2Q&2~. MM23S1~W2T.1A4~FUG~M~8~>@T7FRH.ZOGY#V23H
M2Z1B5U1AUCH1~CHW#3K57&X&CETHZ~<~<T6TM&XFC 6<6P~MTR1.EYCI~1~M.F1Z&2=KOLX~>S1TAQ0~KW C~#16@!<~<53LGDIOEH081@MIE@Y4C~1TI
M0D.S!DOE!~DPGU126C)~<(U~)WSPO(E=UTKIN~W2S)!~+10?PZ1A1;HY-M)=L#KR67IUB.Q"R.9R0L1?3 CX.1%1Q CT\$1~91~QP6#92AWG~3?N:&~
M~ONNI~>=FXN?JPU\$=T65D#W?I29S2Q~>HR+ClS H4XTH83Y0E5+NA1+7BU~MHXO~IE~V?D~5ZD05!<E M4JH7H8Y1)4JO3~Y3%GI
RH+6Q~N&~U!@GG@13KXK&W48V16>~>H&R3L M4P~M~JK~V4Y00!RM4JHCT.HG.LCSD)UQY95!>BKEAZFFJW8Y~H1.6F1~M~M3N~>3/97H1J12=5@=JH~"~JEG?
1~X~4~>P>D?Q?S~H&U~V1 HC1+>M~>~N1PZBH~R1~2ZSDRWSN~FV.91~>~>H3P3X~1~1~<NT@!>=M03B1~R1~M81G+VD3.118A1G~>1H&E(2~>K7~>S~<2NK2 K4?~D~>R~)M>M
(H)8%~1HGLZ?PTG>1NQG?P1021FFH31+5W&OZFG M1224HFF<~>="DP6J.BV-ZJ9P2PWL6.K&N=26V.NR~5~TJ~M81E:OTC1FRS MK9Y~>6~1FV@OT1XCM?D&X&MOW~R~V)~#JO
=SH\$IR5)WDB-M@X~<C9OZ~<~<R=S~<BNCQR-9F7N2THK0>DC&KRUO951VP<09T).DK6="9&~T~M5D1S1U.74HVN)(AH0J&<1&~<U0 ~>@~"H(9.YW~5@SGU~7H\$!<~<5D
M220?N.H>~5.8~2?3.1L@~1~14LHW601)@F@GSY~N JC13197 4.LZCQ~4JH2H M71#0~30U(1UWUB956WL13 ~2H~8U~+KFF1H~U93~<HRN2U6C3.OV.9 A~M5=5H
<1~NXYDKN12~9EW9~>P12~>VW>1~1NZ/WF~)M2~>M&G&GJW9~>M0H7F7SJO~30U1UWUB956WL13 ~2H~8U~+KFF1H~U93~<HRN2U6C3.OV.9 A~M5=5H
M251S3R~<WYN~<SW~221Y1SH1&L~<1K~<RW3?CQ)~YN~>O~<A7%>+M~<M~<DQW~13~6D~>1~>T~V~"B~>+~PHN.A~>D>7LZ)NIHD&8~<O~<U.A.ID.SKM1 MS80~>@I
U5@12~>9D1B~>1%~>QIHH84VCD>1~>K%G17~>4QOI~793D3Y3 MUH~LUM+O~>+51Y~Y0+3~EDZ~9MB7~>0Z5>KU~L~M~JE~215JM&+CC~H&E58Y7~>A1+<C
ZK/E4S3O8E.I8E M=#D#OO>W<~>D)YEWSTAC~>UD&K1>CTBHS4W#<~<2N17MIZ~>E+LM8OITH~M8MSIZ~B~7T>9~<K1~<MK#T67XS~>#~<71?G.H1LK713)~10L16OGH?
M01\$1.42E41&H80:B0P~7 RANKG~M0~08:5.67&25X12N1"68"GB5O>~>M23~>M&GYSRGW<~<SAGNO~>IHR~>9G7~THL?Z7V00PEJLX~1H?VE.OV933?U5@~ M/9~20?R~Y3>+9~
1~>81L02E9Y23@~>U31N?ZIF~DT6H.MWP.G6.67>5>=>112.T1YT2~<C&DG.D:MA36~1T.HZEZ~>1~>S1AC3P~B~RLM=B4G M=UUBZ0~+~<V~
RH@~>0H~U~>JRTO~>1~&

cycc:December2023PlacementAgencyAgreementMember 2023-12-21 0001130166 cycc:CommonStockWarrantsMember cycc:December2023PrivatePlacementMember 2023-12-21 0001130166 2023-09-30 0001130166 2022-12-31 0001130166 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-09-30 0001130166 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-09-30 0001130166 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001130166 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001130166 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001130166 cycc:CommonStockWarrantsMember 2024-01-01 2024-09-30 0001130166 us-gaap:SeriesBPreferredStockMember 2023-01-01 2023-09-30 0001130166 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-09-30 0001130166 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001130166 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001130166 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-09-30 0001130166 cycc:CommonStockWarrantsMember 2023-01-01 2023-09-30 0001130166 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001130166 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001130166 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001130166 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001130166 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001130166 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001130166 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001130166 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001130166 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001130166 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001130166 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001130166 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001130166 2024-11-11 0001130166 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001130166 us-gaap:CommonStockMember cycc:December2023SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 us-gaap:CommonStockMember cycc:April2024SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 cycc:RegularWarrantsMember cycc:December2023SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 cycc:PreFundedWarrantsMember cycc:December2023SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 cycc:PreFundedWarrantsMember cycc:April2024SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 cycc:CommonStockWarrantsMember cycc:April2024SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001130166 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001130166 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001130166 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001130166 us-gaap:CoPlacementAgentsMember 2023-01-01 2023-09-30 0001130166 cycc:CoPlacementAgentsMember 2024-01-01 2024-09-30 0001130166 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001130166 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001130166 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001130166 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001130166 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001130166 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001130166 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001130166 cycc:December2023SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 cycc:April2024SecuritiesPurchaseAgreementMember 2024-01-01 2024-09-30 0001130166 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001130166 cycc:CantorFitzgeraldCo.Member cycc:August2021ControlledEquityOfferingSalesAgreementMember 2022-08-12 2022-08-12 0001130166 cycc:CantorFitzgeraldCo.Member 2022-08-15 2022-08-15 0001130166 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001130166 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-09-30 0001130166 cycc:CoPlacementAgentsMember cycc:CommonStockWarrantsMember cycc:April2024SecuritiesPurchaseAgreementMember 2024-04-01 2024-04-30 0001130166 cycc:PlacementAgentWarrantsMember cycc:December2023PlacementAgencyAgreementMember 2023-12-21 2023-12-21 0001130166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001130166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001130166 2024-04-01 2024-06-30 0001130166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001130166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001130166 2023-04-01 2023-06-30 0001130166 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001130166 2023-01-01 2023-03-31 0001130166 cycc:CoPlacementAgentsMember cycc:CommonStockWarrantsMember 2024-01-01 2024-09-30 0001130166 2024-07-01 2024-09-30 0001130166 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001130166 2023-07-01 2023-09-30 0001130166 us-gaap:SeriesAPreferredStockMember 2017-07-01 2017-07-31 0001130166 srt:MaximumMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-09-30 0001130166 srt:MinimumMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-09-30 0001130166 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-09-30 0001130166 cycc:RocheCapitalPartnersLlcMember 2024-03-14 0001130166 cycc:LadenburgThalmanCo.IncMember 2023-10-30 0001130166 cycc:PlacementAgentWarrantsMember cycc:December2023PrivatePlacementMember 2024-01-01 2024-09-30 0001130166 cycc:PlacementAgentWarrantsMember cycc:April2024WarrantsMember 2024-01-01 2024-09-30 0001130166 cycc:December2023PrivatePlacementMember 2024-01-01 2024-09-30 0001130166 cycc:April2024WarrantsMember 2024-01-01 2024-09-30 0001130166 cycc:PreFundedWarrantsMember us-gaap:SubsequentEventMember 2024-10-23 2024-10-23 0001130166 cycc:PreFundedWarrantsMember cycc:April2024WarrantsMember 2024-01-01 2024-09-30 0001130166 cycc:December2023PlacementAgencyAgreementMember 2024-01-01 2024-09-30 0001130166 cycc:December2020WarrantsMember 2024-01-01 2024-09-30 0001130166 cycc:December2020WarrantsMember 2023-01-01 2023-09-30 0001130166 2024-04-29 0001130166 cycc:December2023PlacementAgencyAgreementMember 2023-12-21 0001130166 cycc:CommonStockWarrantsMember cycc:December2023PrivatePlacementMember 2023-12-26 0001130166 cycc:CantorFitzgeraldCo.Member cycc:August2021ControlledEquityOfferingSalesAgreementMember 2022-08-12 0001130166 2024-04-30 0001130166 2023-12-31 0001130166 2024-01-01 2024-09-30 0001130166 2023-01-01 2023-09-30 iso4217:USD pure shares iso4217:USD shares cycc:Y cycc:M -0.18 -0.48 -2.04 -1.39 0.00 -0.48 0.00 -1.39 Cyclacel Pharmaceuticals, Inc. 335273 335273 264 264 1058892 2152202 0001130166 --12-31 false 2024 Q3 P5Y P6Y 3.660 4.050 1.370 3.605 89.92 87.93 0 P0Y1M6D 119000 P5Y6M 1.5 5.5 1 5.5 P5Y6M 0.33 335273 P5D 258000 321000 470000 1049000 1.34 0.96 0.99 1 7 5 0.0553 0.0391 0.0389 0.00 0.00 0.00 P5Y6M P5Y6M true P1Y 10-Q true 2024-09-30 0.00 50626 DE 91 1707622 200 Connell Drive Suite 1500 Berkeley Heights NJ 07922 908 517-7330 Common Stock par value \$0.001 per share CYCC NASDAQ Preferred Stock \$0.001 par value CYCCP NASDAQ Yes Yes Non-accelerated Filer true false false 6287205 2982000 3378000 1931000 4066000 4913000 7444000 4000 9000 51000 93000 413000 1259000 5381000 8805000 4126000 3543000 2225000 4618000 6351000 8161000 0 37000 6351000 8198000 0.001 0.001 5000000 5000000 0.06 0.06 335273 335273 4157385 4157385 0 0 0.001 0.001 264 264 0 0 0.001 0.001 1 19000 0 0 0.001 0.001 1000000000 100000000 2152202 1058892 2000 1000 436503000 429796000 -1033000 -908000 -436442000 -428282000 -970000 607000 5381000 8805000 10000 16000 43000 389000 10000 16000 43000 389000 950000 5236000 5775000 15637000 1237000 1625000 444000 4845000 2187000 6861000 10219000 20482000 -2177000 -6845000 -10176000 -20093000 2000 104000 6000 -58000 8000 50000 -18000 243000 -9000 52000 50000 10000 145000 40000 235000 -2167000 -6700000 -10136000 -19858000 -210000 -668000 -1976000 -2574000 -1957000 -6032000 -8160000 -17284000 50000 151000 -1957000 -6082000 -8160000 -17435000 -0.18 -0.48 -2.04 -1.39 -0.48 -1.39 -1957000 -6032000 -8160000 -17284000 -14586000 8571000 -12967000 -2050000 14468000 -8642000 12842000 2198000 -2075000 -6103000 -8285000 -17136000 573282 628139 1000 422981000 -1316000 -405727000 15939000 401000 401000 50000 5263000 5263000 -5171000 -5171000 -5804000 -5804000 573282 628139 1000 423332000 -1224000 -411531000 10578000 53213 1105000 1105000 359000 359000 50000 50000 5577000 5577000 -5450000 -5450000 -5448000 -5448000 573282 681352 1000 424746000 -1097000 -416979000 6671000 -154593 -3389000 -3389000 6909 390000 390000 50000 50000 -8642000 -8642000 8571000 8571000 -6032000 -6032000 573282 842854 1000 428475000 -1168000 -423011000 4297000 454537 1058892 1000 429796000 -908000 -428282000 607000 219700 -80000 -80000 -119000 39667 203000 203000 -2130000 -2130000 2140000 2140000 -2946000 -2946000 335537 1318259 1000 429919000 -898000 -431288000 -2206000 486945 1000 6289000 6290000 189000 189000 504000 504000 -521000 -521000 -3257000 -3257000 335537 1805204 2000 436397000 -915000 -434485000 999900 1000 1000 347000 107000 14468000 14468000 -14586000 -14586000 -1957000 -1957000 335537 2152202 2000 436303000 -1033000 -436442000 -970000 -8160000 -17284000 5000 23000 499000 1151000 -37000 -55000 -3129000 -3364000 -2070000 599000 -6634000 -12202000 0 6000 0 -6000 6209000 0 151000 6209000 -151000 29000 -42000 -396000 -12401000 3378000 18345000 2982000 5944000 59000 243000 3715000 4846000 2000 2000 0 50000 <p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">The consolidated balance sheet as of September 30, 2024, the consolidated statements of operations, comprehensive loss, and stockholders' equity (deficit) for the three and nine months ended September 30, 2024 and 2023 and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on March 21, 2024. The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of September 30, 2024, and the results of operations, comprehensive loss, and changes in stockholders' equity (deficit) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024, have been made. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 that are included in the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2024.</p><p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Going Concern</p><p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Pursuant to the requirements of Accounting Standard Codification (ASC) 205-40, <i style="font-style:italic;">Presentation of Financial Statements: Going Concern</i>, management is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern for one year after the date that these financial</p><p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered probable at this time because these plans are not entirely within the Company's control nor have they been approved by the Board of Directors as of the date of these consolidated financial statements.</p><p style="font-family:Times New Roman','Times','serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Based on the Company's current operating plan, it is anticipated that cash and cash equivalents of \$3.0 million as of September 30, 2024, will allow it to meet its liquidity requirements into the fourth quarter of 2024. The Company's history of losses, negative cash flows from operations, liquidity resources currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company's ability tocontinue as a going concern for a period of at least twelve months from the issuance date of these financial statements. While the Company has plans in place to mitigate this risk, which primarily consist of raising additional capital through equity financing or by entering into a strategic transaction, there is no guarantee that it will be successful in these mitigation efforts. In the event that we are not able to secure funding, we may be forced to curtail operations, delay or stop ongoing development activities, cease operations altogether, and/or file for bankruptcy.</p></div>

<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; margin: 0pt 0pt 12pt 0pt;">On August 26, 2024, the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") determined that the Company was not in compliance with the Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule") because the Company reported stockholders' equity of less than \$2.5 million as of June 30, 2024. The notice from the Staff further stated that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the "Panel"), the Company's securities would be subject to delisting. As of September 30, 2024, the Company has a stockholders equity deficit of approximately \$0.97 million which is not in compliance with the Equity Rule. On October 15, 2024, the Company met with the Panel regarding the Company's potential delisting from Nasdaq as a result of its violation of the Equity Rule. On October 22, 2024, the Company received the Panel's decision which granted the Company until December 24, 2024 to regain compliance with the Equity Rule and all applicable criteria for continued listing on Nasdaq. If the Company is unable to regain compliance with the listing standards of the Nasdaq Capital Market by December 24, 2024, the Company's securities may be delisted from Nasdaq.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; margin: 0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Recently Issued Accounting Pronouncements</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; margin: 0pt 0pt 12pt 0pt;">The FASB has issued ASU 2023-07, "Segment Reporting (Topic 280)". This standard will require all public entities – even those like the Company that have a single reportable segment – to disclose additional information about the title and position of the Chief Operating Decision Maker ("CODM"), the measure or measures of segment profit and loss used by the CODM in assessing segment performance and deciding how to allocate resources, an explanation of how the CODM uses the reported measure(s) in assessing segment performance, significant segment expenses that are regularly provided to the CODM, and a reconciliation of segment profit and loss to the closest consolidated totals prepared under United States GAAP. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 will not change the way in which reportable segments are determined. However, the Company is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; margin: 0pt 0pt 12pt 0pt;">The FASB has issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This standard will require all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation of that information.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Fair Value of Financial Instruments</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">Financial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Comprehensive Income (Loss)</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three and nine months ended September 30, 2024 and 2023.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Foreign Currency and Currency Translation</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; background: #ffff; margin: 0pt;">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied to foreign currency-denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable future.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; background: #ffff; margin: 0pt;"></p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 18pt; background: #ffff; margin: 0pt;">The assets and liabilities of the Company's international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans for which</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; background: #ffff; margin: 0pt 0pt 12pt 0pt;">settlement is not planned or anticipated in the foreseeable future and that are of a long-term investment nature, are recorded in other comprehensive loss.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Leases</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company accounts for lease contracts in accordance with ASC 842. As of September 30, 2024, the Company's outstanding leases are classified as operating leases.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company's obligation to make lease payments under the lease. As the Company's leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company's credit risk.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</p><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">The lease payments due in any optional period.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Penalties for failure to exercise (or not exercise) the option.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Market factors, such as the availability of similar assets and current rental rates for such assets.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">The nature of the underlying leased asset and its importance to the Company's operations; and</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">The remaining useful lives of any related leasehold improvements.</td></tr></table><div style="margin-top: 12pt;"></div><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">Lease expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">When the Company enters into contracts with customers, the Company recognizes revenue using the five step model provided in ASC 606.</p><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">(1)</td><td style="padding: 0pt;">Identify the contract with a customer.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">(2)</td><td style="padding: 0pt;">Identify the performance obligations in the contract.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">(3)</td><td style="padding: 0pt;">Determine the transaction price.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">(4)</td><td style="padding: 0pt;">Allocate the transaction price to the performance obligations in the contract, and</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">(5)</td><td style="padding: 0pt;">Recognize revenue when, or as, the Company satisfies a performance obligation.</td></tr></table><div style="margin-top: 12pt;"></div><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers:</p><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Whether achievement of a development milestone is highly susceptible to factors outside the entity's influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="width: 36pt;"></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; vertical-align: text-top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time.</td></tr></table><table style="border-collapse: collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-

layout:fixed; width:100%; border:0pt; "><tr><td style="width:36pt; "></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; vertical-align:top; white-space:nowrap; width:18pt; padding:0pt; ">●</td><td style="padding:0pt; ">Whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and</td></tr></table><table style="border-collapse:collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; margin-bottom:0pt; margin-top:0pt; table-layout:fixed; width:100%; border:0pt; "><tr><td style="width:36pt; "></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; vertical-align:top; white-space:nowrap; width:18pt; padding:0pt; ">●</td><td style="padding:0pt; ">The complexity and inherent uncertainty underlying the achievement of the milestone.</td></tr></table><div style="margin-top:12pt; "></div><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">Grant revenue received from organizations that are not the Company's customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; font-style:italic; font-weight:bold; margin:0pt 0pt 12pt 18pt; ">Basis of Presentation</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The consolidated balance sheet as of September 30, 2024, the consolidated statements of operations, comprehensive loss, and stockholders' equity (deficit) for the three and nine months ended September 30, 2024 and 2023 and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and all related disclosures contained in the accompanying notes, are unaudited. The consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on March 21, 2024. The consolidated financial statements are presented on the basis of accounting principles that are generally accepted in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. In the opinion of management, all adjustments, which include only normal recurring adjustments necessary to present fairly the consolidated balance sheet as of September 30, 2024, and the results of operations, comprehensive loss, and changes in stockholders' equity (deficit) for the three and nine months ended September 30, 2024, and cash flows for the nine months ended September 30, 2024, have been made. The interim results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other reporting period. The consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2023 that are included in the Company's Annual Report on Form 10-K filed with the SEC on March 21, 2024.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; font-style:italic; font-weight:bold; margin:0pt 0pt 12pt 18pt; ">Going Concern</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; margin:0pt; ">Pursuant to the requirements of Accounting Standard Codification (ASC) 205-40, <i style="font-style:italic; ">Presentation of Financial Statements-Going Concern</i>, management is required at each reporting period to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effects of its plans sufficiently alleviate the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern for one year after the date that these financial</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; margin:0pt 0pt 12pt 0pt; ">statements are issued. In performing its analysis, management excluded certain elements of its operating plan that cannot be considered probable. Under ASC 205-40, the future receipts of potential funding from future equity or debt issuances or by entering into partnership agreements cannot be considered probable at this time because these plans are not entirely within the Company's control nor have they been approved by the Board of Directors as of the date of these consolidated financial statements.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; margin:0pt; ">Based on the Company's current operating plan, it is anticipated that cash and cash equivalents of \$3.0 million as of September 30, 2024, will allow it to meet its liquidity requirements into the fourth quarter of 2024. The Company's history of losses, negative cash flows from operations, liquidity resources currently on hand, and its dependence on the ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, have resulted in the assessment that there is substantial doubt about the Company's ability to</p>continue</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; margin:0pt 0pt 12pt 0pt; ">On August 26, 2024, the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") determined that the Company was not in compliance with the Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule") because the Company reported stockholders' equity of less than \$2.5 million as of June 30, 2024. The notice from the Staff further stated that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the "Panel"), the Company's securities would be subject to delisting. As of September 30, 2024, the Company has a stockholders' equity deficit of approximately \$0.97</p>million which is not in compliance with the Equity Rule. On October 15, 2024, the Company met with the Panel regarding the Company's potential delisting from Nasdaq as a result of its violation of the Equity Rule. On October 22, 2024, the Company received the Panel's decision which granted the Company until December 24, 2024 to regain compliance with the Equity Rule and all applicable criteria for continued listing on Nasdaq. If the Company is unable to regain compliance with the listing standards of the Nasdaq Capital Market by December 24, 2024, the Company's securities may be delisted from Nasdaq.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; margin:0pt 0pt 12pt 0pt; ">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business.</p>3000000.0-970000<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; font-style:italic; font-weight:bold; margin:0pt 0pt 12pt 18pt; ">Recently Issued Accounting Pronouncements</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; margin:0pt 0pt 12pt 0pt; ">The FASB has issued ASU 2023-07, "Segment Reporting (Topic 280)". This standard will require all public entities - even those like the Company that have a single reportable segment - to disclose additional information about the title and position of the Chief Operating Decision Maker ("CODM"), the measure or measures of segment profit and loss used by the CODM in assessing segment performance and deciding how to allocate resources, an explanation of how the CODM uses the reported measure(s) in assessing segment performance, significant segment expenses that are regularly provided to the CODM, and a reconciliation of segment profit and loss to the closest consolidated totals prepared under United States GAAP. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. ASU 2023-07 will not change the way in which reportable segments are determined. However, the Company is currently evaluating the effects of ASU 2023-07 on its financial statement presentation and disclosures.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; margin:0pt 0pt 12pt 0pt; ">The FASB has issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". This standard will require all entities to include specified captions when reconciling the statutory income tax rate to the effective tax rate, on both a percentage and absolute dollar basis. ASU 2023-09 will also require entities to disclose the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign for each annual reporting period, with separate disclosure of individual jurisdictions for which tax payments to, or receipts from, exceed a defined threshold. The guidance in ASU 2023-09 becomes effective for annual periods beginning after December 15, 2024. The Company does not anticipate that ASU 2023-09 will require significant adjustments to the presentation of that information.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; font-style:italic; font-weight:bold; margin:0pt 0pt 12pt 18pt; ">Fair Value of Financial Instruments</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">Financial instruments consist of cash equivalents, accounts payable and accrued liabilities. The carrying amounts of cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to the nature of the accounts and their short maturities.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; font-style:italic; font-weight:bold; margin:0pt 0pt 12pt 18pt; ">Comprehensive Income (Loss)</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the three and nine months ended September 30, 2024 and 2023.</p><p>0-0</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; font-style:italic; font-weight:bold; margin:0pt 0pt 12pt 18pt; ">Foreign Currency and Currency Translation</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; background:#ffff; margin:0pt; ">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations. This accounting policy is also applied to foreign currency denominated intercompany payables or receivables for which settlement is planned or anticipated in the foreseeable future.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:18pt; background:#ffff; margin:0pt; ">The assets and liabilities of the Company's international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans for which</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; background:#ffff; margin:0pt 0pt 12pt 0pt; ">settlement is not planned or anticipated in the foreseeable future and that are of a long-term investment nature, are recorded in other comprehensive loss.</p>Leases<p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The Company accounts for lease contracts in accordance with ASC 842. As of September 30, 2024, the Company's outstanding leases are classified as operating leases.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The Company recognizes an asset for the right to use an underlying leased asset for the lease term and records lease liabilities based on the present value of the Company's obligation to make lease payments under the lease. As the Company's leases do not indicate an implicit rate, the Company uses a best estimate of its incremental borrowing rate to discount the future lease payments. The Company estimates its incremental borrowing rate based on observable information about risk-free interest rates that are the same tenure as the lease term, adjusted for various factors, including the effects of assumed collateral, the nature of how the loan is repaid (e.g., amortizing versus bullet), and the Company's credit risk.</p><p style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; text-indent:36pt; margin:0pt 0pt 12pt 0pt; ">The Company evaluates lessee-controlled options included in its lease agreements to extend or terminate the lease. The Company will reflect the effects of exercising those options in the lease term when it is reasonably certain that the Company will exercise that option. In assessing whether it is reasonably certain that the Company will exercise an option, the Company considers factors such as:</p><table style="border-collapse:collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; margin-bottom:0pt; margin-top:0pt; table-layout:fixed; width:100%; border:0pt; "><tr><td style="width:36pt; "></td><td style="font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; vertical-align:top; white-space:nowrap; width:18pt; padding:0pt; ">●</td><td style="padding:0pt; ">The lease payments due in any optional period;</td></tr></table><table style="border-collapse:collapse; font-family: 'Times New Roman', 'Times', 'serif'; font-size:10pt; margin-bottom:0pt; margin-

Table layout: fixed; width: 100%; border: 0pt;
<td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Penalties for failure to exercise (or not exercise) the option:</td></tr><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Market factors, such as the availability of similar assets and current rental rates for such assets:</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">The nature of the underlying leased asset and its importance to the Company's operations; and</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Lease expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments, if any, are recognized in the period when the obligation to make those payments is incurred. Lease incentives received prior to lease commencement are recorded as a reduction in the right-of-use asset. Fixed lease incentives received after lease commencement reduce both the lease liability and the right-of-use asset.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company has elected an accounting policy to account for the lease and non-lease components as a single lease component.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">When the Company enters into contracts with customers, the Company recognizes revenue using the five step model provided in ASC 606.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">(1)</td><td style="padding: 0pt;">Identify the contract with a customer;</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">(2)</td><td style="padding: 0pt;">Identify the performance obligations in the contract;</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">(3)</td><td style="padding: 0pt;">determine the transaction price;</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">(4)</td><td style="padding: 0pt;">allocate the transaction price to the performance obligations in the contract; and</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">(5)</td><td style="padding: 0pt;">recognize revenue when, or as, the Company satisfies a performance obligation.</td></tr></table><div style="margin-top: 12pt;"><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The transaction price includes fixed payments and an estimate of variable consideration, including milestone payments. The Company determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applies a constraint to reduce the consideration to the amount which is probable of being received. When applying the constraint, the Company considers:</p><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Whether the achievement of a development milestone is highly susceptible to factors outside the entity's influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies;</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">Whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and</td></tr></table><table style="border-collapse: collapse; font-family: Times New Roman; Times; serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; table-layout: fixed; width: 100%; border: 0pt;"><tr><td style="width: 36pt;"></td><td style="font-family: Times New Roman; Times; serif; font-size: 10pt; vertical-align: top; white-space: nowrap; width: 18pt; padding: 0pt;">●</td><td style="padding: 0pt;">The complexity and inherent uncertainty underlying the achievement of the milestone.</td></tr></table><div style="margin-top: 12pt;"><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The transaction price is allocated to each performance obligation based on the relative selling price of each performance obligation. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The revenue allocated to each performance obligation is recognized as or when the Company satisfies the performance obligation.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company recognizes a contract asset, when the value of satisfied (or part satisfied) performance obligations is in excess of the payment due to the Company, and deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied (or part satisfied) performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">Grant revenue received from organizations that are not the Company's customers, such as charitable foundations or government agencies, is presented as a reduction against the related research and development expenses.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">3. Revenue</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company recognized \$10,000 and \$43,000 of revenue for the three and nine months ended September 30, 2024 respectively. This revenue is related to recovery of clinical manufacturing costs associated with an investigator sponsored study managed by Cedars-Sinai Medical Center. Revenues recognized for the three and nine months ended September 30, 2023 were \$16,000 and \$389,000 respectively.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">4. Net Loss per Common Share</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company calculates net loss per common share in accordance with ASC 260 "Earnings Per Share" ("ASC 260"). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period.</p><p style="font-family: Times New Roman; Times; serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The following potentially dilutive securities have not been included in the computation of diluted net loss per share for the three months ended September 30, 2024 and 2023, as the result would be anti-dilutive:</p><table style="border-collapse: collapse

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

The 2018 Plan allows for various types of award grants, including stock options and restricted stock units.

On June 21, 2024, the Company's stockholders approved an additional 60,000 shares of common stock that may be issued under the 2018 Plan. On June 13, 2023, the Company's stockholders approved an additional 60,000 shares of common stock that may be issued under the 2018 Plan. As of June 30, 2024, the Company has reserved approximately 204,000 shares of the Company's common stock under the 2018 Plan for future issuances. Stock option awards granted under the Company's equity incentive plans have a maximum life of 10 years and generally vest over a four-year period from the date of grant.

On September 30, 2024, all issued under the 2018 Plan. These options had a grant date fair value of \$1.77 per option. There were 43,342 options granted during the nine months ended September 30, 2023. These options had a grant date fair value ranging between \$0.32-\$1.98 per option.

All of the options granted during the nine months ended September 30, 2023, shall vest six months from their date of grant. Of the options granted during the nine months ended September 30, 2023, 25,633 awards shall vest on the third anniversary of their date of grant or earlier if either of the certain performance conditions are met relating to enrollment goals for various clinical studies. The Company has assumed that these awards will vest after three years as satisfaction of the performance conditions is not probable at this time.

The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model as prescribed by ASC 718 using the following assumptions:

Maturity Date	September 30, 2024
Expected Term (years)	3.660 - 4.050
Volatility	3.995%
Dividend Yield	0.00%
Risk-free Interest Rate	3.660% - 4.050%

As of September 30, 2024, the total remaining unrecognized compensation cost related to the non-vested awards with service conditions amounted to approximately \$0.2 million, which will be amortized over the weighted-average remaining requisite service period of 1.45 years.

Outstanding Options

A summary of the share option activity and related information is as follows:

Options Granted	43,342
Options Exercised	(1,234)
Options Expired	(567)
Options Forfeited	(890)
Options Outstanding	41,741

[illegible]

[illegible]

A total of 17,133 restricted stock units issued in January 2023 vest on the third anniversary of their date of grant, or earlier if certain defined clinical trial related performance targets are met.

A three-year vesting assumption was applied to these restricted stock units as satisfaction of the performance conditions is not probable at this time. Each of these restricted stock units was valued at \$13.50 at the date of grant, which was equivalent to the market price of a share of the Company's common stock on that date. During 2023, 300 of these restricted stock units were forfeited as the recipient voluntarily terminated employment with the Company. Through September 30, 2024, an additional 7,077 of these restricted stock units have been forfeited due to the holders' termination of employment with the Company.

Summarized information for restricted stock units as of September 30, 2024 is as follows:

Restricted Stock Units	Unvested at September 30, 2024	Vested at September 30, 2024
Common Stock	17,133	17,133
Preferred Stock	-	-
Total Restricted Stock Units	17,133	17,133

The following table provides a summary of the restricted stock units outstanding at September 30, 2024, categorized by the type of award and the number of units granted and vested.

Type of Award	Number of Units Granted	Number of Units Vested
Common Stock	17,133	17,133
Preferred Stock	-	-
Total Restricted Stock Units	17,133	17,133

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

The aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued to Wainwright or its designees warrants (the "Placement Agent Warrants") to purchase up to an aggregate of 298,137 shares of Common Stock at an exercise price equal to \$2.0125 per share. The Placement Agent Warrants are exercisable immediately upon issuance and have a term of exercise equal to five years and a half years from the date of issuance. In connection with this transaction, the Company was required to compensate Roth Capital Partners, LLC, pursuant to a tail provision contained in an engagement letter entered into on March 14, 2024, in an amount equal to 7.0% of the aggregate proceeds of the Private Placement plus the reimbursement of certain expenses. The Company was also required to compensate Ladenburg Thalmann & Co. Inc. pursuant to a tail provision contained in an engagement letter entered into on October 30, 2023, in an amount equal to 8.0% of the aggregate proceeds of the Private Placement. Each of the instruments issued in the Private Placement have been classified and recorded as part of shareholders' equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective instruments as follows: The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective instruments as follows:

<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Allocated Amount</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Preferred warrants</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Common shares</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Net proceeds</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Common warrants</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Common warrants</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Pre-Funded Warrants</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Pre-Funded Warrants</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Common Warrants</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Common Warrants</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Placement Agent Warrants</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Placement Agent Warrants</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Expected volatility</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Expected volatility</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Contractual term</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Contractual term</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Risk-free interest rate</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Risk-free interest rate</div>
<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Expected dividend yield</div>	<div style="height: 1pt; overflow: hidden; border-bottom: 1px solid #000000; margin: 0pt; padding: 0pt 5.4pt 0pt 5.4pt;">Expected dividend yield</div>

On December 21, 2023, the Company entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional investors ("Purchasers"). Pursuant to the Securities Purchase Agreement, the Company agreed to sell in a registered direct offering ("Registered Direct Offering") 168,500 shares ("Shares") of the Company's common stock, \$0.001 par value per share ("Common Stock"), and pre-funded warrants ("Pre-Funded Warrants") to purchase up to 219,700 shares of Common Stock. The Pre-Funded Warrants have an exercise price of \$0.001 per share and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share is being sold at an offering price of \$3.315 and each Pre-Funded Warrant is being sold at an offering price of \$3.314 (equal to the purchase price per Share minus the exercise price of the Pre-Funded Warrant). The Pre-Funded Warrants have been included in the calculation of basic and diluted loss per share for all periods outstanding. Pursuant to the Securities Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the "Offerings"), the Company also agreed to issue to the Purchasers unregistered warrants ("Common Warrants") to purchase up to 388,200 shares of Common Stock. Each Common Warrant

has an exercise price of \$3.19 per share, is exercisable immediately following their original issuance and will expire seven years from the original issuance date. The closing of the offering occurred on December 26, 2023, and the net proceeds to the Company were approximately \$1.0 million, after deducting placement agent fees and other offering expenses payable by the Company.

On December 21, 2023, in a separate concurrent insider private placement (the "Insider Private Placement"), the Company also entered into a Securities Purchase Agreement with certain of its executive officers (the "Insider Securities Purchase Agreement") pursuant to which the Company agreed to sell in a private placement (i) 6,070 shares of Common Stock and warrants to purchase 6,070 shares of Common Stock on the same terms as the Common Warrants issued to the Purchasers in the Offerings to Spiro Rombotis, the Company's Chief Executive Officer, and (ii) 1,886 shares of Common Stock and warrants to purchase 1,886 shares of Common Stock on the same terms as the Common Warrants issued to the Purchasers in the Offerings to Paul McBarron, the Company's Executive Vice President Finance, Chief Financial Officer and Chief Operating Officer. Each such share of Common Stock and accompanying warrant was sold at a purchase price of \$3.315, which was the same purchase price for the Shares sold in the Registered Direct Offering.

Pursuant to the Placement Agency Agreement, the Company paid the Placement Agent a cash placement fee equal to 8.0% of the aggregate gross proceeds raised in the Offerings from sales arranged for by the Placement Agent. Subject to certain conditions, the Company also agreed to reimburse all reasonable travel and other out-of-pocket expenses of the Placement Agent in connection with the Offerings, including but not limited to legal fees, up to a maximum of \$85,000. In addition, the Placement Agent also received warrants that have substantially the same terms as the Warrants issued in the concurrent private placement to the Purchasers in the Offerings to purchase that number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Prefunded Warrants sold in the Offerings, or an aggregate of 23,769 shares of Common Stock, at an exercise price of \$4.14375 per share (the "Placement Agent Warrants"). The Placement Agent Warrants will be exercisable immediately following the date of issuance and will expire five years from issuance. The Placement Agency Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The Company has agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act, and liabilities arising from breaches of representations and warranties contained in the Placement Agency Agreement, or to contribute to payments that the Placement Agent may be required to make in respect of those liabilities.

Each of the instruments issued in the Offerings and the Insider Private Placement have been classified and recorded as part of shareholders' equity (deficit). The amounts allocated to each issued security were based on their relative fair values, resulting in initial carrying values of the respective instruments as follows:

On August 12, 2021, the Company entered into a Controlled Equity Offering Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"), pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to \$50.0 million through Cantor as the sales agent. Cantor could sell the Company's common stock by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) of the Securities Act.

On August 12, 2022, the Company became aware that the shelf registration statement on Form S-3 (file number 333-231923) (the "Registration Statement") associated with this Sales Agreement had expired on June 21, 2022. Prior to becoming aware of the expiration, the Company sold an aggregate of 132,473 shares of its common stock at the market price, following the expiration of the Registration Statement and through August 12, 2022, for aggregate proceeds of approximately \$2,721,187. There was no sale of shares post August 12, 2022. The sale of these shares was subject to potential rescission rights by certain shareholders. As a result of these potential rescission rights, the Company reclassified 207,807 shares (including 75,333 shares sold for which the Company did not receive any proceeds), with an aggregate purchase price of \$4,494,496 of its common as stock outside stockholders' equity (deficit) through the expiration date of those rescission rights in August 2023. These shares were treated as issued and outstanding for purposes of calculating basic and diluted loss per share in the three and nine months ended September 30, 2023.

On August 15, 2022, due to expiry of the Registration Statement, the Sales Agreement was mutually terminated. A total of 218,738 shares, for gross proceeds of approximately \$7.6 million, had been sold pursuant to the Sales Agreement.

As of September 30, 2024, warrants to purchase a total of 14,718,927 shares of common stock issued pursuant to a securities purchase agreement in a April 2024 financing transaction (the "April 2024 Securities Purchase Agreement") remained outstanding. A total of 15,059,972 warrants were issued in pursuant to the April 2024 Securities Purchase Agreement. This consisted of (i) pre-funded warrants to purchase 4,823,945 of common stock, exercisable immediately from the date of issuance, and with no expiry date, at an exercise price of \$0.0001 per warrant share, (ii) series A warrants to purchase up to 4,968,945 shares of common stock, exercisable immediately from the date of issuance for a period of five and a half years after the date of issuance, at an exercise price of \$1.36 per warrant share, (iii) series B warrants to purchase up to 4,968,945 shares of common stock, exercisable immediately from the date of issuance for a period of eighteen months after the date of issuance, at an exercise price of \$1.36 per warrant share. A further 298,137 warrants entered in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a period of five and a half years after the date of issuance, at an exercise price of \$2.0125 per warrant share.

As of September 30, 2024, warrants to purchase 44,657 shares of common stock issued pursuant to a securities purchase agreement in a December 2020 financing transaction remained outstanding (the "December 2020 Securities Purchase Agreement"). Each warrant shall be exercisable beginning on the 12-month anniversary of the date of issuance for a period of five years after the date of issuance, at an exercise price of \$61.95 per warrant share. The exercise price of the warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the warrants. The warrants may be exercised on a "cashless" basis.

There were no exercises of these warrants during the nine months ended September 30, 2024 or September 30, 2023.

As of September 30, 2024, warrants to purchase a total of 419,925 shares of common stock issued pursuant to a securities purchase agreement in a December 2023 financing transaction remained outstanding. A total of 396,156 warrants, including 7,956 warrants issued in a concurrent private placement, are exercisable immediately from the date of issuance for a period of seven years after the date of issuance, at an exercise price of \$3.19 per warrant share. A further 23,769 warrants issued in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a period of five years after the date of issuance, at an exercise price of \$4.14375 per warrant share.

There were no exercises of these warrants during the nine months ended September 30, 2024.

December 2020 Warrants

As of September 30, 2024, warrants to purchase a total of 419,925 shares of common stock issued pursuant to a securities purchase agreement in a December 2023 financing transaction remained outstanding. A total of 396,156 warrants, including 7,956 warrants issued in a concurrent private placement, are exercisable immediately from the date of issuance for a period of seven years after the date of issuance, at an exercise price of \$3.19 per warrant share. A further 23,769 warrants issued in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a period of five years after the date of issuance, at an exercise price of \$4.14375 per warrant share.

There were no exercises of these warrants during the nine months ended September 30, 2024.

December 2020 Securities Purchase Agreement

Each warrant shall be exercisable beginning on the 12-month anniversary of the date of issuance for a period of five years after the date of issuance, at an exercise price of \$61.95 per warrant share. The exercise price of the warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the warrants. The warrants may be exercised on a "cashless" basis.

There were no exercises of these warrants during the nine months ended September 30, 2024 or September 30, 2023.

April 2020 Warrants

As of September 30, 2024, warrants to purchase a total of 419,925 shares of common stock issued pursuant to a securities purchase agreement in a December 2023 financing transaction remained outstanding. A total of 396,156 warrants, including 7,956 warrants issued in a concurrent private placement, are exercisable immediately from the date of issuance for a period of seven years after the date of issuance, at an exercise price of \$3.19 per warrant share. A further 23,769 warrants issued in a concurrent placement agency agreement, are exercisable immediately from the date of issuance for a period of five years after the date of issuance, at an exercise price of \$4.14375 per warrant share.

There were no exercises of these warrants during the nine months ended September 30, 2024.

Series B Preferred Stock

Series B Preferred Stock was initially convertible into

"font-family: Times New Roman; Times; 'serif; font-size: 10pt; font-style: normal; font-weight: normal; ">one third (1/3) share of common stock (the "Conversion Shares"), subject to adjustment in accordance with the Certificate of Designation. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;">Holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal, on an as-if converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the Certificate of Designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) increase the number of authorized shares of Series B Preferred Stock, (e) pay certain dividends or (f) enter into any agreement with respect to any of the foregoing. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company. The Purchaser may convert shares of Series B Preferred Stock through a conversion into shares of common stock if and solely to the extent that such conversion would not result in the Purchaser beneficially owning in excess of 9.99% of then-outstanding common stock or aggregate voting power of the Company (such limitation, the "Ownership Limitation") and any portion in excess of such limitation will remain outstanding as Series B Preferred Stock. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-align: justify; text-indent: 36pt; margin: 0pt;"></p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">During the year ended December 31, 2023, 118,745 shares of Series B Preferred Stock were converted, at the option of the holder, into 39,582 shares of common stock. During the nine months ended September 30, 2024, the remaining 119,000 shares of Series B Preferred Stock were converted, at the option of the holder, into 39,667 shares of common stock. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 18pt; margin: 0pt 0pt 12pt 0pt;">Series A Preferred Stock</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">A total of 6,872 shares of the Company's Series A Preferred Stock were issued in a July 2017 Underwritten Public Offering. Each share of Series A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing \$1,000 by the initial conversion price of \$600.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">As of September 30, 2024 and December 31, 2023, 264 shares of the Series A Preferred Stock remain issued and outstanding. The 264 shares of Series A Preferred Stock issued and outstanding at September 30, 2024, are convertible into 440 shares of common stock. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">In the event of a liquidation, the holders of shares of the Series A Preferred Stock may participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company's ability to repurchase shares of Series A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and there are no sinking fund provisions applicable to Series A Preferred Stock. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">Subject to certain conditions, at any time following the issuance of the Series A Preferred Stock, the Company has the right to cause each holder of the Series A Preferred Stock to convert all or part of such holder's Series A Preferred Stock in the event that (i) the volume weighted average price of our common stock for 30 consecutive trading days, or Measurement Period exceeds 300% of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds \$500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of Series A Preferred Stock to convert all or part of such holder's Series A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Series A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 18pt; margin: 0pt 0pt 12pt 0pt;">Convertible Exchangeable Preferred</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">As of September 30, 2024, there were 335,273 shares of the Company's 6% Convertible Exchangeable Preferred Stock (the "6% Preferred Stock") issued and outstanding at an issue price of \$10.00 per share. Dividends on the 6% Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the 6% Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February 1, 2005. Any dividends must be declared by the Company's board of directors and must come from funds that are legally available for dividend payments. The 6% Preferred Stock has a liquidation preference of \$10.00 per share, plus accrued and unpaid dividends. As of September 30, 2024, there were no accrued and unpaid dividends. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company may automatically convert the 6% Preferred Stock into common stock if the per share closing price of the Company's common stock has exceeded \$888.300, which is 150% of the fair market value of the 6% Preferred Stock, for at least 20 trading days during any 30 day trading period, ending within five trading days prior to notice of automatic conversion. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The 6% Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The Company may, at its option, redeem the 6% Preferred Stock in whole or in part, out of funds legally available at the redemption price of \$10.00 per share. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 36pt; margin: 0pt 0pt 12pt 0pt;">The 6% Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November 1, 2005 (the "Exchange Date") for the Company's 6% Convertible Subordinated Debentures (the "Debentures") at the rate of \$10.00 principal amount of Debentures for each share of 6% Preferred Stock. The Debentures, if issued, will mature 25 years after the Exchange Date and have substantially similar terms to those of the 6% Preferred Stock. No such exchanges have taken place to date. </p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-indent: 18pt; margin: 0pt;">Allocated Amount</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; text-align: center; margin: 0pt;">Common shares</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">2,398,831</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">721,088</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">6,290,213</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">2,398,831</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">721,088</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">6,290,213</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">2,398,831</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">721,088</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">6,290,213</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">2,398,831</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">721,088</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">6,290,213</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">2,398,831</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;">721,088</p><p style="font-family: Times New Roman; Times; 'serif; font-size: 10pt; margin: 0pt;"><span style="text-decoration-color: #000000; text-decoration

Prepaid Expenses and Other Current Assets (Tables) Tables http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets23 false false R24.htm 99930703—Disclosure—Accrued and Other Liabilities (Tables) Sheet http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesTables Accrued and Other Liabilities (Tables) Tables http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilities24 false false R25.htm 99930803—Disclosure—Leases (Tables) Sheet http://www.cyclacel.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.cyclacel.com/role/DisclosureLeases25 false false R26.htm 99930903—Disclosure—Stock Based Compensation (Tables) Sheet http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables Stock Based Compensation (Tables) Tables http://www.cyclacel.com/role/DisclosureStockBasedCompensation26 false false R27.htm 99931003—Disclosure—Stockholders Equity (Tables) Sheet http://www.cyclacel.com/role/DisclosureStockholdersEquityTables Stockholders Equity (Tables) Tables http://www.cyclacel.com/role/DisclosureStockholdersEquity27 false false R28.htm 99940201—Disclosure—Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies28 false false R29.htm 99940301—Disclosure—Revenue (Narrative) (Details) Sheet http://www.cyclacel.com/role/DisclosureRevenueNarrativeDetails Revenue (Narrative) (Details) Details http://www.cyclacel.com/role/DisclosureRevenue29 false false R30.htm 99940401—Disclosure—Net Loss Per Common Share—Schedule of Company's Potential Anti Dilutive Securities (Details) Sheet http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanyPotentialAntiDilutiveSecuritiesDetails Net Loss Per Common Share—Schedule of Company's Potential Anti Dilutive Securities (Details) Details 30 false false R31.htm 99940501—Disclosure—Prepaid Expenses and Other Current Assets—Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets—Schedule of Prepaid Expenses and Other Current Assets (Details) Details 31 false false R32.htm 99940601—Disclosure—Non-Current Assets (Details) Sheet http://www.cyclacel.com/role/DisclosureNonCurrentAssetsDetails Non-Current Assets (Details) Details http://www.cyclacel.com/role/DisclosureNonCurrentAssets32 false false R33.htm 99940701—Disclosure—Accrued and Other Liabilities—Schedule of accrued and other current liabilities (Details) Sheet http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails Accrued and Other Liabilities—Schedule of accrued and other current liabilities (Details) Details 33 false false R34.htm 99940801—Disclosure—Leases—Narrative (Details) Sheet http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails Leases—Narrative (Details) Details 34 false false R35.htm 99940802—Disclosure—Leases—Future Minimum Lease Payments (Details) Sheet http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails Leases—Future Minimum Lease Payments (Details) Details 35 false false R36.htm 99940901—Disclosure—Stock Based Compensation—Schedule of Stock Based Compensation Expense (Details) Sheet http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails Stock Based Compensation—Schedule of Stock Based Compensation Expense (Details) Details 36 false false R37.htm 99940902—Disclosure—Stock Based Compensation (Narrative) (Details) Sheet http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails Stock Based Compensation (Narrative) (Details) Details http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables 37 false false R38.htm 99940903—Disclosure—Stock Based Compensation—Schedule of Fair Value of the Stock Options Granted (Details) Sheet http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfFairValueOfStockOptionsGrantedDetails Stock Based Compensation—Schedule of Fair Value of the Stock Options Granted (Details) Details 38 false false R39.htm 99940904—Disclosure—Stock Based Compensation—Schedule of Share Option Activity (Details) Sheet http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails Stock Based Compensation—Schedule of Share Option Activity (Details) Details 39 false false R40.htm 99940905—Disclosure—Stock Based Compensation—Schedule of Restricted Stock Units Activity (Details) Sheet http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails Stock Based Compensation—Schedule of Restricted Stock Units Activity (Details) Details 40 false false R41.htm 99941001—Disclosure—Stockholders Equity (Narrative) (Details) Sheet http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails Stockholders Equity (Narrative) (Details) Details http://www.cyclacel.com/role/DisclosureStockholdersEquityTables 41 false false R42.htm 99941002—Disclosure—Stockholders Equity—Amounts allocated to each instruments (Details) Sheet http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails Stockholders Equity—Amounts allocated to each instruments (Details) Details 42 false false R43.htm 99941003—Disclosure—Stockholders Equity—Valuation assumptions (Details) Sheet http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails Stockholders Equity—Valuation assumptions (Details) Details 43 false false R44.htm 99941101—Disclosure—Subsequent Events—Narrative (Details) Sheet http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails Subsequent Events—Narrative (Details) Details 44 false false R45.htm 99941102—Disclosure—All Reports Book All Reports cyec-20240930.xsd cyec-20240930_cal.xml cyec-20240930_def.xml cyec-20240930_lab.xml cyec-20240930_pre.xml cyec-20240930x10q.htm cyec-20240930x10q001.jpg cyec-20240930x10q002.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/eod/2023 true true JSON 65 MetaLinks.json IDEA XBRL DOCUMENT {"version": "2.2", "instance": { "cyec-20240930x10q.htm", { "nsPrefix": "cyec", "nsuri": "http://www.cyclacel.com/20240930", "dts": { "schema": { "local": { "cyec-20240930.xsd" }, "remote": { "http://www.cyclacel.com/20240930/instance-2023-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2023-12-31.xsd", "http://www.xbrl.org/2003/xl-2023-12-31.xsd", "http://www.xbrl.org/2003/xlink-2023-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arero/e/esma-arero-2018-11-21.xsd", "http://www.xbrl.org/lrr/ro/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/nat-2009-12-16.xsd", "http://www.xbrl.org/lrr/reference-2009-12-16.xsd", "http://www.xbrl.org/2020/extendible-enumerations-2.0.xsd", "http://www.xbrl.org/dtr/type/2022-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts-us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/eod/2023/eod-2023.xsd", "https://xbrl.sec.gov/eod/2023/eod-sub-2023.xsd" } } }, "calculationLink": { "local": { "cyec-20240930_cal.xml" }, "definitionLink": { "local": { "cyec-20240930_def.xml" }, "labelLink": { "local": { "cyec-20240930_lab.xml" } } }, "presentationLink": { "local": { "cyec-20240930_pre.xml" }, "inline": { "local": { "cyec-20240930x10q.htm" } } }, "keyStandard": 54, "axisStandard": 16, "axisCustom": 0, "memberStandard": 20, "memberCustom": 27, "hidden": { "total": 62, "http://xbrl.sec.gov/dei/2023": 6, "http://fasb.org/us-gaap/2023": 51, "http://www.cyclacel.com/20240930": 5 }, "contextCount": 254, "entityCount": 1, "segmentCount": 55, "elementCount": 479, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 572, "http://xbrl.sec.gov/dei/2023": 33, "http://xbrl.sec.gov/eod/2023": 4 }, "report": { "R1": { "role": "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 Document Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 lbuY6Q9dZU2uXxCRF5g1gA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 lbuY6Q9dZU2uXxCRF5g1gA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R2": { "role": "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 Statement CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As Of 9 30 2024 lMq_S10zES98NZUvGXoqA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit Standard USD 1YrkpCbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 lMq_S10zES98NZUvGXoqA", "name": "us-gaap:AssetsCurrent", "unitRef": "Unit Standard USD 1YrkpCbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "unique": true }, "R3": { "role": "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "longName": "995200105 Statement CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As Of 9 30 2024 lMq_S10zES98NZUvGXoqA", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit Divide USD shares B6r-vkNvZ0an6VUIFo7X2w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "p", "td", "tr", "table", "div", "div", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 lMq_S10zES98NZUvGXoqA", "name": "us-gaap:PreferredStockPar

"duration": 1, "2024": 9, "30": 2024, "1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995210501 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "cyec:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "cyec:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R13": { "role": "http://www.cyclacel.com/role/DisclosureNonCurrentAssets", "longName": "995210601 - Disclosure - Non-Current Assets", "shortName": "Non-Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "cyec:Non-CurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "cyec:NonCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R14": { "role": "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilities", "longName": "995210701 - Disclosure - Accrued and Other Liabilities", "shortName": "Accrued and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R15": { "role": "http://www.cyclacel.com/role/DisclosureLeases", "longName": "995210801 - Disclosure - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R16": { "role": "http://www.cyclacel.com/role/DisclosureStockBasedCompensation", "longName": "995210901 - Disclosure - Stock Based Compensation", "shortName": "Stock Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R17": { "role": "http://www.cyclacel.com/role/DisclosureStockholdersEquity", "longName": "995211001 - Disclosure - Stockholders Equity", "shortName": "Stockholders Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R18": { "role": "http://www.cyclacel.com/role/DisclosureSubsequentEvents", "longName": "995211101 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R19": { "role": "http://www.cyclacel.com/role/DisclosurePayPerformance", "longName": "995211201 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:PayPerformanceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:PayPerformanceDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R20": { "role": "http://www.cyclacel.com/role/DisclosureInsiderTradingArrangements", "longName": "995211301 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:InsiderTradingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:InsiderTradingArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "R21": { "role": "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "Duration 1 1 2024 9 30 2024 1buY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef":

"ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "div", "div", "body", "html", "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }], "R31": { "role": "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "99940501-Disclosure-Prepaid Expenses and Other Current Assets-Schedule of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets-Schedule of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "cyec:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "cyec:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.cyclacel.com/role/DisclosureNonCurrentAssetsDetails", "longName": "99940601-Disclosure-Non Current Assets (Details)", "shortName": "Non Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "cyec:DepositsHeldByRelatedParty", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": ["p", "cyec:NonCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "cyec:DepositsHeldByRelatedParty", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": ["p", "cyec:NonCurrentAssetsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails", "longName": "99940701-Disclosure-Accrued and Other Liabilities-Schedule of accrued and other current liabilities (Details)", "shortName": "Accrued and Other Liabilities-Schedule of accrued and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "cyec:AccruedResearchAndDevelopmentCostsCurrent", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-2", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "cyec:AccruedResearchAndDevelopmentCostsCurrent", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-2", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "longName": "99940801-Disclosure-Leases-Narrative (Details)", "shortName": "Leases-Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 lbuY6Q9dZU2uXxCRF5g1gA", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-0", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 lbuY6Q9dZU2uXxCRF5g1gA", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-0", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "longName": "99940802-Disclosure-Leases-Future Minimum Lease Payments (Details)", "shortName": "Leases-Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails", "longName": "99940901-Disclosure-Stock Based Compensation-Schedule of Stock Based Compensation Expense (Details)", "shortName": "Stock Based Compensation-Schedule of Stock Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 NuFLmgD10m03ygy6wuhDg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 7 1 2024 To 9 30 2024 NuFLmgD10m03ygy6wuhDg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "longName": "99940902-Disclosure-Stock Based Compensation (Narrative) (Details)", "shortName": "Stock Based Compensation (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As Of 9 30 2024 Imq S10zES98NZUvGXoQA", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 lbuY6Q9dZU2uXxCRF5g1gA", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": "Unit-Standard_USD_1YrkPcbAuk-Q5bXo8t1L8g", "xsiNil": "false", "lang": "en-US", "decimals": "null", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfFairValueOfStockOptionsGrantedDetails", "longName": "99940903-Disclosure-Stock Based Compensation-Schedule of Fair Value of the Stock Options Granted (Details)", "shortName": "Stock Based Compensation-Schedule of Fair Value of the Stock Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 9 30 2024 us-gaap-AwardTypeAxis-us-gaap-EmployeeStockOptionMember-b8YBzVKwFEaudFOlaoMjgw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": "null", "ancestors": ["p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "cyec-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration

"menuCat": "Details", "order": "44", "firstAnchor": "contextRef": "Duration 1-1-2024 To 9-30-2024 lbaY6Q9dZU2uXxCRF5gIgA", "name": "us-gaap:PreferredStockDividendRatePercentage", "unitRef": "Unit_Standard_pure_VlbYvDmKc56lMr_sdv3w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html", "1", "reportCount", "1", "baseRef": "cycc-202404030x10q.htm", "first": true, "uniqueAnchor": "contextRef": "Duration 10-23-2024 To 10-23-2024 us-gaap-ClassOfWarrantOrRightAxis_cycc-PreFundedWarrantsMember-us-gaap-SubsequentEventItemTypeAxis-us-gaap-SubsequentEventMember_gUdoBZLDfKm4spRuKkh0mQ", "name": "cycc:ClassOfWarrantOrRightExercised", "unitRef": "Unit_Standard_shares_52t0lhZ7GqoA5f04NxoICGg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html", "1", "reportCount", "1", "baseRef": "cycc-20240930x10q.htm", "unique": true }], "tag": { "us-gaap-AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } }, "auth-ref": [] }, "us-gaap-AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilities": { "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued and Other Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth-ref": [] }, "us-gaap-AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth-ref": ["r10", "r490"] }, "cycc-AccrualOfPreferredStockDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "AccrualOfPreferredStockDividends", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "documentation": "Represents amount of accrual of preferred stock dividends.", "label": "Accrual Of Preferred Stock Dividends", "verboseLabel": "Accrual of preferred stock dividends" } } }, "auth-ref": [] }, "us-gaap-AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Accrued and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth-ref": ["r21"] }, "us-gaap-AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued legal and professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth-ref": ["r21"] }, "cycc-AccruedResearchAndDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "AccruedResearchAndDevelopmentCostsCurrent", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "lang": { "en-us": { "role": { "documentation": "Represents the carrying value, as of the balance sheet date, of obligations incurred through that date and payable arising from research and development transactions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)", "label": "Accrued Research and Development Costs Current", "terseLabel": "Accrued research and development" } } }, "auth-ref": [] }, "us-gaap-AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth-ref": ["r26", "r27", "r63", "r102", "r335", "r357", "r358"] }, "us-gaap-AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth-ref": ["r2", "r11", "r27", "r286", "r289", "r319", "r353", "r354", "r591", "r592", "r593", "r598", "r599", "r600"] }, "ecd-Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth-ref": ["r542"] }, "us-gaap-AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock" } } }, "auth-ref": ["r58", "r490", "r662"] }, "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth-ref": ["r267", "r268", "r269", "r368", "r598", "r599", "r600", "r642", "r665"] }, "ecd-AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth-ref": ["r548"] }, "ecd-AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation" } } }, "auth-ref": ["r548"] }, "ecd-AdjToNonPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth-ref": ["r548"] }, "ecd-AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote" } } }, "auth-ref": ["r548"] }, "us-gaap-AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid In Capital Preferred Stock Conversion", "negatedLabel": "Preferred stock dividends", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance" } } }, "auth-ref": ["r12", "r80"] }, "us-gaap-AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement" } } }, "auth-ref": ["r50", "r51", "r233"] }, "us-gaap-AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Expenses related to Securities Purchase Agreement In Private Placement", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth-ref": ["r12", "r80"] }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth-ref": [] }, "cycc-AggregateProceedsFromSaleOfStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "AggregateProceedsFromSaleOfStock", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "documentation": "Represents total proceeds received life-to-date through the sale of stock.", "label": "Aggregate Proceeds From Sale Of Stock", "terseLabel": "Total gross proceeds received" } } }, "auth-ref": [] }, "ecd-AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Errorneous Compensation Amount", "terseLabel": "Aggregate Errorneous Compensation Amount" } } }, "auth-ref": ["r513", "r524", "r534", "r559"] }, "ecd-AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Errorneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Errorneous Compensation Not Yet Determined" } } }, "auth-ref": ["r516", "r527", "r537", "r562"] }, "ecd-AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth-ref": ["r548"] }, "ecd-AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth-ref": ["r555"] }, "ecd-AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth-ref": ["r520", "r528", "r538", "r555", "r563", "r567", "r575"] }, "ecd-AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth-ref": ["r573"] }, "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation costs before income taxes", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized" } } }, "auth-ref": ["r262", "r270"] }, "dei-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": { "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth-ref": [] }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Total shares excluded from calculation", "terseLabel": "Total shares excluded from calculation", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth-ref": ["r154"] }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth-ref": ["r35"] }, "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable

information associated with domain members defined in one or many axes to the table. } } } , { "auth_ref": { } } , { "us-gaap-AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { } } } , { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntidilutiveSecuritiesDetails", "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented. } } } , { "auth_ref": { "r35" } } , { "cyce-April2024SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "April2024SecuritiesPurchaseAgreementMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityTables", "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" } } , { "en-us": { "role": { "documentation": "Represents information pertaining to April 2024, securities purchase agreement. ", "label": "April 2024, Securities Purchase Agreement [Member]", "terseLabel": "April 2024 Securities Purchase Agreement" } } } , { "auth_ref": { } } , { "cyce-April2024WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "April2024WarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represent information pertains to April 2024 Warrants. ", "label": "April 2024 Warrants [Member]", "terseLabel": "April 2024 Warrants" } } } , { "auth_ref": { } } , { "us-gaap-Assets": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } } } , { "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. } } } , { "auth_ref": { "r84", "r98", "r122", "r161", "r167", "r171", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r279", "r283", "r297", "r332", "r404", "r490", "r504", "r609", "r610", "r650" } } } , { "us-gaap-AssetsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } } , { "auth_ref": { } } , { "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } } } , { "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. } } } , { "auth_ref": { "r95", "r104", "r122", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r279", "r283", "r297", "r490", "r609", "r610", "r650" } } } , { "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } } , { "auth_ref": { } } , { "cyce-August2021ControlledEquityOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "August2021ControlledEquityOfferingSalesAgreementMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents information relating to August 2021-Controlled Equity Offering Sales Agreement. ", "label": "August 2021-Controlled Equity Offering Sales Agreement [Member]", "terseLabel": "August 2021-Controlled Equity Offering Sales Agreement" } } } , { "auth_ref": { } } , { "ecd-AwardExrPrice": { "xbrltype": "perShareItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } } , { "auth_ref": { "r570" } } } , { "ecd-AwardGrantDateFairValue": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } } , { "auth_ref": { "r571" } } } , { "ecd-AwardTmgDisclnItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDisclnItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } } , { "auth_ref": { "r566" } } , { "ecd-AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } } , { "auth_ref": { "r566" } } , { "ecd-AwardTmgMethodTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } } , { "auth_ref": { "r566" } } , { "ecd-AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } } , { "auth_ref": { "r566" } } , { "ecd-AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } } , { "auth_ref": { "r566" } } , { "ecd-AwardTmgPredtrmndFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } } , { "auth_ref": { "r566" } } , { "us-gaap-AwardTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfFairValueOfStockOptionsGrantedDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement. } } } , { "auth_ref": { "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" } } } , { "ecd-AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } } , { "auth_ref": { "r569" } } , { "ecd-AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } } , { "auth_ref": { "r568" } } , { "ecd-AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } } , { "auth_ref": { "r567" } } , { "us-gaap-BasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). } } } , { "auth_ref": { } } , { "cyce-BerkeleyHeightsFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "BerkeleyHeightsFacilityMember", "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Berkeley Heights Facility [Member]", "label": "Berkeley Heights Facility [Member]", "terseLabel": "Berkeley Heights facility" } } } , { "auth_ref": { } } , { "cyce-CantorFitzgeraldCo.Member": { "xbrltype": "domainItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "CantorFitzgeraldCo.Member", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Cantor Fitzgerald & Co. [Member]", "terseLabel": "Cantor Fitzgerald & Co.", "auth_ref": { } } , { "us-gaap-CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 1.0 } } , { "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. } } } , { "auth_ref": { "r30", "r97", "r471" } } , { "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. } } } , { "auth_ref": { "r30", "r71", "r118" } } , { "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } } } , { "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. } } } , { "auth_ref": { "r1", "r71" } } , { "us-gaap-CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Non-cash financing activities", "verboseLabel": "Non-cash financing activities" } } } , { "auth_ref": { } } , { "cyce-CashPlacementFeePercentage": { "xbrltype": "percentItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "CashPlacementFeePercentage", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Cash placement fee as a percentage of gross proceeds raised in offerings. ", "label": "Cash Placement Fee Percentage", "terseLabel": "Cash placement fee, percentage of gross proceeds raised" } } } , { "auth_ref": { } } , { "ecd-ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } } , { "auth_ref": { "r546" } } , { "srt-ChiefExecutiveOfficerMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } } , { "auth_ref": { "r604" } } } , { "cyce-ChiefFinancialOfficerAndChiefOperatingOfficerMember": { "xbrltype": "domainItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ChiefFinancialOfficerAndChiefOperatingOfficerMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Chief Financial Officer And Chief Operating Officer", "label": "Chief Financial Officer And Chief Operating Officer [Member]", "terseLabel": "Chief Financial Officer and Chief Operating Officer" } } } , { "auth_ref": { } } , { "doi-CityAreaCode": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/doi/2023", "localname": "CityAreaCode", "presentation": { "http://www.cyclacel.com/role/DocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } } , { "auth_ref": { } } , { "us-gaap-ClassOfStockDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "http://www.cyclacel.com/role/DocumentAndEntityInformation", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock. } } } , { "auth_ref": { "r92", "r99", "r100", "r101", "r122", "r143", "r144", "r151", "r153", "r159", "r160", "r177", "r186", "r188", "r189", "r190", "r193", "r194", "r198", "r199", "r203", "r206", "r214", "r297", "r362", "r363", "r364", "r365", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r392", "r413", "r432", "r450", "r451", "r453", "r454", "r581", "r596", "r602" } } } , { "us-gaap-ClassOfStockLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityTables", "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } } } , { "auth_ref": { "r99", "r100", "r101", "r150", "r188", "r198", "r199", "r201", "r203", "r206", "r212", "r214", "r362", "r363", "r364", "r365", "r480", "r581", "r596" } } } , { "us-gaap-ClassOfWarrantOrRightAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails",

"http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": { "r46" } }, "us-gaap-ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": { "r1" } }, "us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrants, exercise price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r215" } }, "cyce-ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ClassOfWarrantOrRightExercised", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period." }, "label": "Class of Warrant or Right, Exercised", "terseLabel": "Warrants exercised" } } }, "auth_ref": { "r1" } }, "us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of warrant to purchase each share of our common stock", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": { "r1" } }, "us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r215" } }, "us-gaap-ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": { "r1" } }, "cyce-ClassOfWarrantOrRightsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ClassOfWarrantOrRightsExercisable", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercisable", "label": "Class Of Warrant Or Rights, Exercisable", "terseLabel": "Exercisable warrants" } } }, "auth_ref": { "r1" } }, "cyce-ClinicalTrialSupplyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ClinicalTrialSupplyMember", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "documentation": "Clinical trial supply revenue", "label": "Clinical Trial Supply [Member]", "terseLabel": "Clinical trial supply" } } }, "auth_ref": { "r1" } }, "cyce-CoPlacementAgentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "CoPlacementAgentsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Co Placement Agents [Member]", "label": "Co Placement Agents [Member]", "terseLabel": "Co Placement Agents" } } }, "auth_ref": { "r1" } }, "ecd-CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": { "r547" } }, "ecd-CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": { "r547" } }, "us-gaap-CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance upon conversion", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r23" } }, "us-gaap-CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r493", "r404", "r405", "r497", "r498", "r499", "r500", "r508", "r599", "r642", "r661", "r665" } }, "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r57" } }, "us-gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r57", "r302" } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r57" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r12", "r57", "r302", "r410", "r665", "r666" } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, \$0.001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 2,152,202 shares issued and outstanding at September 30, 2024 and 1,958,892 shares issued and outstanding at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r57", "r334", "r490" } }, "cyce-CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "CommonStockWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails", "lang": { "en-us": { "role": { "documentation": "Information of common stock warrant", "label": "Common Stock Warrants" } } }, "auth_ref": { "r1" } }, "ecd-CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": { "r552" } }, "ecd-CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": { "r551" } }, "ecd-CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": { "r553" } }, "ecd-CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": { "r550" } }, "cyce-CompensationPercentageToAggregateGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "CompensationPercentageToAggregateGrossProceeds", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Compensation amount as a percentage of the aggregate gross proceeds raised in the offering", "label": "Compensation Percentage to the Aggregate Gross Proceeds", "terseLabel": "Percentage of compensation raised" } } }, "auth_ref": { "r1" } }, "us-gaap-ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r28", "r106", "r108", "r113", "r320", "r343" } }, "us-gaap-ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": { "r1" } }, "srt-CondensedBalanceSheetStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedBalanceSheetStatementTable", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statement [Table]", "auth_ref": { "r125", "r583" } } }, "us-gaap-ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Converted", "verboseLabel": "Number of shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period." } } }, "auth_ref": { "r32", "r33", "r34" } }, "cyce-ConversionTriggerMeasurementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ConversionTriggerMeasurementPeriod", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "The number of consecutive trading days used as the measurement period in determining whether specified triggers are met which would allow the entity to require the conversion of all or part of outstanding preferred stock", "label": "Conversion Trigger, Measurement Period", "verboseLabel": "Measurement period of consecutive trading days used in determining whether specified triggers are met which would allow the entity to require the conversion of all or part of outstanding preferred stock" } } }, "auth_ref": { "r1" } }, "cyce-ConversionTriggerPercentageOfWeightedAverageCommonStockPriceDuringMeasurementPeriodInExcessOfInitialConversionPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ConversionTriggerPercentageOfWeightedAverageCommonStockPriceDuringMeasurementPeriodInExcessOfInitialConversionPrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Percentage by which the weighted average price of common stock during the measurement period exceeds the initial conversion price which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted", "label": "Conversion Trigger, Percentage of Weighted Average Common Stock Price During Measurement Period in Excess of Initial Conversion Price", "verboseLabel": "Percentage by which the weighted average price of common stock during the measurement period exceeds the initial conversion price which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted" } } }, "auth_ref": { "r1" } }, "cyce-ConversionTriggerThresholdOfDailyTradingVolumeDuringMeasurementPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ConversionTriggerThresholdOfDailyTradingVolumeDuringMeasurementPeriod", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Threshold amount of daily trading volume on each trading day during the measurement period which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted", "label": "Conversion Trigger, Threshold of Daily Trading Volume During Measurement Period", "verboseLabel": "Threshold amount of daily trading volume on each trading day during the measurement period which triggers the right of the entity to cause all or part of the outstanding preferred stock to be converted" } } }, "auth_ref": { "r1" } }, "cyce-ConvertiblePreferredStockConversionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ConvertiblePreferredStockConversionPercentage", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents the percentage of conversion price", "label": "Convertible Preferred Stock, Conversion Percentage", "verboseLabel": "Conversion percentage" } } }, "auth_ref": { "r1" } },


```

{"ConvertiblePreferredStockConversionPercentageBlockerProvision": {"xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ConvertiblePreferredStockConversionPercentageBlockerProvision", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"documentation": "Represents the percentage of blocker provision."}, "label": "Convertible Preferred Stock, Conversion Percentage, Blocker Provision", "verboseLabel": "Percentage of blocker provision"}}, {"auth-ref": []}, {"us-gaap-ConvertiblePreferredStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [{"http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCommonSPotentialAntiDilutiveSecuritiesDetails"}, {"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}, {"http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails"}, {"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets"}, {"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals"}], "lang": {"en-us": {"role": {"label": "6% Convertible Exchangeable Preferred Stock", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."}}, {"auth-ref": [{"r198", "r199", "r203", "r497", "r498", "r499", "r500"}]}, {"us-gaap-ConvertiblePreferredStockSharesIssuedUponConversion": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Number of common shares issued upon conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."}}, {"auth-ref": [{"r18", "r41", "r56", "r78", "r209"}]}, {"srt-CounterpartyNameAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"label": "Counterparty Name [Axis]"}}, {"auth-ref": [{"r123", "r124", "r195", "r201", "r320", "r472", "r474"}]}, {"dei-CoverAbstract": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": {"en-us": {"role": {"label": "Document and Entity Information [Abstract]", "documentation": "Cover page."}}, {"auth-ref": [{"dei-CurrentFiscalYearEndDate": {"xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD-"}}, {"auth-ref": [{"us-gaap-DebtInstrumentTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term", "documentation": "Period of time between issuance and maturity of debt instrument, in PhYnMndTnHnMs format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."}}, {"auth-ref": [{"ecyc-December2020WarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "December2020WarrantsMember", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"documentation": "Represent information pertains to December 2020 Warrants.", "label": "December 2020 Warrants [Member]", "terseLabel": "December 2020 Warrants"}}, {"auth-ref": [{"ecyc-December2023InsiderPrivatePlacementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "December2023InsiderPrivatePlacementMember", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"documentation": "December 2023 Insider Private Placement", "label": "December 2023 Insider Private Placement [Member]", "terseLabel": "December 2023 Insider Private Placement"}}, {"auth-ref": [{"ecyc-December2023PlacementAgencyAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "December2023PlacementAgencyAgreementMember", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"documentation": "December 2023 Placement Agency Agreement", "label": "December 2023 Placement Agency Agreement [Member]", "terseLabel": "December 2023 Placement Agency Agreement"}}, {"auth-ref": [{"ecyc-December2023PrivatePlacementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "December2023PrivatePlacementMember", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"documentation": "December 2023 Private Placement", "label": "December 2023 Private Placement [Member]", "terseLabel": "December 2023 Private Placement"}}, {"auth-ref": [{"ecyc-December2023SecuritiesPurchaseAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "December2023SecuritiesPurchaseAgreementMember", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails"}, {"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}, {"http://www.cyclacel.com/role/DisclosureStockholdersEquityTables"}, {"http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"}], "lang": {"en-us": {"role": {"documentation": "December 2023 Securities Purchase Agreement", "label": "December 2023 Securities Purchase Agreement [Member]", "terseLabel": "December 2023 Securities Purchase Agreement"}}, {"auth-ref": [{"us-gaap-DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [{"http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"}], "lang": {"en-us": {"role": {"label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet, and other deferred costs."}}, {"auth-ref": [{"us-gaap-DeferredIncomeTaxesAndOtherTaxReceivableCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndOtherTaxReceivableCurrent", "crdr": "debit", "calculation": [{"http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"}]. {"parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 }}, {"presentation": [{"http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"}], "lang": {"en-us": {"role": {"label": "Deferred Income Taxes and Other Tax Receivable, Current", "terseLabel": "Research and development tax credit receivable", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer."}}, {"auth-ref": [{"us-gaap-DepositsAssetsNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": [{"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets"}]. {"parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 }}, {"presentation": [{"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets"}], "lang": {"en-us": {"role": {"label": "Deposits Assets, Noncurrent", "terseLabel": "Non-current deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."}}, {"auth-ref": [{"ecyc-DepositsHeldByRelatedParty": {"xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "DepositsHeldByRelatedParty", "crdr": "debit", "presentation": [{"http://www.cyclacel.com/role/DisclosureNonCurrentAssetsDetails"}], "lang": {"en-us": {"role": {"documentation": "Represents the value of deposits held by a third-party but considered an asset to the Company.", "label": "Deposits Held By Related Party", "terseLabel": "Clinical trial deposits held by a contract research organization"}}, {"auth-ref": [{"us-gaap-Depreciation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": [{"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows"}]. {"parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }}, {"presentation": [{"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows"}], "lang": {"en-us": {"role": {"label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."}}, {"auth-ref": [{"k7", "r36"}]}, {"us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockBasedCompensation"}], "lang": {"en-us": {"role": {"label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock Based Compensation", "documentation": "The entire disclosure for share based payment arrangement."}}, {"auth-ref": [{"r231", "r235", "r263", "r264", "r266", "r484"}]}, {"us-gaap-DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": {"en-us": {"role": {"label": "Stock-Based Compensation"}}, {"auth-ref": [{"us-gaap-DividendsPayableCurrentAndNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [{"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails"}], "lang": {"en-us": {"role": {"label": "Dividends Payable", "terseLabel": "Accrued and unpaid dividends", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."}}, {"auth-ref": [{"r54", "r55", "r85", "r501", "r659"}]}, {"dei-DocumentsFiscalPeriodFocus": {"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsFiscalPeriodFocus", "presentation": [{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."}}, {"auth-ref": [{"dei-DocumentsFiscalYearFocus": {"xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsFiscalYearFocus", "presentation": [{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."}}, {"auth-ref": [{"dei-DocumentsInformationLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsInformationLineItems", "presentation": [{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, {"auth-ref": [{"dei-DocumentsInformationTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsInformationTable", "presentation": [{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"}], "lang": {"en-us": {"role": {"label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."}}, {"auth-ref": [{"dei-DocumentsPeriodEndDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname":
```


"EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems","presentation":{
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"},"lang":{"en-us":{"role":{"label":"Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"}},"us-gaap-
gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1":{"xbrltype":"durationItemType","nsuri":
"http://fasb.org/us-gaap/2023"},"localname":"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1","presentation":{
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails"},"lang":{"en-us":{"role":{"label":"Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition","terseLabel":"Weighted-average remaining requisite service period of recognition of unrecognized compensation cost","documentation":"Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."}}},"auth_ref":{"r265"}}},"us-gaap-
gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions","erdr","debit","presentation":{
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails"},"lang":{"en-us":{"role":{"label":"Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options","terseLabel":"Remaining unrecognized compensation cost of non-vested stock options","documentation":"Amount of cost to be recognized for option under share-based payment arrangement."}}},"auth_ref":{"r641"}}},"us-gaap-EmployeeStockOptionMember":{"xbrltype":"domainItemType","nsuri":
"http://fasb.org/us-gaap/2023"},"localname":"EmployeeStockOptionMember","presentation":{
"http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails"},
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails"},
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails"},
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails"},"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"verboseLabel":"Stock options","label":"Employee Stock Option [Member]","terseLabel":"Employee Stock Option","documentation":"Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."}}},"auth_ref":{"}}},
"dei-EntityAddressAddressLine1":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityAddressAddressLine1","presentation":{
"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Address, Address Line One","documentation":"Address Line 1 such as Attn, Building Name, Street Name."}}},"auth_ref":{"}},"dei-EntityAddressAddressLine2":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityAddressAddressLine2","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Address, Address Line Two","documentation":"Address Line 2 such as Street or Suite number."}}},"auth_ref":{"}},"dei-EntityAddressCityOrTown":{"xbrltype":"normalizedStringItemType","nsuri":
"http://xbrl.sec.gov/dei/2023"},"localname":"EntityAddressCityOrTown","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Address, City or Town","documentation":"Name of the City or Town."}}},"auth_ref":{"}},"dei-EntityAddressPostalZipCode":{"xbrltype":"normalizedStringItemType","nsuri":
"http://xbrl.sec.gov/dei/2023"},"localname":"EntityAddressPostalZipCode","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Address, Postal Zip Code","documentation":"Code for the postal or zip code."}}},"auth_ref":{"}},"dei-EntityAddressStateOrProvince":{"xbrltype":"stateOrProvinceItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityAddressStateOrProvince","presentation":{
"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Address, State or Province","documentation":"Name of the state or province."}}},"auth_ref":{"}},"dei-EntityCentralIndexKey":{"xbrltype":"centralIndexKeyItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityCentralIndexKey","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Central Index Key","documentation":"A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."}}},"auth_ref":{"r506"}}},"dei-EntityCommonStockSharesOutstanding":{"xbrltype":"sharesItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityCommonStockSharesOutstanding","presentation":{
"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Common Stock, Shares Outstanding","documentation":"Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."}}},"auth_ref":{"}},"dei-EntityCurrentReportingStatus":{"xbrltype":"yesNoItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityCurrentReportingStatus","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Current Reporting Status","documentation":"Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}},"auth_ref":{"}},"dei-EntityEmergingGrowthCompany":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityEmergingGrowthCompany","presentation":{
"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Emerging Growth Company","documentation":"Indicate if registrant meets the emerging growth company criteria."}}},"auth_ref":{"r506"}}},"dei-EntityFileNumber":{"xbrltype":"fileNumberItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityFileNumber","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity File Number","documentation":"Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters; and the fields are separated with a hyphen."}}},"auth_ref":{"}},"dei-EntityFilerCategory":{"xbrltype":"filerCategoryItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityFilerCategory","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Filer Category","documentation":"Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."}}},"auth_ref":{"r506"}}},"dei-EntityIncorporationStateCountryCode":{"xbrltype":"edgarStateCountryItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityIncorporationStateCountryCode","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Incorporation, State or Country Code","documentation":"Two character EDGAR code representing the state or country of incorporation."}}},"auth_ref":{"}},"dei-EntityInteractiveDataCurrent":{"xbrltype":"yesNoItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityInteractiveDataCurrent","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Interactive Data Current","documentation":"Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."}}}},"auth_ref":{"r500"}}},"dei-EntityRegistrantName":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityRegistrantName","presentation":{
"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Registrant Name","documentation":"The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."}}},"auth_ref":{"r506"}}},"dei-EntityShellCompany":{"xbrltype":"booleanItemType","nsuri":
"http://xbrl.sec.gov/dei/2023"},"localname":"EntityShellCompany","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Shell Company","documentation":"Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."}}},"auth_ref":{"r506"}}},"dei-EntitySmallBusiness":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntitySmallBusiness","presentation":{
"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Small Business","documentation":"Indicates that the company is a Smaller Reporting Company (SRC)."}}}},"auth_ref":{"r506"}}},"dei-EntityTaxIdentificationNumber":{"xbrltype":"employerIdItemType","nsuri":"http://xbrl.sec.gov/dei/2023"},"localname":"EntityTaxIdentificationNumber","presentation":{"http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation"},"lang":{"en-us":{"role":{"label":"Entity Tax Identification Number","documentation":"The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS."}}},"auth_ref":{"r506"}}},"us-gaap-EquityComponentDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"EquityComponentDomain","presentation":{
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations"},"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit"},"lang":{"en-us":{"role":{"label":"Equity Component [Domain]","documentation":"Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."}}},"auth_ref":{"r12","r93","r109","r110","r111","r126","r127","r128","r130","r136","r138","r158","r178","r179","r216","r267","r268","r269","r273","r274","r285","r286","r287","r288","r289","r290","r292","r303","r304","r305","r306","r307","r308","r319","r353","r354","r355","r368","r432"}}},"ecyc-EquityIncentivePlan2018Member":{"xbrltype":"domainItemType","nsuri":"http://www.cyclacel.com/20240930"},"localname":"EquityIncentivePlan2018Member","presentation":{
"http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails"},"lang":{"en-us":{"role":{"documentation":"Information about plan name."},"label":"2018 Equity Incentive Plan (the '2018 Plan') [Member]","terseLabel":"2018 Plan"}}},"auth_ref":{"}},"ecd-EquityValuationAssumptionDifferenceFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":
"http://xbrl.sec.gov/ecd/2023"},"localname":"EquityValuationAssumptionDifferenceFnTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Equity Valuation Assumption Difference, Footnote [Text Block]","terseLabel":"Equity Valuation Assumption Difference, Footnote"}}},"auth_ref":{"r549}}},"ecd-ErrCompAnalysisTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2023"},"localname":"ErrCompAnalysisTextBlock","presentation":{
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"label":"Erroneous Compensation Analysis [Text Block]","terseLabel":"Erroneous Compensation Analysis"}}},"auth_ref":{"r513","r524","r534","r559"}}},"ecd-ErrCompRecoveryTable":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2023"},"localname":"ErrCompRecoveryTable","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"label":"Erroneously Awarded Compensation Recovery [Table]","terseLabel":"Erroneously Awarded Compensation Recovery"}}},"auth_ref":{"r510","r521","r531","r556"}}},"ecd-ExecutiveCategoryAxis":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2023"},"localname":"ExecutiveCategoryAxis","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"label":"Executive Category [Axis]","terseLabel":"Executive Category"}}},"auth_ref":{"r555}}},"us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems":{"xbrltype":"stringItemType","nsuri":
"http://fasb.org/us-gaap/2023"},"localname":"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems","presentation":{
"http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"},"lang":{"en-us":{"role":{"label":"Fair Value Measurement Inputs and Valuation Techniques [Line Items]","documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"}}},"us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable","presentation":{
"http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails"},"lang":{"en-us":{"role":{"label":"Fair Value Measurement Inputs and Valuation Techniques [Table]","documentation":"Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."}}},"auth_ref":{"r13"}}},"us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock","presentation":{
"http://www.cyclacel.com/role/DisclosureStockholdersEquityTables"},"lang":{"en-us":{"role":{"label":"Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]","terseLabel":"Schedule of fair value of warrants valuation assumption","documentation":"Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."}}},"auth_ref":{"r13"}}},"us-gaap-FairValueOfFinancialInstrumentsPolicy":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"FairValueOfFinancialInstrumentsPolicy","presentation":{
"http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"},"lang":{"en-us":{"role":{"label":"Fair Value of Financial Instruments, Policy [Policy Text Block]","terseLabel":"Fair Value of Financial Instruments","documentation":"Disclosure of accounting policy for determining the fair value of financial instruments."}}},"auth_ref":{"r9","r17"}}},"us-gaap-ForeignCurrencyTransactionGainLossBeforeTax":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"ForeignCurrencyTransactionGainLossBeforeTax","erdr","credit","calculation":{"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations":{"parentTag":"us-gaap-NonoperatingIncomeExpense","weight":1.0,"order":1.0},"presentation":{"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"label":"Foreign Currency Transaction Gain (Loss), before Tax","terseLabel":"Foreign exchange gains (losses)","documentation":"Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."}}},"auth_ref":{"r299","r301","r302","r429"}}},"us-gaap-ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2023"},"localname":"ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock","presentation":{
"http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"},"lang":{"en-us":{"role":{"label":"Foreign Currency Transactions and Translations Policy [Policy Text Block]","terseLabel":"Foreign Currency and Currency Translation","documentation":"Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."}}},"auth_ref":{"r298"}}},"ecd-ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2023"},"localname":"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"label":"Forgone Recovery due to Disqualification of Tax Benefits, Amount","terseLabel":"Forgone Recovery due to Disqualification of Tax Benefits, Amount"}}},"auth_ref":{"r517","r528","r538","r563}}},"ecd-ForgoneRecoveryDueToExpenseOfEnforcementAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2023"},"localname":"ForgoneRecoveryDueToExpenseOfEnforcementAmt","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"label":"Forgone Recovery due to Expense of Enforcement, Amount","terseLabel":"Forgone Recovery due to Expense of Enforcement, Amount"}}},"auth_ref":{"r517","r528","r538","r563}}},"ecd-ForgoneRecoveryDueToViolationOfHomeCountryLawAmt":{"xbrltype":"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2023"},"localname":

"ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terselabel": "Amount" }, "auth-ref": { "r517", "r528", "r538", "r563" } } }, "ecd-ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terselabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth-ref": { "r517", "r528", "r538", "r563" } } }, "ecd-ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terselabel": "Name" } } }, "auth-ref": { "r517", "r528", "r538", "r563" } } }, "us-gaap-GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth-ref": { "r66" } } }, "cyec-GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "GoingConcernPolicyTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies" }, "lang": { "en-us": { "role": { "documentation": "Represents policy disclosure related to Going Concern", "label": "Going Concern [Policy Text Block]", "terselabel": "Going Concern" } } }, "auth-ref": { } }, "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total", "totalLabel": "Loss before taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth-ref": { "r0", "r64", "r87", "r161", "r166", "r170", "r172", "r330", "r339", "r478" } }, "us-gaap-IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth-ref": { } }, "us-gaap-IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth-ref": { "r180", "r181", "r416" } }, "us-gaap-IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth-ref": { "r181", "r416" } }, "us-gaap-IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth-ref": { "r89", "r90", "r137", "r138", "r164", "r272", "r275", "r345" } }, "us-gaap-IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terselabel": "Taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth-ref": { "r31" } }, "us-gaap-IncomeTaxesPaidNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNetAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net [Abstract]", "terselabel": "Cash paid during the period for." } } }, "auth-ref": { } }, "us-gaap-IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terselabel": "Accounts payable, accrued and other current liabilities", "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other." } } }, "auth-ref": { "r595" } }, "us-gaap-IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terselabel": "Changes in operating assets and liabilities." } } }, "auth-ref": { } }, "us-gaap-IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Changes In Lease Liability", "terselabel": "Changes in lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth-ref": { "r585", "r595" } }, "us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth-ref": { "r6" } }, "cyec-IncreaseInCarryingAmountOfRedeemableCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "IncreaseInCarryingAmountOfRedeemableCommonStock", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "documentation": "Adjustment to retained earnings for the increase in carrying amount of redeemable common stock that is classified as temporary equity", "label": "Increase in Carrying Amount of Redeemable Common Stock", "negatedLabel": "Reclassification of redeemable common stock" } } }, "auth-ref": { } }, "ecd-IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terselabel": "Individual." } } }, "auth-ref": { "r520", "r528", "r538", "r555", "r563", "r567", "r575" } }, "cyec-InducementEquityIncentivePlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "InducementEquityIncentivePlan2020Member", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to inducement equity incentive plan 2020", "label": "Inducement Equity Incentive Plan 2020 [Member]", "terselabel": "Inducement Plan" } } }, "auth-ref": { } }, "ecd-InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terselabel": "Insider Trading Arrangements." } } }, "auth-ref": { "r573" } }, "ecd-InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terselabel": "Insider Trading Policies and Procedures." } } }, "auth-ref": { "r509", "r579" } }, "ecd-InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terselabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth-ref": { "r509", "r579" } }, "ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terselabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth-ref": { "r509", "r579" } }, "cyec-InvestmentInterestIncomeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "InvestmentInterestIncomeExpenses", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income expense on nonoperating securities", "label": "Investment Interest Income Expenses", "terselabel": "Interest (expense) income" } } }, "auth-ref": { } }, "cyec-LadenburgThalmannCo.IncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "LadenburgThalmannCo.IncMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ladenburg Thalmann & Co. Inc.", "label": "Ladenburg Thalmann & Co. Inc [Member]", "terselabel": "Ladenburg Thalmann & Co. Inc" } } }, "auth-ref": { } }, "us-gaap-LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth-ref": { } }, "us-gaap-LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies" }, "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terselabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth-ref": { "r314" } }, "us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" }, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease obligation", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth-ref": { "r318" } }, "cyec-LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" }, "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)", "label": "Lessee Operating Lease Liability Payments Due After Year Two", "terselabel": "Thereafter" } } }, "auth-ref": { } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" }, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terselabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth-ref": { "r318" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" }, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terselabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth-ref": { "r648" } }, "us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" }, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terselabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth-ref": { "r318" } }, "us-gaap-LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum

of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. } } } }, "auth_ref": ["r20", "r122", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r280", "r283", "r284", "r297", "r391", "r477", "r504", "r609", "r650", "r651"] }, "us-gaap-LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } } }, "auth_ref": ["r62", "r86", "r337", "r490", "r597", "r605", "r645"] }, "us-gaap-LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } } } }, "auth_ref": [] }, "us-gaap-LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } } }, "auth_ref": ["r22", "r96", "r122", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r280", "r283", "r284", "r297", "r490", "r609", "r650", "r651"] }, "us-gaap-LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities." } } } } }, "auth_ref": [] }, "dei-LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": { "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } } }, "auth_ref": [] }, "cyec-ManagementFeePercentageToAggregateGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ManagementFeePercentageToAggregateGrossProceeds", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "documentation": "Management fee as a percentage of gross proceeds raised in offerings", "label": "Management fee Percentage to the Aggregate Gross Proceeds", "terseLabel": "Management fee percentage" } } } } }, "auth_ref": [] }, "srt-MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Maximum" } } } } } } }, "auth_ref": ["r182", "r183", "r184", "r185", "r229", "r325", "r352", "r383", "r384", "r437", "r440", "r444", "r445", "r447", "r466", "r467", "r479", "r480", "r483", "r492", "r611", "r652", "r653", "r654", "r655", "r656", "r657"] }, "ced-MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure", "auth_ref": ["r547"] }, "ced-MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } } } }, "auth_ref": ["r547"] }, "us-gaap-MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividend yield", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } } } }, "auth_ref": ["r643"] }, "us-gaap-MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Contractual term", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } } } }, "auth_ref": ["r643"] }, "us-gaap-MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } } } }, "auth_ref": ["r643"] }, "us-gaap-MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } } } }, "auth_ref": ["r643"] }, "us-gaap-MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } } } }, "auth_ref": ["r295"] }, "us-gaap-MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } } } }, "auth_ref": [] }, "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Minimum" } } } } } } }, "auth_ref": ["r182", "r183", "r184", "r185", "r229", "r325", "r352", "r383", "r384", "r437", "r440", "r444", "r445", "r447", "r466", "r467", "r479", "r480", "r483", "r492", "r611", "r652", "r653", "r654", "r655", "r656", "r657"] }, "ced-MnpIDisTimeForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "MnpIDisTimeForCompValFlag", "presentation": { "http://xbrl.sec.gov/ced/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } } } }, "auth_ref": ["r566"] }, "ced-MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } } } }, "auth_ref": ["r574"] }, "ced-NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } } } }, "auth_ref": ["r548"] }, "us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used) in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed; or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } } }, "auth_ref": ["r177"] }, "us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Financing activities." } } } } }, "auth_ref": [] }, "us-gaap-NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing activities." } } } } }, "auth_ref": [] }, "us-gaap-NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } } }, "auth_ref": ["r71", "r72", "r73"] }, "us-gaap-NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Operating activities." } } } } }, "auth_ref": [] }, "us-gaap-NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "positiveVerboseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Loss for the period", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } } } } } }, "auth_ref": ["r65", "r73", "r88", "r94", "r105", "r107", "r111", "r122", "r129", "r131", "r132", "r133", "r134", "r137", "r138", "r149", "r161", "r166", "r170", "r172", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r294", "r297", "r341", "r412", "r430", "r431", "r478", "r502", "r609"] }, "us-gaap-NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted, Total", "totalLabel": "Net loss applicable to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } } } }, "auth_ref": ["r115", "r142", "r145", "r146", "r147", "r148", "r150", "r153"] }, "cyec-NonCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "NonCurrentAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Non-Current Assets" } } } }, "auth_ref": [] }, "cyec-NonCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "NonCurrentAssetsTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureNonCurrentAssets": { "lang": { "en-us": { "role": { "documentation": "Entire disclosure for non-current assets", "label": "Non-Current Assets [Text Block]", "terseLabel": "Non-Current Assets" } } } } }, "auth_ref": [] }, "ced-NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } } } }, "auth_ref": ["r547"] }, "ced-NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ced/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } } } }, "auth_ref": ["r517", "r528", "r538", "r555", "r563"] }, "ced-NonPeeNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonPeeNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } } } }, "auth_ref": ["r545"] }, "ced-NonPeeNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonPeeNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } } } }, "auth_ref": ["r544"] }, "ced-NonPeeNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonPeeNeoMember", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } } } }, "auth_ref": ["r555"] }, "ced-NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } } } }, "auth_ref": ["r574"] }, "ced-NonRule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ced/2023", "localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ced/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } } } }, "auth_ref": ["r574"] }, "us-gaap-NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-

gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."} } }, "auth-ref": { "r68" } }, "us-gaap-NonoperatingIncomeExpenseAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other (expense) income." } } }, "auth-ref": { } }, "cyce-NoticePeriodFromHolderToIncreaseOwnershipPercentage": { "xbrltype": "durationItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "NoticePeriodFromHolderToIncreaseOwnershipPercentage", "presentation": {
"http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Notice period from the holder to increase the percentage of ownership of outstanding common stock after exercise of warrants." }, "label": "Notice Period from Holder to Increase Ownership Percentage", "terseLabel": "Notice period from the holder to increase the percentage of ownership of outstanding common stock after exercise of warrants" } } }, "auth-ref": { } },
"cyce-NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight": { "xbrltype": "perShareItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents the number of securities equivalent price per share called by each warrant." }, "label": "Number Of Securities Equivalent Price Per Share Called By Each Warrant Or Right", "verboseLabel": "Price per share used to determine number of shares of common stock" } } }, "auth-ref": { } }, "us-gaap-OperatingExpenses": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": {
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth-ref": { } }, "us-gaap-OperatingExpensesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses." } } }, "auth-ref": { } }, "us-gaap-OperatingIncomeLoss": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth-ref": { "r161", "r166", "r170", "r172", "r478" } }, "us-gaap-OperatingLeaseExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": {
"http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth-ref": { "r647" } }, "us-gaap-OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": {
"http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]", "terseLabel": "Operating Lease Obligation" } } }, "auth-ref": { } }, "us-gaap-OperatingLeaseLiability": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cyclacel.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth-ref": { "r312" } }, "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": {
"documentation": "Present value of lessee's right to use underlying asset under operating lease, classified as noncurrent." } } }, "auth-ref": { "r312" } }, "us-gaap-OperatingLeasePayments": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": {
"http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating lease, payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth-ref": { "r313", "r315" } }, "us-gaap-OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 4.0 } }, "presentation": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth-ref": { "r311" } }, "us-gaap-OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": {
"http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discount rate lease liability", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth-ref": { "r317", "r489" } }, "us-gaap-OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r316", "r489" } }, "cyce-OptionsVestingOnThirdAnniversaryOfGrantMember": { "xbrltype": "domainItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "OptionsVestingOnThirdAnniversaryOfGrantMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Options Vesting On Third Anniversary Of Grant." }, "label": "Options Vesting On Third Anniversary Of Grant [Member]", "terseLabel": "Options Vesting On Third Anniversary Of Grant" } } }, "auth-ref": { } }, "us-gaap-OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Company Overview" } } }, "auth-ref": { } }, "us-gaap-OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureCompanyOverview", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "Company Overview", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth-ref": { "r53", "r83", "r359", "r360" } }, "us-gaap-OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year of the normal operating cycle, if longer." } } }, "auth-ref": { "r21" } }, "us-gaap-OtherAssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": {
"Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth-ref": { "r103", "r490" } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign-currency transactions that are of a long-term investment nature." } } }, "auth-ref": { "r3" } }, "us-gaap-OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": {
"http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Tax on other comprehensive income (loss)", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth-ref": { "r4", "r109", "r112", "r272", "r276", "r277", "r303", "r306", "r308", "r327", "r342" } }, "cyce-OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax": { "xbrltype": "monetaryItem", "nsuri": "http://www.cyclacel.com/20240930", "localname": "OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "lang": { "en-us": { "role": { "documentation": "Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax. If the entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. It includes gain (loss) on foreign exchange on intercompany loans." }, "label": "Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax", "terseLabel": "Unrealized foreign exchange on intercompany loans", "verboseLabel": "Unrealized foreign exchange gain (loss) on intercompany loans" } } }, "auth-ref": { } }, "us-gaap-OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth-ref": { "r69" } }, "ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth-ref": { "r547" } }, "ecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth-ref": { "r515", "r526", "r536", "r561" } }, "ecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth-ref": { "r518", "r529", "r539", "r564" } }, "ecd-OutstandingRecoveryIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth-ref": { "r518", "r529", "r539", "r564" } }, "ecd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth-ref": { "r543" } }, "us-gaap-PayablesAndAccrualsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued and Other Liabilities" } } }, "auth-ref": { } }, "us-gaap-PaymentsOfDividendsPreferredStockAndPreferenceStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "crdr": "credit", "calculation": {
"http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedLabel": "Payment of preferred stock dividend", "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity." } } }, "auth-ref": { "r29" } }, "us-gaap-PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth-ref": { "r70" } }, "ecd-PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth-ref": { "r546" } }, "ecd-PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2023",

"localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": { "r546" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r545" } }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": { "r555" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": { "r548" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": { "r544" } }, "cycc_PercentageOfOutstandingCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PercentageOfOutstandingCommonStock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding common stock", "label": "Percentage Of Outstanding Common Stock", "terseLabel": "Percentage of outstanding common stock" } } }, "auth_ref": { } }, "cycc_PercentageOfOutstandingCommonStockAtElectionOfPurchaser": { "xbrltype": "percentItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PercentageOfOutstandingCommonStockAtElectionOfPurchaser", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Percentage of outstanding common stock at the election of purchaser, immediately following the consummation of the public offering.", "label": "Percentage of Outstanding Common Stock, at Election of Purchaser", "terseLabel": "Outstanding common stock at election of purchaser" } } }, "auth_ref": { } }, "cycc_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PlacementAgentWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "auth_ref": { } }, "us_gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640" } }, "us_gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": { "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640" } }, "cycc_PreFundedWarrantsAndCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PreFundedWarrantsAndCommonWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants and common warrants.", "label": "Pre-Funded Warrants and Common Warrants [Member]", "terseLabel": "Pre-funded warrants and common warrants" } } }, "auth_ref": { } }, "cycc_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "lang": { "en-us": { "role": { "documentation": "Represents the number of trading days within a period of 30 consecutive trading days the closing price of the entity's common stock must exceed the applicable price in order for the preferred stock to be convertible.", "label": "Preferred Stock Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price", "terseLabel": "Percentage of closing sales price of common stock that conversion price must exceed in order for preferred stock to be convertible" } } }, "auth_ref": { } }, "cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOffTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOffTradingDays", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents the number of trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the preferred stock to be convertible.", "label": "Preferred Stock Conversion Obligation Number of Trading Days", "terseLabel": "Number of trading days during which closing price of common stock must exceed conversion price for at least 20 days in order for the preferred stock to be convertible" } } }, "auth_ref": { } }, "cycc_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock, Conversion Price", "verboseLabel": "Conversion price of convertible preferred stock", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": { "r200" } }, "us_gaap_PreferredStockConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionRatio", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Preferred stock conversion ratio", "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted." } } }, "auth_ref": { "r200" } }, "us_gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate (in percent)", "verboseLabel": "Dividend rate on convertible exchangeable preferred stock (in percent)", "documentation": "The percentage rate used to calculate dividend payments on preferred stock" } } }, "auth_ref": { "r199", "r438", "r441", "r443", "r448" } }, "us_gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsIncomeStatementImpact", "ordr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "parentTag": "us_gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Preferred Stock Dividends, Income Statement Impact", "negatedTerseLabel": "Dividend on convertible exchangeable preferred shares", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": { } }, "cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation": { "xbrltype": "perShareItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents the unit of measurement in dollars which establishes the exchange rate of the preferred stock into debt.", "label": "Preferred Stock Exchange Rate Principal Amount of Notes Used in Calculation", "terseLabel": "Debt principal amount per share, basis for exchange (in dollars per share)" } } }, "auth_ref": { } }, "us_gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference (in dollars per share)", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": { "r41", "r42", "r56", "r596", "r612" } }, "us_gaap_PreferredStockLiquidationPreferenceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreferenceValue", "ordr": "credit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Preferred Stock, Liquidation Preference, Value", "terseLabel": "Preferred stock, liquidation preference value (in dollars)", "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares." } } }, "auth_ref": { "r120", "r203" } }, "us_gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": { "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": { "r493", "r494", "r497", "r498", "r499", "r500", "r661", "r665" } }, "us_gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r56", "r198" } }, "us_gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionPricePerShare", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Preferred Stock, Redemption Price Per Share", "terseLabel": "Redemption price per share (in dollars per share)", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": { "r40", "r41", "r44" } }, "us_gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r56", "r392" } }, "us_gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": { "r56", "r198" } }, "us_gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r56", "r392", "r410", "r665", "r666" } }, "us_gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "ordr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "parentTag": "us_gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "positiveLabel": "Preferred stock, value", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r56", "r333", "r490" } }, "us_gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "ordr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "parentTag": "us_gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic

benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth-ref": { "r590" } } }, "us-gaap-PrepaidExpenseAndOtherAssetsCurrentAbstract". { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Abstract]" } } } }, "auth-ref": { } }, "cyce-PrepaidExpensesAndOtherCurrentAssetsAbstract". { "xbrltype": "stringItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PrepaidExpensesAndOtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } } }, "auth-ref": { } }, "cyce-PrepaidExpensesAndOtherCurrentAssetsTextBlock". { "xbrltype": "textBlockItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets". "lang": { "en-us": { "role": { "documentation": "This element represent as Prepaid Expenses and Other Current Assets.", "label": "Prepaid Expenses and Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } } }, "auth-ref": { } }, "cyce-PrepaymentsAndValueAddedTaxReceivableCurrent". { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "PrepaymentsAndValueAddedTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails". { "parentTag": "us-gaap-PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } } }, "presentation": { "http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails". "lang": { "en-us": { "role": { "documentation": "Represents the amount of current prepayments and value added tax receivable." } } }, "label": "Prepayments And Value Added Tax Receivable Current", "terseLabel": "Prepayments and VAT receivable" } } }, "auth-ref": { } }, "us-gaap-ProceedsFromIncomeTaxRefunds". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows". "lang": { "en-us": { "role": { "label": "Proceeds From Income Tax Refunds", "terseLabel": "Research & development tax credits", "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes." } } } }, "auth-ref": { "r31", "r72" } } }, "us-gaap-ProceedsFromInterestReceived". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows". "lang": { "en-us": { "role": { "label": "Proceeds from Interest Received", "verboseLabel": "Interest", "documentation": "Interest received on loans and other debt instruments during the current period." } } } }, "auth-ref": { "r594" } } }, "cyce-ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts". { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantExercisesNetOfIssuanceCosts", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows". { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows". "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of common stock and warrant exercises, net of issuance costs." } } }, "label": "Proceeds from Issuance of Common Stock and Warrant Exercises, Net of Issuance Costs", "verboseLabel": "Proceeds from issuing common stock and pre-funded warrants, net" } } }, "auth-ref": { } }, "cyce-ProceedsFromIssuanceOfCommonStockCross". { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockCross", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "documentation": "The gross amount of proceeds from issuance of common stock." } } }, "label": "Proceeds from Issuance of Common Stock, Cross", "terseLabel": "Proceeds from issuance of common stock, cross" } } }, "auth-ref": { } }, "us-gaap-ProceedsFromIssuanceOrSaleOfEquity". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Gross proceeds", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } } }, "auth-ref": { "r5", "r362" } } }, "srt-ProductOrServiceAxis". { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations". "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } } }, "auth-ref": { "r173", "r326", "r346", "r347", "r348", "r349", "r350", "r351", "r469", "r481", "r491", "r586", "r607", "r608", "r614", "r660" } } }, "srt-ProductsAndServicesDomain". { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations". "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } } }, "auth-ref": { "r173", "r326", "r346", "r347", "r348", "r349", "r350", "r469", "r481", "r491", "r586", "r607", "r608", "r614", "r660" } } }, "us-gaap-ProfessionalFees". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "label": "Professional Fees", "terseLabel": "Placement agent fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } } }, "auth-ref": { "r502", "r663", "r664" } } }, "us-gaap-ProfitLoss". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows". { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows". "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } } }, "auth-ref": { "r94", "r105", "r107", "r166", "r122", "r129", "r137", "r138", "r161", "r166", "r170", "r172", "r177", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r278", "r281", "r282", "r294", "r297", "r330", "r340", "r367", "r412", "r430", "r431", "r478", "r487", "r488", "r593" } } }, "us-gaap-PropertyPlantAndEquipmentNet". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets". { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets". "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } } }, "auth-ref": { "r8", "r331", "r338", "r490" } } }, "ecd-PvpTable". { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure". "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } } }, "auth-ref": { "r543" } } }, "ecd-PvpTableTextBlock". { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure". "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } } }, "auth-ref": { "r543" } } }, "srt-RangeAxis". { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails". "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails". "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails". "lang": { "en-us": { "role": { "label": "Range [Axis]" } } } }, "auth-ref": { "r182", "r183", "r184", "r185", "r228", "r229", "r258", "r259", "r260", "r324", "r325", "r352", "r383", "r384", "r437", "r440", "r444", "r445", "r447", "r466", "r467", "r470", "r480", "r483", "r492", "r495", "r606", "r611", "r653", "r654", "r655", "r656", "r657" } } }, "srt-RangeMember". { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails". "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails". "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails". "lang": { "en-us": { "role": { "label": "Range [Domain]" } } } }, "auth-ref": { "r182", "r183", "r184", "r185", "r228", "r229", "r258", "r259", "r260", "r324", "r325", "r352", "r383", "r384", "r437", "r440", "r444", "r445", "r447", "r466", "r467", "r470", "r480", "r483", "r492", "r495", "r606", "r611", "r653", "r654", "r655", "r656", "r657" } } }, "cyce-RecentlyIssuedAccountingPronouncementsPolicyTextBlock". { "xbrltype": "textBlockItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies". "lang": { "en-us": { "role": { "documentation": "Represent recently issued accounting pronouncements." } } }, "label": "Recently Issued Accounting Pronouncements [Policy Text Block]", "verboseLabel": "Recently Issued Accounting Pronouncements" } } }, "auth-ref": { } }, "us-gaap-ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails". "lang": { "en-us": { "role": { "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassifications out of other comprehensive income (loss)", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } } }, "auth-ref": { "r16", "r27", "r110", "r303", "r307", "r308", "r591" } } }, "cyce-ReclassificationOfCommonStockShares". { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ReclassificationOfCommonStockShares", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "documentation": "Shares reclassified to outside equity." } } }, "label": "Reclassification of Common Stock, Shares", "terseLabel": "Reclassified shares" } } }, "auth-ref": { } }, "cyce-ReclassificationOfCommonStockSharesNoProceedsReceived". { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ReclassificationOfCommonStockSharesNoProceedsReceived", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "documentation": "The number of shares of reclassified common stock for which no proceeds were received." } } }, "label": "Reclassification Of Common Stock, Shares, No Proceeds Received", "terseLabel": "Reclassified shares for which no proceeds were received" } } }, "auth-ref": { "r1", "cyce-ReclassificationOfCommonStockValue". { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ReclassificationOfCommonStockValue", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "documentation": "Amount of Shares reclassified to outside equity." } } }, "label": "Reclassification of Common Stock, Value", "terseLabel": "Aggregate purchase price" } } }, "auth-ref": { } }, "cyce-ReclassificationOfRedeemableCommonStockShares". { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ReclassificationOfRedeemableCommonStockShares", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit". "lang": { "en-us": { "role": { "documentation": "Number of shares of stock reclassified to temporary equity during the period." } } }, "label": "Reclassification of redeemable common stock, Shares", "negatedLabel": "Reclassification of redeemable common stock (in shares)" } } }, "auth-ref": { } }, "ecd-RecoveryOfErrCompDisclosureLineItems". { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } } }, "auth-ref": { "r510", "r521", "r531", "r556" } } }, "cyce-RedeemableCommonStockMember". { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "RedeemableCommonStockMember", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations". "lang": { "en-us": { "role": { "documentation": "Represents redeemable common shareholders", "label": "Redeemable Common Stock [member]", "terseLabel": "Redeemable common shareholders" } } } }, "auth-ref": { } }, "cyce-RegularWarrantsMember". { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "RegularWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails". "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails". "lang": { "en-us": { "role": { "documentation": "Regular Warrants warrants", "label": "Regular Warrants [Member]", "terseLabel": "Regular Warrants" } } } }, "auth-ref": { } }, "srt-RepurchaseAgreementCounterpartyNameDomain". { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails". "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } } }, "auth-ref": { "r123", "r124", "r195", "r201", "r320", "r473", "r474" } } }, "us-gaap-ResearchAndDevelopmentExpense". { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations". { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations". "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } } }, "auth-ref": { "r52", "r271", "r658" } } }, "us-gaap-ResearchAndDevelopmentExpenseMember". { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails". "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } } }, "auth-ref": { } }, "ecd-RestatementDateAxis". { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure". "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } } }, "auth-ref": { "r511", "r522", "r532", "r557" } } }, "ecd-RestatementDeterminationDate". { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure". "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } } }, "auth-ref": { "r512", "r523", "r533", "r558" } } }, "ecd-RestatementDoesNotRequireRecoveryTextBlock". { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure". "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } } }, "auth-ref": { "r510", "r530", "r540", "r565" } } }, "us-gaap-RestrictedStockUnitsRSUMember". { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails". "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails". "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails". "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } } }

"auth_ref": [], "us-gaap-RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "order": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap-StockholdersEquity", "weight": "1.0", "order": "5.0" } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r59", "r60", "r336", "r356", "r358", "r366", "r393", "r490" } }, "us-gaap-RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit": { "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r93", "r126", "r127", "r128", "r130", "r136", "r138", "r178", "r179", "r267", "r268", "r269", "r273", "r274", "r285", "r287", "r288", "r290", "r292", "r353", "r355", "r368", "r665" } } }, "us-gaap-RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue" } } }, "auth_ref": [], "us-gaap-RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "order": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": "1.0", "order": "1.0" } }, "presentation": { "http://www.cyclacel.com/role/DisclosureRevenueNarrativeDetails": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r162", "r163", "r165", "r168", "r169", "r173", "r174", "r176", "r225", "r226", "r326" } }, "us-gaap-RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureRevenue": { "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": { "r91", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r227" } }, "us-gaap-RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": { "r414", "r468", "r475" } }, "us-gaap-RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues", "documentation": "" } } }, "auth_ref": [] }, "cyce-RothCapitalPartnersLLcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "RothCapitalPartnersLLcMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Roth Capital Partners, LLC", "label": "Roth Capital Partners, LLC [Member]", "terseLabel": "Roth Capital Partners, LLC" } } }, "auth_ref": [] }, "eecd-Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/eecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/eecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b51 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b51 Arrangement Adopted" } } }, "auth_ref": { "r574" } }, "eecd-Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/eecd/2023", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/eecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b51 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b51 Arrangement Terminated" } } }, "auth_ref": { "r574" } }, "us-gaap-SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityTables": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails": { "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [], "us-gaap-SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of share sold under the sales agreement", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": { "srt-ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "auth_ref": { "r139", "r230", "r582", "r601" } }, "us-gaap-ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureAccruedAndOtherLiabilitiesTables": { "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued and Other Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [], "us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails": { "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": { "r35" } }, "us-gaap-ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareTables": { "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of Basic and Diluted Net Loss Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations." } } }, "auth_ref": { "r603" } }, "us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": { "r40" } }, "us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables": { "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of Stock Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": { "r40" } }, "cyce-ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ScheduleOfInstrumentsIssuedInOfferingAndTheirClassificationUnderShareholdersEquityTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityTables": { "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each instrument issued in an offering and their classification as part of shareholders equity.", "label": "Schedule of Instruments Issued in an Offering and their Classification Under Shareholders Equity [Table Text Block]", "terseLabel": "Schedule of fair values of instruments issued in an offering" } } }, "auth_ref": [], "us-gaap-ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffairValueOfStockOptionsGrantedDetails": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails": { "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r232", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r259", "r260", "r261" } }, "us-gaap-ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables": { "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "verboseLabel": "Schedule of Restricted Stock Units Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "r48" } }, "us-gaap-ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables": { "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of Share Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r14", "r15", "r48" } }, "us-gaap-ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables": { "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Schedule of Fair Value of the Stock Options Granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r82" } }, "us-gaap-ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityTables": { "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": { "r37", "r38", "r39", "r41", "r42", "r43", "r45", "r77", "r79", "r80", "r99", "r100", "r101", "r150", "r198", "r199", "r201", "r203", "r206", "r212", "r214", "r362", "r363", "r364", "r365", "r480", "r581", "r596" } }, "dei-Security12bTitle": { "xbrltype": "securityTitleItem", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": { "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r505" } }, "dei-SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItem", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": { "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r507" } }, "srt-SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails": { "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": { "r174", "r175", "r380", "r381", "r382", "r439", "r442", "r446", "r449", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r470", "r482", "r495", "r614", "r660" } }, "us-gaap-SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "order": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap-OperatingExpenses", "weight": "1.0", "order": "2.0" } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": { "r67" } }, "us-gaap-SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals": { "lang": { "en-us": { "role": { "label": "Series A Convertible Preferred Stock", "documentation": "Series A preferred stock." } } }, "auth_ref": { "r588", "r589", "r613" } }, "us-gaap-SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": { "http://www.cyclacel.com/role/DisclosureNetLossPerCommonShareScheduleOfCompanySPotentialAntiDilutiveSecuritiesDetails": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets",

"http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentheticals", "lang": { "en-us": { "role": { "label": "Series B Convertible Preferred Stock", "documentation": "Series B preferred stock." } } }, "auth-ref": { "r588", "r589", "r613" } }, "cycc-SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "SeriesBWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series B warrants.", "label": "Series B Warrants [Member]", "terseLabel": "Series B Warrants" } } }, "auth-ref": { "cycc-SeriaSawarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "SeriesAWarrantsMember", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to series A warrants.", "label": "SeriesA Warrants [Member]", "terseLabel": "Series A warrants" } } }, "auth-ref": { "us-gaap-ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "order": "debit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth-ref": { "r6" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Vesting period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r484" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock awards vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth-ref": { "r484" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock awards vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth-ref": { "r484" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Cancelled/forfeited", "terseLabel": "Shares forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth-ref": { "r252" } } }, "cycc-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions": { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAdditions", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "documentation": "The number of additional equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth-ref": { "r252" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "verboseLabel": "Restricted Stock Units, Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth-ref": { "r250" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth-ref": { "r250" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted Stock Units outstanding, Ending balance", "periodStartLabel": "Restricted Stock Units outstanding, Beginning balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth-ref": { "r247", "r248" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Number of Options Outstanding", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth-ref": { "r247", "r248" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Restricted stock units, grant date fair value", "verboseLabel": "Restricted stock units, grant date fair value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth-ref": { "r247", "r248" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Value Per Share" } } }, "auth-ref": { "r247", "r248" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Restricted stock units, Weighted average remaining term", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r81" } } }, "cycc-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumber", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "documentation": "The number of unvested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth-ref": { "r247", "r248" } } }, "cycc-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedWeightedAverageRemainingContractualTerms", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, unvested, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r247", "r248" } } }, "cycc-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerms", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, vested and exercisable, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r247", "r248" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "verboseLabel": "Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth-ref": { "r251" } } }, "cycc-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingTermAbstract", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "auth-ref": { "r251" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected Dividend Rate", "verboseLabel": "Expected dividend yield over expected term", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth-ref": { "r259" } } }, "us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "positiveLabel": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a

share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth-ref": { "r258" } } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } } }, "auth-ref": { "r260" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth-ref": { "r232", "r234", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } } }, "auth-ref": { } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } } }, "auth-ref": { } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of shares reserved for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments, and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } } }, "auth-ref": { "r47" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Cancelled/forfeited", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } } }, "auth-ref": { "r621" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled/forfeited (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } } }, "auth-ref": { "r621" } } }, "cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents the grant date fair value of options granted during the reporting period." }, "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Grant Date Fair Value", "terseLabel": "Options granted, grant date fair value" } } } }, "auth-ref": { } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "verboseLabel": "Options granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } } }, "auth-ref": { "r243" } } }, "cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateCumulativeFairValue", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails" }, "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Weighted Average Grant Date Cumulative Fair Value", "terseLabel": "Resulting weighted average grant date fair value" } } } }, "auth-ref": { } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding", "periodStartLabel": "Options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } }, "auth-ref": { "r239", "r240" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Options Outstanding", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth-ref": { } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]", "terseLabel": "Weighted Average Exercise Price Per Share" } } } }, "auth-ref": { } } }, "cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term", "terseLabel": "Unvested" } } } }, "auth-ref": { } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "verboseLabel": "Vested and exercisable", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth-ref": { "r256" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and exercisable", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth-ref": { "r256" } } }, "cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Stock-based compensation (in shares)", "documentation": "Number of shares issued under share-based payment arrangement." } } } }, "auth-ref": { "r47" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails" }, "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOffFairValueOfStockOptionsGrantedDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsActivityDetails", "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } } }, "auth-ref": { "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } } }, "auth-ref": { "r244" } } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails" }, "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } } }, "auth-ref": { "r243" } } }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Share Price", "documentation": "Share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } } }, "auth-ref": { "r258" } } } }

"Price of a single share of a number of saleable stocks of a company." } } }, "auth-ref": [] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "verboseLabel": "Life of stock option awards granted", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r485" } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfFairValueOfStockOptionsGrantedDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terselabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r257" } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "verboseLabel": "Unvested", "documentation": "Number of non-vested options outstanding." } } }, "auth-ref": [] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price, Beginning Balance", "terselabel": "Unvested", "documentation": "Weighted average grant date fair value of non-vested options outstanding." } } }, "auth-ref": [] }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terselabel": "Options outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r81" } }, "us-gaap-SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationScheduleOfShareOptionActivityDetails", "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terselabel": "Vested and exercisable", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth-ref": { "r256" } }, "us-gaap-SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth-ref": { "r12" } }, "us-gaap-SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terselabel": "Share issue price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth-ref": [] }, "us-gaap-SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth-ref": { "r74", "r119" } }, "us-gaap-StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails", "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth-ref": { "r92", "r99", "r100", "r101", "r122", "r143", "r144", "r151", "r153", "r159", "r160", "r177", "r186", "r188", "r189", "r190", "r193", "r194", "r198", "r199", "r203", "r206", "r214", "r297", "r362", "r363", "r364", "r365", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r392", "r413", "r432", "r450", "r451", "r452", "r453", "r454", "r581", "r596", "r602" } }, "us-gaap-StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth-ref": { "r12", "r25", "r93", "r109", "r110", "r111", "r126", "r127", "r128", "r130", "r136", "r138", "r158", "r178", "r179", "r216", "r267", "r268", "r269", "r273", "r274", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r303", "r304", "r305", "r306", "r307", "r308", "r319", "r353", "r354", "r355", "r368", "r432" } }, "srt-StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": ["http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical area." } } }, "auth-ref": { "r174", "r175", "r380", "r381", "r382", "r439", "r442", "r446", "r449", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r470", "r482", "r495", "r614", "r660" } }, "us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r126", "r127", "r128", "r158", "r326", "r361", "r379", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r411", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } } }, "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": [] }, "us-gaap-StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": [] }, "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": [] }, "srt-StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": ["http://www.cyclacel.com/role/DisclosureStockBasedCompensationNarrativeDetails", "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario." } } }, "auth-ref": { "r139", "r230", "r582", "r584", "r601" } }, "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://www.cyclacel.com/role/DisclosureLeasesNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth-ref": { "r126", "r127", "r128", "r158", "r326", "r361", "r379", "r385", "r386", "r387", "r388", "r389", "r390", "r392", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r411", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } } }, "us-gaap-StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terselabel": "Series B Preferred stock conversions (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth-ref": { "r12", "r24", "r41", "r60", "r196" } }, "us-gaap-StockIssuedDuringPeriodSharesFractional": { "xbrltype": "sharesItemType", "nsuri": "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "presentation": ["http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Fractional", "terselabel": "Fractional shares issued", "documentation": "Number of fractional shares issued during period." } } }, "auth-ref": [] }, "us-gaap-StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheetsParentHicals", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfOperations", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Number of shares issued (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth-ref": { "r12", "r56", "r57", "r80", "r362", "r432", "r451" } },

"localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Proceeds from further issuance of share", "verboseLabel": "Aggregate offering price", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } }, "auth ref": { "r12", "r56", "r57", "r80", "r368", "r432", "r451", "r503" } }, "ecyc-StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingIssuanceCosts", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period upon conversion of pre-funded warrants in an offering, net of issuance costs." }, "label": "Stock Issued During Period, Value, Upon Conversion Of Pre-Funded Warrants In An Offering, Issuance Costs", "terseLabel": "Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering" } }, "auth ref": { } }, "ecyc-StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cyclacel.com/20240930", "localname": "StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInOfferingNetOfIssuanceCosts", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "documentation": "The value of stock issued during the period upon conversion of pre-funded warrants in an offering, net of issuance costs." }, "label": "Stock Issued During Period, Value, Upon Conversion Of Pre-Funded Warrants In An Offering, Net Of Issuance Costs", "terseLabel": "Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses" } }, "auth ref": { } }, "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets" }, "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets", "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "negatedLabel": "Stockholder's Equity Deficit", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } }, "auth ref": { "r57", "r60", "r61", "r75", "r394", "r410", "r433", "r434", "r490", "r504", "r597", "r605", "r645", "r665" } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit)" } }, "auth ref": { } }, "us-gaap-StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Abstract", "auth ref": { } }, "us-gaap-StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquity" }, "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } }, "auth ref": { "r76", "r121", "r197", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r211", "r213", "r216", "r291", "r435", "r436", "r455" } }, "us-gaap-SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": { "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } }, "auth ref": { "r309", "r322" } }, "us-gaap-SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": { "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Subsequent event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }, "auth ref": { "r309", "r322" } }, "us-gaap-SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": { "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } }, "auth ref": { "r309", "r322" } }, "us-gaap-SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }, "auth ref": { "r309", "r322" } }, "us-gaap-SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureSubsequentEventsNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } }, "auth ref": { "r309", "r322" } }, "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } }, "auth ref": { } }, "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": { "http://www.cyclacel.com/role/DisclosureSubsequentEvents" }, "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } }, "auth ref": { "r321", "r323" } }, "us-gaap-SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityAmountsAllocatedToEachInstrumentsDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails", "http://www.cyclacel.com/role/DisclosureStockholdersEquityTables", "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" }, "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } }, "auth ref": { } }, "us-gaap-SubstantialDoubtAboutGoingConcernWithinOneYear": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear", "presentation": { "http://www.cyclacel.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern, within One Year [true false]", "terseLabel": "Substantial Doubt about Going Concern, within One Year", "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued." } }, "auth ref": { "r10" } }, "us-gaap-SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Cash received during the period for" } }, "auth ref": { } }, "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.cyclacel.com/role/StatementConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } }, "auth ref": { } }, "eod-TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } }, "auth ref": { "r554" }, "srt-TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } }, "auth ref": { "r604", "r649" }, "srt-TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Relationship to Entity [Domain]" } }, "auth ref": { } }, "eod-TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } }, "auth ref": { "r546" }, "eod-TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } }, "auth ref": { "r553" }, "eod-TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } }, "auth ref": { "r573" }, "eod-TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } }, "auth ref": { "r575" }, "dei-TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": { "http://www.cyclacel.com/role/DocumentDocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } }, "auth ref": { } }, "eod-TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TrdArrAdoptionDate", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } }, "auth ref": { "r576" }, "eod-TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TrdArrDuration", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } }, "auth ref": { "r577" }, "eod-TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TrdArrIndName", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } }, "auth ref": { "r575" }, "eod-TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TrdArrIndTitle", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } }, "auth ref": { "r575" }, "eod-TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } }, "auth ref": { "r578" }, "eod-TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "TrdArrTerminationDate", "presentation": { "http://xbrl.sec.gov/eod/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } }, "auth ref": { "r576" }, "eod-UndrlygSecurityMktPriceChngPet": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/eod/2023", "localname": "UndrlygSecurityMktPriceChngPet", "presentation": { "http://xbrl.sec.gov/eod/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } }, "auth ref": { "r572" }, "us-gaap-WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Aggregate fair value Warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } }, "auth ref": { } }, "us-gaap-WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityValuationAssumptionsDetails" }, "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and rights outstanding", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } }, "auth ref": { "r296" }, "us-gaap-WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": { "http://www.cyclacel.com/role/DisclosureStockholdersEquityNarrativeDetails" }, "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant outstanding Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } }, "auth ref": { "r644" } } } }, "std ref": { "r0", "role": { "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "040", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481913/940-20-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "030", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481877/830-230-45-1", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1", "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147497710/205-40-50-13", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "SubTopic": "40",

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

0Q1A555WE1015Q, 1005Q, @#%#11,D, _#00W(#D,1,5 M 0/L:501-DR10ZW14LE1)11 -R01#1E]0 EE101-02M1%N 4,7E1N _%Q10 -%N 11,11]0Q00%0E V0510021H05NE]V.

[illegible]

[The content of this block is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or encrypted document. It contains no legible text.]

[illegible]

[illegible]

6EP.UOP.A5IRD&GSNPM2S[XL-Y*1M,M]*EIAJ*KB480TJ%KIAVB;E1I MU:L:INSFYH7<HIMJ-M;L:6L=KH>N,\$E*6#YP H-PQR#F/G,9J0>\$,F:6&IGHMWJ/G<9AZ8L#*B) MNK8P+ZW+4C+K=K=TOIPNSC10X-HM\$+T IK< B3.YS@>ZFYH)2<U MT<B.BY F+>=QOQH428=U955*2M/Z+SVL 05=1LH&539RB8 MZF+Y L1S2MH0.TX7QOU6B#AZ.CYQ3PG:L4K.Z2<+LP3=2MIS.CBHL)B)M.DIZ124>VPIQ?7>O-CQ#63EFX8Q0L<=WU.ZIH"=M>\$U17-0NH5FM\$JZ.M/1@OO:~C#1 F11URB>@.1R=<@3*KBP2P>N-H/2+Q.UUFTG56I*~@GX315ND.M3ELP.B-BW6/6LR:9TFQBG\$3Y.M-7MU"U.T.HKP<.OOEXSEFKBCGM9%=<=0>~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~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~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